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ABSTRACT
BACKGROUND: Molecular approaches have expedited the discovery of human 
obesity genes, however the heritability explained by these loci remains low (<2%). 
Gene-by-environment interactions may partially account for the “missing heritability” 
attributed to variation in obesity phenotypes. OBJECTIVE: The specific aims of this 
dissertation were to (i) identify genetic polymorphisms associated with obesity-related 
phenotypes in Yup’ik people and (ii) evaluate how n-3 polyunsaturated fatty acid (n-3 
PUFA) intake modifies associations between genetic polymorphisms and obesity- 
related phenotypes in a population with widely varying intake of n-3 PUFAs. 
APPROACH: We genotyped genetic polymorphisms in (1) candidate genes with a 
strong physiological role in obesity pathophysiology; (2) candidate genes identified in 
obesity whole-genome linkage studies that were regulated by n-3 PUFAs; and (3) 
candidate genes reproducibly implicated in obesity genome-wide association studies 
(GWAS). DATA & ANALYSES: We used Center for Alaska Native Health Research 
(CANHR) data collected between 2001 and 2008. We estimated dietary intake of n-3 
PUFA using nitrogen stable isotope ratios (815N) of red blood cells (RBC) and obesity- 
related phenotypes were obtained by trained staff. Genotype-phenotype analyses used 
generalized linear models that accounted for familial correlations. RESULTS: Our 
analyses of candidate genes based on physiology revealed a polymorphism called 
P479L in carnitine palmitoyltransferase 1A (CPT1A) that was associated with elevated 
fasting HDL-cholesterol and all obesity phenotypes. Our investigation of candidate 
genes that are regulated by n-3 PUFAs and implicated in obesity whole-genome linkage 
studies demonstrate that polymorphisms in stearoyl CoA desaturase (SCD) and steroyl 
regulatory element binding protein (SLC2A4) were associated with obesity-related 
phenotypes; however n-3 PUFA intake did not modify associations between SCD and 
SLC2A4 polymorphisms and obesity phenotypes. Finally, our investigation of 
candidate genes reproducibly implicated in obesity GWAS demonstrated that genetic 
predisposition to obesity is associated with adiposity and that interactions with n-3
PUFA intake accounted for more than twice the phenotypic variation in adiposity. 
CONCLUSION: Taken together, results from this dissertation suggest that selecting 
candidate genes based on large-scale genomic analyses, such as linkage analyses and 
GWAS, has the potential to identify gene-by-environment interactions that partially 
account for the “missing heritability” attributed to obesity.
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1INTRODUCTION
1.1 OBESITY EPIDEMIC
Obesity is characterized by excess body fat and increases the risk of developing 
type 2 diabetes (T2D), stroke, cancer, and other chronic diseases (1). Current estimates 
indicate that nearly 70% of adults in the United States are overweight and more than half 
of these individuals are obese (2). The development of obesity occurs in response to 
joint actions of multiple genetic and environmental factors that increase the risk of 
accumulating excess body fat (3). Although moderate levels of weight loss (~10% of 
body weight) have been shown alleviate many of the major health risks attributed to 
obesity (4), a large number of overweight and obese individuals are unsuccessful with 
long-term weight management (5). Given the increasing public health burden associated 
with obesity and the difficulty achieving and maintaining weight loss (6-8), 
understanding the genetic and environmental factors that influence obesity has 
implications for designing more effective therapies and personalized interventions.
1.2 DISSECTING THE HERITABILITY OF OBESITY
Studies of large families, twins, sibling pairs, and adopted individuals have been 
used to estimate the heritability of body mass index (BMI kg/m2) to be between 40 and 
70% (9, 10). Heritability is a measure of the phenotypic variance in a population that is 
attributable to genetic factors (11). For approximately 20 years, molecular approaches 
attempting to identify genetic factors that explain the high heritability of obesity were 
limited to either candidate genes studies or linkage analyses (12). Candidate gene 
approaches are hypothesis-driven experiments that select genes based on a priori 
knowledge about the molecular physiology that underlies the development of obesity (3). 
In contrast, linkage analyses are hypothesis-generating experiments that rely on the 
relatedness of the study participants and test whether genomic regions are co-segregating 
with obesity phenotypes across generations (13). Although these molecular approaches 
have advanced the understanding of monogenic obesity (12), progress identifying genes
2implicated in common obesity using candidate gene and linkage analyses has been 
extremely limited (3).
More recently, the search for common obesity candidate genes has been expedited 
by genome wide association studies (GWAS). The GWAS approach is a hypothesis- 
generating experiment that extends the idea of linkage analyses by screening single 
nucleotide polymorphisms (SNPs) throughout the genome for association with a 
phenotype of interest (14). In 2007, the first GWAS for BMI and body weight identified 
a gene that encodes fat mass and obesity-associated protein (FTO) (15) and subsequent 
investigations were quick to expand the list of gene reproducibly associated with obesity 
(16-18). Current meta-analysis based on all obesity GWAS (249,796 participants and
2.8 million markers) reported that 32 genetic loci were now reproducibly associated with 
variation in BMI (19). Although GWAS has expedited the discovery of human obesity 
genes and provided opportunities to define mechanistic insights into the regulation of 
body weight, the heritable component of obesity explained by the aggregate of these loci 
remains low (<2%) (19).
1.3 GENE-BY-ENVIRONMENT INTERACTIONS
Increasingly, gene-by-environment interactions have been identified as a potential 
strategy to partially account for the “missing heritability” that is attributed to complex 
phenotypes like obesity (20). Gene-by-environment interactions (GEI) studies are aimed 
at determining whether the response or adaptation to an environmental exposure is 
conditional upon the genotype of the individual (21). Observational studies can test for 
GEIs when information on both environmental exposure (lifestyle and dietary intake) and 
genetic factors (SNPs) are collected in large cohort studies (22).
1.4 POLYUNSATURATED FATTY ACIDS AND HEALTH
Polyunsaturated fatty acids (PUFAs) are essential fats that are required by humans 
and other mammals for survival (23). Two types of naturally occurring PUFAs are found 
in mammalian tissues that include the n-6 series (n-6 PUFAs) derived from cis-linoleic
3acid (LA) and the n-3 series (n-3 PUFAs) derived from a-linolenic acid (ALA) (24). 
Dietary sources of n-6 PUFAs include cereals, eggs, poultry, most vegetable oils, whole- 
grain breads, baked goods, margarine as well as sunflower oil, safflower oil, and com oils 
(25). Dietary sources of n-3 PUFAs include canola oil, flaxseed oil, linseed oil, rapeseed 
oil, walnuts, leafy green vegetables as well as marine foods (25). Animal and human 
studies demonstrate that dietary intake of PUFAs impact diverse physiological processes 
including immune regulation (26), inflammation (24), neurological conditions (26), 
cardiovascular disease (26), cancer (27), diabetes (26) as well as metabolic syndrome 
(23). Moreover, accumulating evidence suggest that regular consumption of marine 
derived n-3 polyunsaturated fatty acids (n-3 PUFAs), namely eicosapentaenoic (EPA) 
and docosahexaenoic acids (DHA), may also have anti-obesity effects (28).
1.5 ANTI-OBESITY EFFECTS of n-3 PUFA INTAKE IN ANIMALS
In rodent models, significant reductions in fat mass were observed when dietary 
n-3 PUFAs were substituted for saturated fats (29), monosaturated fats (30), and n-6 
polyunsaturated fats (31). Supplementing mice on a high fat diet with n-3 PUFAs was 
also associated with less weight gain (32, 33) and minimized visceral fat accumulation 
(34, 35). Although a growing body of literature demonstrates that n-3 PUFA intake can 
reduce body fat in animal studies, the anti-obesity effects of n-3 PUFAs in humans has 
not been fully characterized.
1.6 ANTI-OBESITY EFFECTS OF n-3 PUFA INTAKE IN HUMANS
A limited number of studies have evaluated the extent to which n-3 PUFA intake 
influences adiposity in humans. In healthy adults, replacing control diets with n-3 
PUFAs (1.1 g/day EPA and 0.7 g/day DHA) for 3 weeks, was associated with increased 
fatty acid oxidation (22%) at rest and reductions in body fat (-0.9 kg) (36). Similarly, 
supplementing n-3 PUFAs (1.08 g/day EPA and 0.7 g/day DHA) for 3 months in obese 
women with T2D, was associated with reduced total fat mass (3.5%) and smaller 
adipocyte diameter (6%) (37). In young adults on an energy-restricted diet (8 weeks), the
4addition of either lean fish (0.3 g/day n-3 PUFA), fatty fish (3.0 g/day n-3 PUFA), or fish 
oil (1.5 g/day n-3 PUFA), was associated with greater weight loss (~lkg) relative to 
similar diets without seafood or fish oil supplements (38). Taken together, these studies 
demonstrate that modest increases in n-3 PUFA intake (0.3-3.0 g/day) over short periods 
of time (< 3 months) may be effective in reducing body fat in humans.
Observational studies have provided indirect evidence that long-term n-3 PUFA 
intake may reduce obesity. Baseline data from the Health Professionals Follow-Up 
(HPFU) study, a 12 year prospective study investigating stroke in 43,671 men, found that 
regular consumption of fish enriched with n-3 PUFAs (>5 times a week) was inversely 
associated with proportion of men that were overweight (39). In contrast, the Nurse’s 
Health (NH) Study, a 14 year prospective study that investigated the effects of fish 
consumption on stroke in 79,839 women, found that higher intakes (>5 times a week) of 
fish containing n-3 PUFAs was positively associated with BMI, independent of energy 
intake (40). Although these studies provide mixed results regarding the contribution of 
long-term n-3 PUFA intake to changes in obesity, it is not clear whether these differences 
are related to gender-specific effects of n-3 PUFA intake on obesity or dietary assessment 
tools that were not sensitive enough to precisely quantify n-3 PUFA intake (28). 
Methods that precisely track consumption of n-3 PUFA intake, such as a physiological 
biomarker, may help clarify the extent to which n-3 PUFA intake influences the risk of 
developing obesity.
In summary, rodent studies demonstrate that supplementing the diet with n-3 
PUFAs attenuated weight gain and reduces the accumulation of body fat. Consistent with 
these findings, human studies indicate that modest consumption of n-3 PUFA intake (0.3­
3.0 g/day) can reduce body weight in overweight or obese individuals (36-38). Although 
animal and human studies suggest modest levels of n-3 PUFA intake may have anti­
obesity effects (28), the extent to which intake of n-3 PUFA modifies the genetic risk of 
developing obesity is unknown.
51.7 MEASURING n-3 PUFA INTAKE
Evidence that consumption of n-3 PUFAs modifies genetic risk of developing 
obesity in large cohort studies is limited, in part because estimates of dietary EPA and 
DHA intakes are difficult to quantify (41). Estimates of dietary intake are traditionally 
captured by either self-reported food frequency questionnaires (FFQs) or 24-hour food 
recall interviews (24HRs) (42). FFQs ask participants to select from a number of food 
items and report the frequency of consumption and portion size during a specific time 
interval (week, month, or year) (43). In contrast, 24HRs ask participants to quantify all 
liquids and foods consumed in the past 24 hour period (44); however it is widely 
recognized that a single 24HR is not representative of “usual intake” (45). Estimating n- 
3 PUFA intake in large cohort studies using self-report questionnaires has proven 
difficult, in part, because methods which are feasible to collect in large populations (i.e., 
FFQ) suffer large error and biases (46, 47), whereas more reliable methods (i.e., multiple 
24HR) can be prohibitively time consuming and costly (48,49).
Alternative dietary assessment approaches such as biomarkers, may provide a 
more accurate measure of n-3 PUFA intake in large epidemiologic studies (50). 
Membrane composition of red blood cell (RBC) are effective biomarkers of n-3 PUFA 
intake (51), however their application in large cohort studies is limited because 
measurements are technically challenging, expensive, and time consuming (41). 
Nitrogen stable isotope ratios (815N) have been developed as a validated biomarker of n-3 
PUFA intake in large samples (41, 52). In a cohort of Yup’ik adults (n=496), 815N of 
RBC was positively correlated with EPA (r=0.84) and DHA (r=0.75) in RBC (41). 
Given that measurement of 815N in RBC is inexpensive, accurate, and can easily be 
assayed in large numbers of samples (41), estimating n-3 PUFA intake using 815N in 
RBC as a validated biomarker for EPA and DHA consumption in Yup’ik people may 
increase the ability to detect gene-by-environment interactions.
61.8 CENTER FOR ALASKA NATIVE HEALTH RESEARCH STUDY
Southwest Alaska is home to approximately 20,000 Yup’ik people who reside in 
approximately 50 rural villages (53). The Center for Alaska Native Health Research 
(CANHR) study is a long-term epidemiological investigation based in Southwest Alaska 
that is dedicated to understanding genetic, behavioral, and dietary risk factors underlying 
obesity and their relationship to diabetes and cardiovascular disease among Yup’ik 
people (54). For the past 10 years, the CANHR field team has worked with 10 remote 
villages (coastal/inland). The rural communities CANHR works with are not on the road 
system and most of the residents engage in subsistence hunting and fishing to generate 
much of their food. Most residents speak the indigenous Yup’ik language and the culture 
of this region is considered one of the most intact in the state. CANHR investigators 
have collected health histories, family history information, body measurements, dietary 
assessments and fasting blood samples (54). The prevalence of obesity among CANHR 
participants is comparable to the general US population, yet the prevalence of metabolic 
syndrome (8.6 % in Yup’ik men and 19.8% in Yup’ik women) (55) and T2D (<3% in 
Yup’ik people) (54) is significantly less than that observed in the general US population 
(56, 57). Based on these observations, the health of Yup’ik people, may in part, be 
influenced by their subsistence diet, including regular consumption of n-3 
polyunsaturated fatty acids (n-3 PUFAs) (58, 59). Although the mechanisms that allow 
Yup’ik people to carry excess body fat without developing features of metabolic 
syndrome and T2D are unknown, dietary intake of n-3 PUFAs and genetic factors (60) 
are likely to be relevant.
1.9 SCOPE OF DISSERTATION
Given that gene-by-environment interactions are hypothesized to account for the 
missing heritability attributed to obesity (20), cross-sectional studies in a Yup’ik study 
population that demonstrate n-3 PUFA intake modifies genetic factors associated with 
obesity may help elucidate important mechanisms that can modulate the risk of obesity 
through dietary interventions. Regular consumption of n-3 PUFAs has been associated
7with protection from obesity-related diseases in Yupik people (61, 62), yet information 
regarding whether the anti-obesity effects attributed to n-3 PUFA are dependent upon a 
specific genotype remains limited. This dissertation examined the contribution of 
interactions between n-3 PUFA intake and obesity candidate genes in a Yup’ik study 
population with up to 30-fold variation in n-3 PUFA intake. We selected the candidate 
genes based on a strategy that identified obesity candidate genes with 1) strong 
physiological evidence; 2) candidate genes implicated in obesity whole-genome linkage 
studies and known to be regulated by PUFAs; and 3) candidate genes reproducibly 
implicated in obesity genome-wide association studies.
1.10 CANDIDATE GENES
1.10.1 PHYSIOLOGY
We selected carnitine palmitoyltransferase 1A (CPT1A) as a candidate gene 
because this gene has a strong physiological role in regulating fatty acid oxidation in the 
liver and unique polymorphisms that are common among Eskimo/ Inuit populations (63). 
Impaired fatty acid oxidation is associated with obesity (64, 65) and may have 
consequences that include hepatic steatosis, hepatic insulin resistance, and impaired 
hepatic lipid handeling (66). Carnitine palmitoyltransferase 1 (CPT1) is a gene that 
controls mitochondrial fatty acid oxidation in skeletal, adipose, and liver tissue (67). 
Mammalian tissues express three CPT1 isoforms: CPT1A (liver), CPT1B (muscle) and 
CPT1C (brain), which are encoded on separate genes (68-70). Functional studies 
indicate that n-3 PUFA increase mitochondrial fatty acid oxidation, largely by stimulating 
the activity of CPT1 (71). A meta-analysis for obesity whole-genome linkage studies 
implicates the 1 lq region that harbors CPT1A as an obesity linked gene region harboring 
potential candidate genes (72).
1.10.2 WHOLE-GENOME LINKAGE STUDIES
We selected candidate genes for this part of our study from chromosomal regions 
that have been identified in three or more linkage studies and functional studies showing
8these genes are regulated by n-3 PUFAs. These three candidate genes included: stearoyl 
CoA desaturase (SCD), insulin sensitive glucose transporter (SLC2A4), and steroyl 
regulatory element binding protein (SREBF1).
SCD is the rate-controlling enzyme catalyzing the biosynthesis of 
monounsaturated fatty acids (MUFAs) from saturated fatty acid substrates (73). SCD1 
(mouse SCD homolog) deficiency in mice is associated with increased energy 
expenditure (74), reduced adiposity (75), increased insulin sensitivity (76), protection 
against hypertriglyceridemia (77), and elevated HDL levels (77). Consumption of n-3 
PUFA was associated with inhibition of SCD1 transcription in the liver (78) and 
adipocytes (79). Whole-genome studies in humans have demonstrated that the lOq 
region harboring the SCD gene is linked with obesity (80-82).
SLC2A4 codes for the glucose transporter (GLUT4) that is a specialized insulin- 
stimulated glucose transporter that regulates glucose uptake in skeletal muscle, heart, and 
adipose tissue (83). In the presence of insulin, GLUT4 is translocated to the cell 
membrane and facilitates glucose disposal (84). Inhibition of GLUT4 transport has been 
implicated in insulin resistance (85). Rodent studies show that n-3 PUFA intake increase 
GLUT4 transport (86) and GLUT4 protein levels (87, 88). Finally, whole-genome 
linkage studies have demonstrated the 17p region that harbors SLC2A4 is linked with 
obesity-related phenotypes that include plasma leptin (89), BMI (90) and plasma 
adiponectin levels (91).
SREBF1 is a transcription factor that plays a critical role in energy homeostasis by 
promoting glycolysis, lipogenesis, and adipogenesis (92). PUFAs influence the activity 
of SREBF1 by increasing SREBF1 mRNA turnover (93, 94). Whole-genome linkage 
studies have demonstrated the 17pll region harboring the SREBF1 gene is linked to 
obesity-related traits that include plasma leptin (89), BMI (90), and type 2 diabetes (95).
1.10.3 GENOME-WIDE ASSOCIATION STUDIES
We selected candidate genes for this part of our studies based on highly replicated 
SNPs that were identified in large-scale obesity GWAS. These candidate genes included:
9FTO, ETV5, NEGRI, TMEM18, GNPDA2, BDNF, MTCH2, SH2B1, MC4R mdKCD15.
In 2007, the first GWAS for T2D identified a SNP that was associated with BMI 
in the first intron of a gene called fat mass and obesity-associated protein (FTO) (15). 
FTO is a gene encoding a 2-oxoglutarate-dependent nucleic acid demethylase that is 
responsible for catalyzing the demethylation of 3-methylthymine in single-stranded DNA 
(96, 97). To date this is the most highly replicated obesity candidate gene (98). Candidate 
gene studies in European (99), African (100), and Asian (101) study populations have 
largely confirmed the association of FTO with BMI.
ETV5 is a transcription factor (ets variation 5) that is involved in a diverse range 
of developmental and pathogenic processes (102). In 2007, large-scale GWAS for 
obesity reported a SNP near ETV5 (rs7647305) that was associated with variation in BMI 
(17). Functional studies demonstrate that ETV5 knockout mice had reduced body weight 
compared to controls (103).
NEGRI (neuronal growth regulator 1) is a member of the immunoglobulin 
superfamily of cell adhesion molecules (104) that is highly expressed in the brain 
(hypothalamus) and adipose tissue (105). In 2009, large-scale GWAS for obesity 
reported a SNP in NEGRI (rs2815752) that was associated with variation in BMI (18). 
In mice, loss of NEGRI function in mice was associated with reduced body mass, 
relative to controls (106).
TMEM18 (iransmembrane protein 18) is transmembrane protein that expressed 
throughout the brain and involved with neural cell migration (107). In 2007, large-scale 
GWAS for obesity reported a SNP in TMEM18 (rs7561317) that was associated with 
variation in BMI (17). In rats, body weight was positively associated with expression of 
TMEM18 in the prefrontal cortex of the brain (108).
GNPDA2 (glucosamine-6-phosphate deaminase) is an enzyme that catalyzes the 
conversion of glucosamine-6-phosphate to fructose-6-phosphate (109). In 2009, large- 
scale GWAS for obesity reported a SNP in GNPDA2 (rs 10938397) that was associated 
with variation in BMI (18). Functional studies have yet to define the role of GNPDA2 in 
regulation of body weight.
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BDNF (brain-derived neurotrophic factor) is a member of the neurotrophic family 
of growth factors that is expresses throughout the central nervous system (110). In 2009, 
large-scale GWAS for obesity reported a SNP in BDNF (rs6265) that was associated with 
variation in BMI (18). Functional studies show that BDNF activity is associated with 
changes in eating behavior (111).
MTCH2 (mitochondrial carrier homolog 2) is a member of the mitochondrial 
carrier proteins that has been implicated in regulation of cell growth, motility, and 
tumorigenicity (112). In 2009, large-scale GWAS for obesity reported a SNP in MTCH2 
(rsl0838738) that was associated with variation in BMI (18). Functional studies have yet 
to define the role of MTCH2 in the development of obesity.
SH2B1 (SH2B adaptor protein) is an adapter protein for tyrosine kinase receptors 
that is highly expressed in skeletal muscles and ovaries (113). Several large-scale GWAS 
for obesity reported a SNP in SH2B1 (rs7498665) that was associated with variation in 
BMI (17, 18). In mice, SH2B1 is required for normal body weight maintenance and acts 
as an endogenous enhancer of leptin sensitivity (114).
MC4R (melanocortin 4 receptor) belongs to the melanocortin family of receptors 
that have been implicated in a wide range of physiological functions including energy 
homeostasis (115). In 2008, a large-scale GWAS reported a SNP in MC4R (rs1778213) 
was associated with BMI (16). Functional studies demonstrate that MC4R knockout 
mice are overweight (116).
KCD15 (potassium channel tetramerization domain containing 15) is a member of 
the volt-gated potassium channel proteins that maintain cellular membrane potential 
(117). In 2007, large-scale GWAS for obesity reported a SNP in KCD15 (rs29941) that 
was associated with variation in BMI (17). Functional studies have yet to define the role 
of KCD15 in the development of obesity.
1.10.3.1 CANDIDATE GENE SUMMARY
Numerous candidate genes have been implicated in obesity pathophysiology, 
however there is currently a lack of information that characterizes the interplay between
11
genetic factors and consumption of n-3 PUFA that may facilitate the choice of more 
effective and specific measures of obesity prevention based upon individualized genetic 
make-up.
1.11 DISSERTATION SPECIFIC AIMS
1) Determine whether single nucleotide polymorphism (SNPs) in obesity candidate 
genes were associated with obesity phenotypes in a Yup’ik study population.
2) Identify SNPs that interact with n-3 PUFA intake and modify the genetic 
associations with obesity phenotypes in a population with highly variable intake 
of n-3 PUFAs.
1.12 APPROACH
This dissertation will address the specific aims outlined above using CANHR data 
collected between 2003 and 2008. SNP selection was based on criteria that included: (1) 
maximally informative tagging SNPs within or near each obesity candidate genes using 
publicly available HapMap data, (2) previously identified SNPs that were associated with 
obesity-related phenotypes, and (3) SNPs identified by resequencing 30 unrelated Yup’ik 
participants enrolled in the CANHR study. Genetic associations and gene-diet interaction 
analyses were conducted using the program ASSOC (118) in the Statistical Analysis for 
Genetic Epidemiology (S.A.G.E. 2009) software package that can incorporate complex 
pedigree data, covariates and interactions into association analysis. Significance of 
association was evaluated at conventional significance levels (p<0.05) and multiple test 
correction was adjusted according to the number of non-redundant genetic markers.
1.13 DISSERTATION ORGANIZATION
In Chapter 2, I present a published manuscript where we examined a gene that 
controls hepatic lipid oxidation called carnitine palmitoyltransferase 1A (CPT1A). 
Chapter 3 presents a manuscript that examines genes regulated by n-3 PUFA intake that 
were implicated in multiple obesity whole-genome linkage studies. Chapter 4
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investigates candidate genes identified in multiple obesity genome-wide association 
studies (GWAS) using a genetic risk score. Chapter 5 presents the discussion and future 
direction.
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GENETIC POLYMORPHISMS IN CARNITINE PALMITOYLTRANSFERASE 1A 
GENE ARE ASSOCIATED WITH VARIATION IN BODY COMPOSITION AND 
FASTING LIPID TRAITS IN YUP’IK PEOPLE1
2.1 ABSTRACT
Variants of carnitine palmitoyltransferase 1A (CPT1A), a key hepatic lipid oxidation 
enzyme, may influence how fatty acid oxidation contributes to obesity and metabolic 
outcomes. CPT1A is regulated by diet, suggesting interactions between gene variants and 
diet may influence outcomes. The objective of this study was to test the association of 
CPT1A variants with body composition and lipids, mediated by consumption of 
polyunsaturated fatty acids (PUFAs). Obesity phenotypes and fasting lipids were 
measured in a cross-sectional sample of Yup’ik individuals (n=l 141) from the Center of 
Alaska Native Health Research (CANHR) study. Twenty-eight tagging CPTIA SNPs 
were evaluated with outcomes of interest in regression models accounting for family 
structure. Several CPTIA polymorphisms were associated with HDL-cholesterol and 
obesity phenotypes. The P479L (rs80356779) variant was associated with all obesity- 
related traits and fasting HDL-cholesterol. Interestingly, the association of P479L with 
HDL-cholesterol was still significant after correcting for either BMI, percent body fat 
(PBF), and waist circumference (WC). Our findings are consistent with the hypothesis 
that the L479 allele of the CPTIA P479L variant confers a selective advantage that is 
both cardio-protective (through increased HDL-cholesterol) and associated with reduced 
adiposity.
1 Lemas, DJ, Weiner HW, O’Brien DM, Hopkins S, Stanhope KL, Havel PJ, et al. 2012. 
Genetic Polymorphisms in Carnitine Palmitoyltransferase 1A Gene are Associated with 
Variation in Body Composition and Fasting Lipid Traits in Yup’ik People. Journal of 
Lipid Research. January l;53(l):175-84.
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2.2 INTRODUCTION
Obesity is associated with a series of metabolic conditions clinically referred to as 
metabolic syndrome, which includes hypertension, dyslipidemia, hyperglycemia, and the 
development of type 2 diabetes (T2D). Approximately sixty percent of obese individuals 
have metabolic complications (1), however “healthy obese” individuals have been 
identified with excessive accumulation of body fat that does not translate to dyslipidemia 
and insulin resistance (2, 3). For example, some Eskimo/Inuit people indigenous to 
Alaska are obese, but have historically demonstrated low prevalence of insulin resistance, 
metabolic syndrome, and T2D (4—7). Specifically, Yup’ik people living in Southwest 
Alaska have obesity prevalence comparable to the general US population, yet the 
prevalence of metabolic syndrome (8) and T2D (9) is significantly less than that observed 
in the general US population (10, 11). Although the mechanisms that allow Yup’ik 
people to carry excess body fat without developing features of metabolic syndrome and 
T2D are unknown, dietary and genetic factors are likely to be relevant (12, 13). Because 
weight loss as a treatment for obesity related co-morbidities is difficult to achieve and 
maintain (14-17), understanding the underlying mechanisms that protect this population 
from features of metabolic syndrome despite their adiposity would have implications for 
treatment of obesity without the necessity of weight loss.
It has been proposed that the ‘healthy obesity’ observed in Yup’ik individuals is 
in part related to exposure to a diet rich on n-3 polyunsaturated fatty acids (n-3 PUFAs) 
(18, 19). n-3 PUFAs consumed by Yup’ik people are principally composed of 
eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), and PUFA intake is 20 times 
greater than the current mean intake of the general US population (4.1 ± 0.5 g/day versus 
0.05 g/day in men and 2.8 ± 0.3 g/day versus 0.09 g/day in women) (20, 21). Cross­
sectional studies in a Yup’ik population offer a unique opportunity to examine the 
association of elevated n-3 PUFA exposure with body composition, fasting lipids and 
lipoprotein levels. Studies in both animals and humans have demonstrated that EPA and 
DHA impact body composition and circulating fasting lipid levels by modulating gene 
expression to favor increased fatty acid oxidation and reduction of fat deposition (22).
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Evidence that elevated n-3 PUFA consumption has a direct influence on ‘healthy’ obesity 
remains inconclusive (12, 13) and warrants experimental designs which evaluate gene- 
diet interactions that may mediate this effect in populations with elevated daily dietary 
intake of n-3 PUFA.
Mitochondrial carnitine palmitoyltransferase 1 (CPT1), a member of the carnitine 
palmitoyltransferase family, is a gene that controls fatty acid oxidation in skeletal, 
adipose, and liver tissue (23). Fatty acid oxidation is often impaired in the obese 
condition (24, 25), which may contribute to hepatic steatosis, hepatic insulin resistance, 
and impaired hepatic lipid handeling (26). CPT1 as a major control point for fatty acid 
oxidation may therefore be a key player in “healthy obesity”, especially if certain single 
nucleotide polymorphisms (SNPs) are resistant to impaired fatty acid oxidation which 
often accompanies obesity. Interestingly, n-3 PUFA increases mitochondrial fatty acid 
oxidation by stimulating the activity of CPT1 (27), the interaction between n-3 PUFAs 
and SNPs in CPT1 may improve lipid profiles.
Mammalian tissues express three CPT1 isoforms: CPTIA (liver), CPT1B (muscle) 
and CPT1C (brain), which are encoded on separate genes (28-30). In the presence of L- 
camitine, CPT1 facilitates the transfer of long-chain fatty acids (LCFA) across the 
mitochondrial membrane for (3-oxidation (31). Mitochondrial (3-oxidation of dietary and 
endogenous LCFA is tightly regulated through allosteric inhibition of CPT1 by malonyl- 
CoA, an intermediate in fatty acid synthesis (32). In liver cells, the partnership between 
malonyl-CoA and CPTIA has been shown to be a key regulatory point that modulates the 
oxidation of dietary and endogenous LCFA (33). Although, CPTIA is a candidate gene 
for obesity (34) and CPTIA SNPs are associated with elevated fasting HDL-cholesterol 
levels (35); it is unknown whether the interactions between n-3 PUFA intake and CPTIA 
SNPs influence changes in body composition and fasting lipids.
In this study we tested the hypothesis that SNPs within or near the CPTIA gene 
are associated with body composition and fasting lipid phenotypes in a large cross 
sectional cohort of Yup’ik people, a population whose daily dietary intake involves 30-
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fold range of exposure of n-3 PUFA, and examined whether these associations were 
modified by n-3 PUFA intake.
2.3 PARTICIPANTS & METHODS
2.3.1 PARTICIPANTS AND STUDY DESIGN
The Center for Alaska Native Health Research (CANHR) studies genetic, 
behavioral, and dietary risk factors underlying obesity and their relationship to diabetes 
and cardiovascular disease among Yup’ik people (9). A community-based participatory 
research framework guides all CANHR investigations, such that participant 
ascertainment is open to all members of the community meeting a specified age 
minimum. Recruitment of Yup’ik participants was initiated in 2003 and continues in 11 
Southwest Alaska communities. All residents 14 years of age and older are invited to 
participate and the resulting distribution of age in our study sample reflects the age 
distribution among eligible participants according to 2000 U.S. census data. Participants 
sign informed-consent documents before entering the study using protocols that were 
approved by the University of Alaska Institutional Review Board, the National and 
Alaska Area Indian Health Service Institutional Review Boards, and the Yukon- 
Kuskokwim Health Corporation Human Studies Committee. The analyses in this report 
were performed on 1141 non-pregnant Yup’ik participants with ages that ranged between 
14 and 94 years at the time of enrollment.
2.3.2 ANTHROPOMETERIC AND BIOCHEMICAL MEASUREMENTS
Anthropometric measurements were obtained by trained staff using protocols 
from the NHANES III Anthropometric Procedures Manual (36) as previously described 
(8). These measurements included height, weight and 4 circumferences (waist, hip, 
triceps, and thigh). Percent body fat (PBF) was measured by electrical bioimpedance 
using a Tanita TBF-300A body composition analyzer (Tanita Corp, Arlington Heights, 
IL, U.S.A.). Blood samples were collected from participants after an overnight fast, and 
lipoprotein measures including total cholesterol, HDL-cholesterol, LDL-cholesterol,
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VLDL-cholesterol, apolipoprotein Al and plasma triglycerides levels were assayed as 
previously described in Boyer et al (8).
2.3.3 BIOMARKER FOR MARINE n-3 PUFA INTAKE
n-3 PUFA intake was assessed in Yup'ik individuals using the nitrogen stable 
isotope ratio (81SN) of red blood cells (RBC) as previously described (37). RBC aliquots 
were autoclaved for 20 minutes at 121° C to destroy blood-borne pathogens, and samples 
were weighed into 3.5 x 3.75 mm tin capsules and freeze dried to a final mass of 0.2 - 0.4 
mg. Samples were analyzed at the Alaska Stable Isotope Facility by continuous-flow 
isotope ratio mass spectrometry, using a Costech ECS4010 Elemental Analyzer (Costech 
Analytical Technologies, Valencia, CA, USA) interfaced to a Finnigan Delta Plus XP 
isotope ratio mass spectrometer via the Conflo III interface (Thermo-Finnigan Inc., 
Breman, Germany). Isotope ratios are analyzed relative to IAEA-certified reference 
materials calibrated to atmospheric nitrogen, for which 15N /14N = 0.0036765. By 
convention and for ease of interpretation, isotope ratios are presented as delta values in 
“permil” relative to atmospheric nitrogen: 815N  = [(15N /14Nsampie -  15N /14N standaid)/( 
15N /14N standaid)] ' 1000%o. We concurrently prepared and ran multiple laboratory 
standards (peptone, S15N  = 7.00) to assess analytical accuracy and precision; these were 
analyzed after every eighth sample and gave values of 815N  = 7.01 ± 0.24%o (mean ± 
SD). The range of isotopic variation in our dataset (9%o) was very large relative to 
analytical precision (0.2%o). We modeled the effects of n-3 PUFA intake as a categorical 
variable, which is hereafter referred to as 815N.
2.3.4 SNP SELECTION AND GENOTYPING
A comprehensive list of DNA variants were selected for genotyping within and 
near (5 kb upstream and 5 kb downstream) the CPTIA gene collected from HapMap data, 
release #3, National Center for Biotechnology Information (NCBI) B36, dbSNP 126 (38). 
Given that no publically available genotypic information exists on Yup’ik people, we 
referenced the Caucasian (CEU) and Han Chinese (CHB) populations in HapMap using
30
the SeattleSNPs database (http://pga.mbt.washington.edu/) to identify potential genetic 
variants that may be common in our study population. A set of 27 maximally informative 
tagging SNPs (tSNPs) were selected to represent common linkage disequilibrium clusters 
with the LDselect algorithm as implemented in the MultiPop-TagSelect program using 
thresholds of ^=0.80 and minor allele frequency >1% (39, 40). We chose to relax our 
MAF criteria to include SNPs with MAF >0.01 in order to genotype tagging SNPs in the 
CPT1A gene which may be common (MAF>0.05) in Yup’ik people despite being rare 
(MAF<0.05) in CEU and CHB populations. We also included the non-synonymous 
P479L (rs80356779) CPT1A SNP for genotyping based on previous associations with 
elevated plasma HDL-cholesterol and apolipoprotein A1 levels in the Greenland Inuit 
(35). Genotyping of the 28 SNPs including P479L was carried out by allele-specific 
primer extension of multiplex amplified products and detection using matrix-assisted 
laser desorption ionization time-of-flight spectrometry on a Sequenom iPLEX platform at 
the Broad Institute (41). Linkage disequilibrium (LD) among SNPs was based on 
pairwise haplotype frequencies calculated using the hapfreq command in the FBAT 
program (42).
2.3.5 QUALITY CONTROL OF PHENOTYPIC AND GENOTYPIC DATA
Simple linear models were fit to each of the outcome variables using all of the 
covariates (age, sex, community membership) included in the association models, and the 
distributions of the residuals were examined for normality with the R statistical 
programming language (v2.10.1, R Development Core 2009). Box-Cox transformations 
were applied to traits whose residuals did not follow a normal distribution (43). Family 
data was extracted from a Progeny database (Progeny Software LLC, South Bend, IN, 
U.S.A.) and merged into a single extended pedigree using PedMerge (44). Genotypic 
data were tested for Mendelian inconsistencies using PEDCHECK (45). In this sample, 
Illumina IV linkage panel (Illumina, Inc., San Diego, CA, USA) genotypes were 
available from ongoing linkage study and were used to construct principal components of 
ancestry (PCA) using the PCA program in the EIGENSTRAT analysis package (46).
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The second PCA discriminated the individuals in the study into two groups that 
correspond to the proximity of the community to the coast. Based on this observation, 
we defined a dichotomous community group variable. We assessed Hardy-Weinberg 
equilibrium (HWE) using PLINK (vl.07) (47) and determined allele frequencies for each 
SNP using the FREQ module in the program Statistical Analysis for Genetic 
Epidemiology (S.A.G.E 2009). The present study restricted analysis to only include SNPs 
with MAF > 5% that did not deviate from HWE after Bonferroni correction (p<0.002).
2.3.6 ASSOCIATION ANALYSIS
Each SNP was tested for association with obesity-related phenotypes using the 
program ASSOC (48) in the S.A.G.E software package that can incorporate complex 
pedigree data, covariates and interactions into association analysis. We included both 
demographic (age, community, and sex) and environmental variables (815N) in the 
ASSOC analysis. Likelihood ratio statistics were calculated to compare 3 nested models 
and test the null hypothesis of no association between CPTIA SNPs and obesity traits 
after including demographic and environmental covariates. Effect sizes (P) were 
presented as the change in transformed phenotypes according to minor allele that was 
determined in a linear model adjusted for demographic and environmental covariates.
Model 1 included baseline covariates (age, sex, community membership, and 815N 
quartiles); Model 2 included baseline covariates and SNP to test for an additive genetic 
effect of SNP (defined as the number of minor alleles); and Model 3 included baseline 
covariates, the additive genetic effect of SNP, and interactions between the additive 
genetic effect and 815N quartiles. Note that the model 3 is the only model to test directly 
gene-diet interaction under the null hypothesis. We have treated each phenotype being 
tested as representing a separate family of null hypotheses and correct for the number of 
tests within each family (49). Multiple test correction to control the familywise error rate 
was calculated according to the number of non-redundant SNPs with MAF >0.05 that 
were tested for association and interaction. Given the correlation among neighboring
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genetic markers, the effective numbers of non-redundant SNPs in this study was 
estimated using spectral decomposition of LD matrices (50, 51).
2.4 RESULTS
2.4.1 CHARACTERISTICS OF YUP’IK PARTICIPANTS
General clinical characteristics and descriptive statistics on Yup'ik men and 
women are presented in Table 2.7.1. Yup'ik women in this study had a mean age of 37.6 
(± 17.3) years and men reported a mean age of 35.9 (±17.3) years. Women had 
significantly greater BMI, percentage body fat, hip circumference, fasting total 
cholesterol, HDL-cholesterol, and ApoAl levels compared to men (p<0.05). According 
to the standard cut-off points for overweight (BMI 25-29.9 kg/m2) and obese (BMI >30 
kg/m2), 28.6% of women and 30.7% of men were overweight while 37.0% of women and 
7.9% of the men were classified as obese.
2.4.2 DISTRIBUTION OF 815N IN STUDY POPULATION
In 1138 Yup'ik participants, we assessed n-3 PUFA intake using RBC 815N as a 
biomarker of EPA and DHA intake. Summary statistics grouped by gender and 8,5N 
quartiles are reported in Table 2.7.2. The mean 8,SN value was 9.0%o with a range of 
6.2%o-15.2%o. This range was large relative to analytical precision (0.2%o) and was 3.75 
times greater than the RBC (clot) 815N values previously reported for a random sample of 
US residents (52). According to the linear relationship between RBC 815N and RBC EPA 
reported elsewhere for this population (37), the corresponding mean EPA (% RBC fatty 
acids) was 2.66% with a range of ~0%-9.1%. Measurement of 8,5N by gender yielded 
means of 9.1%o for females and 8.8%o for males. The mean RBC 815N values by quartile 
were: 7.3%o, 8.2%o, 9.1%o, and 11.0%o in quartiles 1-4 respectively. These values 
correspond to EPA (% RBC fatty acids) quartile means of: 0.9%, 1.8%, 2.8%, and 4.7% 
(37). The standard deviation of 81SN in this sample did not differ by gender (1.5%o for 
both females and males).
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2.4.3 GENETIC VARIATION IN THE CPTIA GENE
DNA was available in 1141 Yup’ik participants and the mean number of 
individuals successfully genotyped was 1078 (range of 986-1137, depending on the 
SNP). Twenty-eight CPTIA SNPs were genotyped with a mean success rate of 94.7% 
(range 76.1-99.7%). In this sample, 4 SNPs were monomorphic, 12 SNPs had MAF 
<0.05 and >0.01, and 12 SNPs had MAF > 0.05. Genotyping results for SNPs with MAF 
>0.05 are presented in Table 2.7.3. The rs2924697 SNP (MAF=0.28) was the only 
polymorphism with MAF >0.05 that deviated significantly from Hardy-Weinberg 
proportions and was excluded from the analysis. The non-synonymous P479L SNP was 
common in our sample and the major L479 allele had a frequency of 0.74. We selected 
the 11 CPTIA SNPs with MAF > 0.05 that did not deviate from HWE proportions for 
genetic analysis (Table 2.7.3). The spectral decomposition of LD matrix (51) estimated 
that 8 of the 11 markers with MAF >0.05 were non-redundant genetic markers and 
corrected our analysis for 8 tests, setting the per-test a level to <0.0063 (two-tailed).
2.4.4 CPTIA SNPS AND FASTING LIPID PARAMETERS
The results of association analysis between fasting lipid traits and CPTIA SNPs 
with MAF > 0.05 are summarized in Figure 2.6.1 and Table 2.7.4. HDL-cholesterol was 
significantly associated with 7 SNPs: rs2278908 (p=0.0007, P=-2.3, SE=0.7), rs3019598 
(p=0.0014, p=-2.2, SE=0.7), P479L (p=0.0001, p=-1.0, SE=0.3), rsl 1228372 (p=0.0013, 
P=-1.2, SE=0.4), rsl 1228373 (p<0.0001, p=-1.3, SE=0.3), rs3019594 (p<0.0001, p=-1.4, 
SE=0.3) and rs597316 (p=0.0014, p=-2.2, SE=0.7). The rsl 1228373 and rs3019594 
SNPs were also significantly associated with ApoAl (p=0.0014, P=-l.l, SE=0.4; and 
p=0.0008, P=-1.2, SE=0.4, respectively), and total cholesterol (p=0.0063, p=-0.7, 
SE=0.2; and p=0.0031, P=-0.7, SE=0.2, respectively) (Table 2.7.4). Note that 
rsl 1228373 and rs3019594 are in moderately strong LD (^=0.75). The P479L variant 
was also associated with HDL-cholesterol (p=0.0001) and was not in strong LD with 
either the rsl 1228373 (r^O.58) or rs3019594 (i^=0.61) SNPs (Supplementary Table
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2.9.1). Our model predicted that individuals homozygous for the common allele (L479) 
of P479L had elevated fasting HDL-cholesterol levels compared to individuals 
homozygous for the P479L minor allele (P479) (Table 2.7.6). After adjusting Model 2 
for BMI, the CPT1A SNPs (rs2278908, rs3019598, P479L, rsl 1228373, rs3019594, and 
rs597316) associated with fasting total cholesterol, HDL-cholesterol, ApoAl were still 
significant (Supplementary Table 2.9.2),
2.4.5 CPT1A SNPS AND OBESITY PHENOTYPES
The results of association analysis between obesity traits and CPT1A SNPs with 
MAF > 0.05 are summarized in Figure 2.6.2 and Table 2.7.5. Thigh circumference was 
associated with 7 SNPs: rs2278908 (p=0.0024, p=2.1, SE=0.7), rs2278907 (p=0.0002, 
P=1.9, SE=0.5), P479L (p<0.0001, p=1.2, SE=0.3), rs4930248 (p=0.0042, p=1.3, 
SE=0.5), rsl 1228372 (p=0.0011, p=1.3, SE=0.4), rsl 1228373 (p=0.0006, p=l.l, 
SE=0.3), and rs3019594 (p=0.0001, P=1.3, SE=0.3). Hip circumference was associated 
with 5 SNPs: rs2278907 (p=0.0057, p=1.2, SE=0.4), P479L (p<0.0001, P=0.9, SE=0.2), 
rsl 1228372 (p=0.0034, p=0.9, SE=0.3), rsl 1228373 (p=0.0063, p=0.7, SE=0.3) and 
rs3019594 (p=0.0005, p=0.9, SE=0.3).
The P479L SNP and rs3019594 (^=0.61 between these SNPs) were SNPs most 
significantly associated with both thigh circumference and hip circumference (p<0.0001 
and p=0.0034, respectively). The P479L SNP was the only SNP associated with all 
obesity measures that included BMI (p=0.0021, P=0.7, SE=0.2), percentage body fat 
(p=0.0007, p=0.0007, SE=0.2), hip circumference (p<0.0001, P=0.9, SE=0.2), thigh 
circumference (p<0.0001, P=1.2, SE=0.3), and waist circumference (p=0.0006, P=1.0, 
SE=0.3). Individuals homozygous for the common P479L allele (L479) have a lower 
percentage body fat, smaller BMI, and reduced thigh, hip, and waist circumferences 
compared to P479 homozygotes (Table 2.7.6).
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2.5 DISCUSSION
CPTIA has been implicated as candidate obesity gene in a meta-analysis of 
whole-genome linkage studies (34); however the contribution of CPTIA polymorphisms 
to variation in the metabolic consequences of obesity and obesity phenotypes remains 
unclear. Our results demonstrate that CPTIA polymorphisms are associated with obesity 
and fasting lipid phenotypes in this Yup’ik study population and may influence the 
‘healthy obesity’ phenotype. Specifically, the P479L SNP was associated with all 
measures of body composition (BMI, PBF, HC, ThC and WC) and fasting HDL- 
cholesterol levels. We found that individuals homozygous for the major L479 allele of 
the P479L variant had reduced body fat and central adiposity relative to individuals 
homozygous for the minor P479 allele. These data indicate that individuals carrying both 
copies of the L479 allelle of the non-synonomous P479L variant in CPTIA have reduced 
adiposity and elevated HDL-cholesterol, even after controlling for BMI. Interestingly, 
when we investigated whether the P479L association with HDL was mediated by other 
obesity phenotypes, we found die L479 allele was still significantly associatied with 
HDL-cholesterol after correction for either PBF and WC (Supplementary Table 2.9 J ) . 
We hypothesize that the L479 allele may contribute to ‘healthy obesity’ observed in 
Yup’ik people by modulating hepatic lipid oxidation.
Three studies have previously investigated the influence of CPTIA 
polymorphisms on obesity and lipid phenotypes in humans (35, 53, 54). Hirota and 
colleagues (53) found no association between CPTIA polymorphisms and obesity or 
fasting lipid phenotypes in Japanese individuals with T2D. In a cross-sectional cohort of 
French-Canadians, Robitaille et al. reported an association between the non-synonymous 
A275T (rsl7610395) SNP with BMI (p=0.05) and waist circumference (p=0.008) only 
after accounting for dietary fat intake (54). Finally, in Greenland Inuit, Rajakumar et al. 
showed the L479 allele in the non-synonymous P479L variant was associated with 
elevated fasting HDL-cholesterol and ApoAl levels (35).
The present study found an association between SNPs (rs2278908, rs3019598 and 
rs597316) investigated by Hirota et al. with fasting HDL-cholesterol and replicated the
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P479L association with fasting HDL-cholesterol and ApoAl levels reported by 
Rajakumar et a l We have shown that these SNPS were still significantly associated with 
HDL-cholesterol and ApoAl after controlling for either BMI, PBF, or WC. Furthermore 
we used a log likelihood ratio test to determine whether the P479L SNP association with 
HDL-cholesterol and ApoAl was independent of the rsl 1228373 and rs3019594 
SNPs. We found that both rsl 1228373 and rs3019594 SNPs were still significant 
predictor for HDL-cholesterol and ApoAl levels even when P479L was already in the 
model. Given that the rsl 1228373 and rs3019594 SNPs were in moderately strong 
linkage disequilibrium with P479L as measured by r2 (^=0.58 and 0.61, respectively), we 
cannot rule out the possibility that the apparent association with P479L is not due to a 
true association with either rsl 1228373 or rs3019594 or both.
We extend the findings of Rajakumar et al to show the L479 allele of P479L is 
also associated with reduced adiposity in an independent Eskimo/Inuit population. 
Interestingly, our analysis did not replicate the A275T (rsl7610395) association with 
BMI and WC reported by Robitaille et al because this SNP was not included in the 
analysis due to a low MAF (MAF=0.02). Factors which may account for differences in 
results reported in the present study may include, but are not limited to, differences in 
statistical analysis, small sample size and population stratification (SS). Our study, 
however, benefited from a sample size large enough to detect significant SNP 
associations and we used a statistical approach that accounts for family structure while 
allowing for covariates.
Our Yup’ik study population was ideally suited to investigate the contribution of 
n-3 PUFA and genetic factors to ‘healthy obesity’ due to the 30-fold range of EPA and 
DHA consumption (20) which can be precisely estimated in large samples using nitrogen 
stable isotope ratios from red blood cell samples (37). When we examined whether the 
interaction between n-3 PUFA intake and CPT1A SNPs modifies the association with 
‘healthy obesity’ phenotypes (Supplementary Table 2.9.4), we did not find significant 
gene-diet interactions that modified the association with body composition. Interestingly, 
interactions between n-3 PUFA intake and rs3794020 and rs2305508 were associated
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with HDL-cholesterol and ApoAl levels, whereby n-3 PUFA intake enhanced the 
positive association of rs3794020 and rs2305508 minor alleles on these traits. Although 
n-3 PUFA interactions with genetic factors have received considerable attention, our 
results should be interpreted with caution given the sample size and nominal significance.
We hypothesize that the observed association between the P479L variant on body 
composition and fasting lipid phenotypes in the presence of n-3 PUFA intake, may in part 
explain the presence of a ‘healthy obese’ phenotype among Yup’ik people. In humans, 
low rates of endogenous lipid oxidation are associated with obesity (25) and mechanisms 
that alter an individual’s metabolic profile in favor of fatty acid oxidation have been 
suggested to reduce the accumulation of body fat (56). Consumption of n-3 PUFA 
increases hepatic fatty acid p-oxidation, primarily through activity of CPTIA (57, 58). 
Functional studies in fibroblast cells have demonstrated that the L479 allele of P479L 
variant in CPTIA results in a CPTIA enzyme with diminished catalytic activity 
compared to control cells (59). However, expression of the L479 allele in fibroblasts was 
also shown to abolish the ability of malonyl-CoA to inhibit CPTIA (59). Interestingly, 
these data are consistent with a study in rats demonstrating that malonyl-CoA-insensitive 
CPTIA was more effective than overexpression of wild-type CPTIA at oxidizing lipid 
substrates (33). Therefore, in the presence of n-3 PUFAs, there may be a net increase in 
the basal activity of CPTIA among individuals carrying the L479 allele and fatty acids 
normally packaged in the liver as VLDL will instead be oxidized in the hepatocyte (60). 
Taken together, we hypothesize that the combined effects of n-3 PUFA intake and the 
high frequency of the P479L variant in Eskimo/ Inuit populations may influence ‘healthy 
obesity’ phenotypes primarily through reduced hepatic VLDL formation and subsequent 
reductions of plasma triglycerides and VLDL. This model is consistent with our 
observations that obese Yup’ik people with high intake of n-3 PUFAs have low 
triglyceride levels, reduced c-reactive protein levels (13), and high circulating HDL- 
cholesterol levels (12), suggesting that n-3 PUFAs may protect from chronic disease in 
the presence of obesity.
38
CPU A deficiency has been associated with risk for hypoketotic hypoglycemia, 
hepatic encephalopathy, and sudden infant death syndrome (61-64), as well as muscle 
cramps, vomiting, and occasional loss of consciousness (59, 65). Nevertheless, the high 
frequency of the L479 allele in Inuit and Yup’ik people suggested to us, and several 
others, that it may confer a selective advantage (60, 65, 66). We hypothesized that 
genetic variants in CPT1A may be associated with obesity because of the central role of 
the CPU A enzyme in fatty acid oxidation. Our results and those of Rajakumar and 
colleagues(35) are consistent with a cardio-protective role of the L479 allele of P479L 
through its association with elevated HDL-cholesterol levels. In this study, we have also 
shown that genetic variants of CPT1A are associated with reduced adiposity and we have 
replicated the association of elevated fasting HDL-cholesterol and ApoAl levels with 
carriers of the L479 allele in this Yup’ik study population. Furthermore, we found that 
CPT1A SNPs associated with HDL-cholesterol and ApoAl levels were independent of 
obesity as measured by BMI, PBF, and WC. The P479L variant was not in strong LD 
(^>0.8) with any other CPT1A polymorphisms associated with body composition and 
fasting lipid parameters and suggests that the P479L may have a causal role in ‘healthy 
obesity.’ Although we cannot exclude the possibility that other variants are in strong LD 
with the P479L, our data suggest that the P479L variant in CPT1A increases hepatic fatty 
acid oxidation and may contribute to ‘healthy obesity’ observed in this Yup’ik study 
population. Functional genomic studies of the CPT1A variant and its modulation by n-3 
PUFA intake, in addition to further investigation of the CPT1A gene in epidemiological 
studies among Arctic populations with variable n-3 PUFA intake will be required to 
validate the larger public health impact of these results. This study lays the foundation for 
future population-specific dietary recommendations based-on gene-diet interactions.
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2.6 FIGURES
CPTIA polymorphisms w ith MAF 2596
Figure 2.6.1: CPTIA polymorphisms with MAF > 5% associated with obesity phenotypes. 
Association of CPTIA SNPs in a linear regression model adjusted for age, sex, community 
membership, and n-3 PUFA intake. The red line represents multiple test correction 8 tests that were 
estimated using the spectral decomposition of LD matrix (SI). Total cholesterol (Choi), high-density 
lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density lipoprotein (LDL), very-low density 
lipoprotein (VLDL) and triglycerides (TG).
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Figure 2.6.2: CPT1A polymorphisms with MAF > 5% that are associated with obesity phenotypes. 
Association of CPT1A SNPs in a linear regression model adjusted for age, sex, community 
membership, and n-3 PUFA intake. The red line represents multiple test correction 8 tests that were 
estimated using the spectral decomposition of LD matrix (51). Body mass index (BMI), percent body 
fat (PBF), hip circumference (HC), thigh circumference (ThC) and waist circumference (WC).
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2.7 TABLES
Table 2.7.1: Description of obesity-related traits in Yup’ik people1’2.
Variables Women Men p-values
No. of participants 601 539
Age (yrs) 37.6 ±17.3 35.9 ±17.4 0.1113
Height (cm) 156.1 ±6.2 167.7 ±7.0 <0.0001
Weight (kg) 69.8 ±16.7 73.0 ±15.6 0.0003
Obesity Measures
BMI (kg/m*) 28.7 ± 6.8 25.9 ±4.8 <0.001
Percentage Body Fat (%) 35.1 ±8.9 21.1 ±8.0 <0.0001
Waist Circumference (cm) 90.4 ±15.9 89.2 ± 14.0 0.2102
Hip Circumference (cm) 104.1 ±12.8 96.7 ± 8.3 <0.0001
Thigh Circumference (cm) 51.1 ±5.6 50.2 ±5.4 0.0071
Lipid Measures
Cholesterol (mg/dL) 216.4 ±44.6 208.9 ± 48.0 0.0088
HDL (mg/dL) 64.8 ± 18.5 56.2 ±15.4 <0.0001
Apoiipoprotein A l (mg/dL) 170.8 ±26.7 159.5 ±26.8 <0.0001
LDL (mg/dL) 134.9 ±36.5 135.9 ±40.2 0.5500
VLDL (mg/dL) 16.9 ±8.8 17.3 ± 10.6 0.4760
Triglyceride (mg/dL) 83.6 ±42.8 84.8 ± 52.5 0.5967
1 Values are reported as mean (± SD).
2 Differences by gender are derived using student t-test.
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Table 2.7.2: RBC nitrogen stable isotope ratio (SlsN) in Yup’ik people1,2
Sex Quartiles of 8'*N
Total Women Men Q1 Q2 Q3 Q4
No. of participants 1138 598 540 272 278 290 298
Mean ± SD (%•) 9.0 ±1.5 9.1 ±1.5 8.8 ±1.5 7.3 ±0.3 8.2 ±0.2 9.1 ±0.3 11.0 ±1.0
Maximum 15.2 15.2 13.5 7.8 8.6 9.8 15.2
Minimum 6.2 6.3 6.2 6.2 7.8 8.6 9.8
Range (X.) 9.0 8.9 7.3 1.6 0.81 1.2 5.4
'isotope ratios are presented as delta values in “permil” relative to atmospheric nitrogen: 8I5N = [(l5N/14NHmpic -
15N/14Nw*urt)/( 15N/14N «Ktard)]' 1000%,.
2The relationship between 815N and EPA follows the linear model: EPA (%RBC fatty acid) =1.04 • 8ISN -  6.7%o, 
as previously described for this population (37).
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Table 2.7.3: CPTIA polymorphisms with MAF >0.05.
SNP1 Allele2 MAF3 Genotype4 Individuals3Genotyped
HWE4
p-values
AA AB BB
rs2278908 C/T 0.06 2 40 1024 1066 0.1004
rs2278907 AJG 0.09 9 54 1074 1137 0.0270
rs3019598 G/A 0.05 2 37 1011 1050 0.0664
P479L (rs80356779) A/G* 0.26 44 272 759 1075 0.1080
rs2305508 C/T 0.47 158 507 407 1072 0.7469
rs4930248 T/C 0.10 10 88 974 1072 0.0369
rs3794020 C/T 0.34 103 447 461 1011 1
rs2924697 G/C 0.28 1 533 452 986 0
rsl1228372 G/A 0.14 7 158 906 1071 1
rsl 1228373 G/C 0.20 27 192 913 1132 0.0077
rs3019594 C/T 0.21 26 185 861 1072 0.0120
rs597316 G/C 0.05 1 42 1026 1069 0.4096
'Seattle SNPs Genome Variation Server on March 2008 (dbSNP build 126) Version 5.01.
2Major/ Minor allele.
3MAF computed using FREQ module in S.A.G.E.
4AA=Homozygous Recessive for minor allele, AB= Heterozygous, BB=Homozygous Dominant allele, 
dumber of individuals genotyped for each CPTIA SNP.
®HWE p-values computed using PLINK.
The P479L SNP is an A —» G missense mutation at nucleotide position c.1436 of CPTIA which results in 
the substitution of a conserved proline (P479) for a leucine (L479) at position 479 in the CPTIA 
polypeptide.
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Table 2.7.4: CPT1A polymorphisms associated with fasting lipids1,2
Lipid Measures
SNP Choi HDL ApoAl LDL VLDL TG
ra2278988 0.0842 8.8807 0.0501 0.9124 0.9449 0.8209
(D--0.9, SE-0.5) (P--2.3, SE-0.7) (P—-1.5, SE-0.8) (PMI.l, SE-0.7) (0—0.1, SE-0.8) (P-0.2, SE-0.8)
ra2278987 0.1478 0.0335 0.4893 0.7316 0.4551 0.7217
(P=-0.6, SE-0.4) (PM .0, SE=0.5) (PMJ.4, SE-0.6) (PM).2, SE-0.5) (P-0.4, SE-0.6) (P—-0.2, SE-O.5)
r»3019598 0.1357 0.0814 0.2382 0.9588 0.9073 0.7069
(P-O.8, SE=0.6) (P—2.2, SE-0.7) (P--1.0, SE-0.8) (P-0.0, SE-0.7) (B-0.1, SE-0.8) (P-0.3, SE-0.8)
P479L 0.0834 8.0801 0.0077 0.6629 0.6355 0.1407
(rsW356779) (PM).4, SE-O.2) (P—1.0, SE-0.3) (PM).8, SE-0.3) (P--0.1, SE-0.3) (P-0.1, SE-0.3) (P-0.4, SE-0.3)
rs23055*8 0.0321 0.6052 0.0520 0.0250 0.7030 0.2284
(PM1.4, SE-O.2) (P=0.1, SE=0.2) (P=0.5, SE=0.2) (P--0.5, SE-0.2) (P--0.1, SE-0.2) (P--0.3. SE-0.2)
rs4930248 0.0912 0.2834 0.9245 0.4413 0.8735 0.9755
(BM).6, SE=0.4) (PM1.5. SE-0.4) (0=0.1, SE-0.5) (P--0.3, SE-0.4) (PM).l, SE-O.5) (P-0.0, SE-0.5)
rs3794*20 0.5539 0.2261 0.0132 0.2244 0.7530 0.6833
(P--0.1, SE-0.2) (P-0.3, SE-0.2) (P=0.7, SE-0.3) (P--0.3, SE-0.2) (P-0.1. SE-0.3) (PM).l, SE-0.3)
r s l1228372 0.0139 0.0813 0.0150 0.2982 0.6986 0.6246
(P=-0.7, SE-0.3) (8--1A  SE-0.4) (P=-l,l, SE=0.4) (P—-0.4, SE-0.4) (PM).2. SE-0.4) (P-0.2. SE-0.4)
r s l1228373 0.8863 <8.0881 0.0014 0.3095 0.8199 0.3369
(BMi.7, SE -8J) (PM -3, SE -0J) (8--1.1, SE-OA) (P--0.3, SE-0.3) (PMI.l, SE-0.4) (P-0.3, SE-0.3)
rs3019594 8.8831 <8.8881 8.8888 0.2377 0.6516 0.1691
(BM1.7, SE-82) (R--1.4. S E -8J) (8M .2, SE-0.4) (B--0.4. SE-0.3) (P-0.2, SE-0.4) (P-0.5. SE-0.3)
ri597316 0.2712 0.0814 0.0449 0.8213 0.2500 0.0417
(BM).6,SE=0.6) (B--2.2, SE-8.7) (P=-l .6, SE-0.8) (PM).2, SB-0.7) (P-0.9, SE-0.8) (P—1.6, SE-0.8)
'Association of CPT1A SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 PUFA intake. Estimates of effect 
size (P) are reported using transformed phenotypes.
^Results are significant at p< 0.0063 and highlighted in bold. Multiple test correction for 8 tests for a phenotype was estimated using the spectral 
decomposition of LD matrix (51). Total cholesterol (Choi), high-density lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density lipoprotein 
(LDL), very-low density lipoprotein (VLDL) and triglycerides (TG).
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Table 2.7.5: CPTIA polymorphisms associated with obesity1,2
Obesity Measures
SNP BMI PBF HC ThC WC
r>2278908 0.5137 0.4006 0.0179 0.0024 0.5103
(B=0.4. SE=0.6) (6=0.4. SE-0.5) (6=1.4. SE-0.6) (8-2.1. SE-0.7) (8=0.5. SE-0.8)
n2278907 0.3778 0.4339 0.0057 0.0002 0.6956
(6=0.4, SE-0.42) (6=0.3. SE=0.4) (6=1.2. SE-8.4) (6-1.9. SE-0.5) (8=0.2. SE-0.5)
1x3019598 0.7691 0.6930 0.0578 0.0089 0.9006
(6=0.2, SE= 0.6) (6=0.2,SE= 0.5) (6=1.1. SE-0.6) (8=1.9, SE-0.7) (6=0.1. SE-0.8)
P479L 0.0821 0.0007 <0.0001 <0.0001 0.0006
(rs80356779) (6-0.7. SE-0.2) (6-0.7, SE-0.2) (6-0.9, SE-0.2) (6-1.2.SE- 0.3) (8-1-8. SE-0.3)
n2305508 0.7108 0.6326 0.7604 0.1701 0.4912
(P=-0.1, SE=0.2) (6=-0.1, SE-0.2) (6=0.1, SE-0.2) (6=0.3, SE-0.2) (6=0.2. SE-0.2)
re4930248 0.2369 0.1874 0.0191 0.0042 0.1503
(6=0.4. SE=0.4) (6=0.4, SE-0.3) (6-0.9. SE-0.4) (8-1 J . SE-0.5) (6=0.7. SE-0.5)
1x3794020 0.4386 0.2276 0.3897 0.8763 0.1390
(6=0.2. SE-0.2) (6=0.2, SE-0.2) (6=0.2. SE-0.2) (6=0.0. SE-0.2) (6=0.4. SE-0.3)
1111228372 0.0277 0.0244 0.0034 0.0011 0.0294
(6=0.7. SE=0.3) (6=0.6, SE-0.3) (8-0.9. SE-0.3) (6—13. SE-0.4) (6=0.9. SE-0.4)
rsl1228373 0.1605 0.2517 0.0063 0.0006 0.1095
(6=0.4. SE=0.3) (8=0.3, SE-0.2) (6-0.7. SE-0J) (6-1.1. SE-0.3) (6=0.5. SE-0.3)
1x3019594 0.0294 0.0312 0.0005 <0.0001 0.0154
(6=0.6. SE=0.3) (8=0.5. SE-0.2) (8-0.9. SE-0.3) (6-1-3. SEHL3) (6-0.8, SE-0.3)
tx597316 0.3342 0.6079 0.0731 0.0161 0.2518
(6=0.6. SE-0.6) (6=0.3. SE-0.5) (6=1.1. SE-0.6) (6=1.8, SE-0.7) (6=0.9. SE-0.8)
'Association of CPTIA SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 PUFA 
intake. Estimates of effect size (8) are reported using transformed phenotypes.
'Results are significant at p< 0.0063 and highlighted in bold. Multiple test correction for g tests for a phenotype was 
estimated using the spectral decomposition of LD matrix (SI). Body mass index (BMI), percent body fat (PBF), hip 
circumference (HC), thigh circumference (ThC) and waist circumference (WC).
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Table 2.7.6: Obesity-related trait distribution within P479L genotypes
liW
Obesity Measures L479/L479 L479/P479 P479/P479 p-value
BMI (In/m2) 26.2 (24.4-28.1) 28.0(25.3-31.3) 31.1 (26.2-37.8) 0.0021
Percentage Body Fat (%) 27.8(24.9-30.7) 30.0 (25.8-34.3) 33.7(26.8-41.0) 0.0007
Waist Circumference (cm) 87.1 (82.7-91.9) 91.9 (85.2-99.8) 100.4(88.1-116.4) 0.0006
Hip Circumference (cm) 98.2(95.1-101.7) 101.6 (96.8-107.3) 106.6(98.0-118.2) <*.0001
Thigh Circumference (cm) 49.8(48.0-51.7) 53.4 (50.6-56.4) 57.9 (52.9-63.5) <0.0001
Lipids Measures L479/L479 L479/P479 P479/P479 p-value
Cholesterol (mg/dL) 211.0(197.4-225.6) 199.6(181.6-219.8) 193.9(166.5-266.8) 0.0834
HDL (mg/dL) 58.3 (53.3-64.1) 53.3(47.2-60.6) 49.6(41.1-60.7) 0.0001
ApoHpoproteta Al (mg/dL) 164.2 (155.2-173.9) 156.1 (144.2-169.1) 150.1 (132.4-170.5) 0.0077
LDL (mg/dL) 134.6(122.4-147.8) 128.1(111.6-146.4) 125.0(99.7-155.1) 0.6629
VLDL (mg/dL) 15.1 (12.9-18.0) 15.8(12.5-20.4) 17.2(11.8-26.9) 0.6355
Triglyceride (mg/dL) 71.7(61.7-84.2) 75.4 (60.9-95.5) 83.0(58.6-125.1) 0.1407
1 Values are reported as predicted mean (95% Cl) obtained from ASSOC output.
2 Association of the P479L (L479>P479) minor allele in the linear regression model adjusted for age, sex, community membership, 
and n-3 PUFA intake.
’Results are significant at p< 0.0063 and highlighted in bold. Multiple test correction for 8 tests for a phenotype was estimated using 
the spectral decomposition of LD matrix (51).
47
2.8 REFERENCES
1. Park, Y.-W., S. Zhu, L. Palaniappan, S. Heshka, M. R. Camethon, and S. B.
Heymsfield. 2003. The metabolic syndrome: prevalence and associated risk factor 
findings in the US population from the Third National Health and Nutrition 
Examination Survey, 1988-1994. Archives o f Internal Medicine. 163: 427-36.
2. Blither, M. 2010. The distinction of metabolically “healthy” from “unhealthy” obese
individuals. Current Opinion in Lipidology. 21: 38-43.
3. Wildman, R. P. 2009. Healthy obesity. Current Opinion in Clinical Nutrition and
Metabolic Care. 12:438-43.
4. Ebbesson, S. O. E., C. D. Schraer, P. M. Risica, A. I. Adler, L. O. E. Ebbesson, A. M.
Mayer, E. V. Shubnikof, J. Yeh, O. T. Go, and D. C. Robbins. 1998. Diabetes and 
impaired glucose tolerance in three Alaskan Eskimo populations. The Alaska- 
Siberia Project. Diabetes Care. 21: 563-569.
5. Murphy, N. J., C. D. Schraer, L. R. Bulkow, E. J. Boyko, and A. P. Lanier. 1992.
Diabetes mellitus in Alaskan Yup’ik Eskimos and Athabascan Indians after 25 yr. 
Diabetes Care. 15: 1390-1392.
6. Schraer, C. D., S. O. E. Ebbesson, A. I. Adler, J. S. Cohen, E. J. Boyko, and E. D.
Nobmann. 1998. Glucose tolerance and insulin-resistance syndrome among St. 
Lawrence Island Eskimos. International Journal o f Circumpolar Health. 57 Suppl 
1: 348-354.
7. Schraer, C. D., P. M. Risica, S. O. E. Ebbesson, O. T. Go, B. V. Howard, and A. M.
Mayer. 1999. Low fasting insulin levels in Eskimos compared to American 
Indians: are Eskimos less insulin resistant? International Journal o f Circumpolar 
Health. 58:272-280.
8. Boyer, B. B., G. V. Mohatt, R. Plaetke, J. Herron, K. L. Stanhope, C. Stephensen, and
P. J. Havel. 2007. Metabolic syndrome in Yup’ik Eskimos: The Center for Alaska 
Native Health Research (CANHR) Study. Obesity. 15: 2535-2540.
9. Mohatt, G. V., R. Plaetke, J. Klejka, B. Luick, C. Lardon, A. Bersamin, S. Hopkins, M.
Dondanville, J. Herron, and B. B. Boyer. 2007. The Center for Alaska Native 
Health Research Study: a community-based participatory research study of obesity 
and chronic disease-related protective and risk factors. International Journal o f 
Circumpolar Health. 66: 8-18.
48
10. Cowie, C. C., K. F. Rust, E. S. Ford, M. S. Eberhardt, D. D. Byrd-Holt, C. Li, D. E.
Williams, E. W. Gregg, K. E. Bainbridge, S. H. Saydah, and L. S. Geiss. 2009.
Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 
and 2005-2006. Diabetes Care. 32: 287-294.
11. Ford, E. S. 2004. Prevalence of the metabolic syndrome in US populations.
Endocrinology and Metabolism Clinics o f North America. 33: 333-350.
12. Makhoul, Z., A. R. Kristal, R. Gulati, B. Luick, A. Bersamin, B. B. Boyer, and G. V.
Mohatt. 2010. Associations of very high intakes of eicosapentaenoic and 
docosahexaenoic acids with biomarkers of chronic disease risk among Yup’ik 
Eskimos. American Journal o f Clinical Nutrition. 91: 777-785.
13. Makhoul, Z., A. R. Kristal, R. Gulati, B. Luick, A. Bersamin, D. M. O’Brien, S. E.
Hopkins, C. B. Stephensen, K. L. Stanhope, P. J. Havel, and B. B. Boyer. 2011. 
Associations of obesity with triglycerides and C-reactive protein are attenuated in 
adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. 
European Journal o f Clinical Nutrition. 65: 808-817.
14. Curioni, C. C., and P. M. Lourenyo. 2005. Long-term weight loss after diet and
exercise: a systematic review. International Journal o f Obesity. 29: 1168-1174.
15. Dansinger, M. L., A. Tatsioni, J. B. Wong, M. Chung, and E. M. Balk. 2007. Meta­
analysis: the effect of dietary counseling for weight loss. Annals o f Internal 
Medicine. 147: 41-50.
16. Foster, G. D., T. A. Wadden, R. A. Vogt, and G. Brewer. 1997. What is a reasonable
weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. 
Journal o f Consulting and Clinical Psychology. 65: 79-85.
17. Tsai, A. G., and T. A. Wadden. 2005. Systematic review: an evaluation of major
commercial weight loss programs in the United States. Annals o f Internal 
Medicine. 142: 56-66.
18. Bersamin, A., S. Zidenberg-Cherr, J. S. Stem, and B. R. Luick. 2007. Nutrient intakes
are associated with adherence to a traditional diet among Yup’ik Eskimos living in 
remote Alaska Native communities: the CANHR Study. International Journal o f 
Circumpolar Health. 66: 62-70.
19. Schumacher, C., M. Davidson, and G. Ehrsam. 2003. Cardiovascular disease among
Alaska Natives: a review of the literature. International Journal o f Circumpolar 
Health. 62: 343-362.
49
20. Bersamin, A., B. R. Luick, I. B. King, J. S. Stem, and S. Zidenberg-Cherr. 2008.
Westernizing diets influence fat intake, red blood cell fatty acid composition, and 
health in remote Alaskan Native communities in the center for Alaska Native 
health study. Journal o f the American Dietetic Association. 108: 266-273.
21. Johnson, J. S., E. D. Nobmann, E. Asay, and A. P. Lanier. 2009. Dietary intake of
Alaska Native people in two regions and implications for health: the Alaska Native 
Dietary and Subsistence Food Assessment Project. International Journal o f 
Circumpolar Health. 68: 109-122.
22. Buckley, J. D., and P. R. C. Howe. 2010. Long-chain omega-3 polyunsaturated fatty
acids may be beneficial for reducing obesity—a review. Nutrients. 2: 1212-1230.
23. McGarry, J. D., and N. F. Brown. 1997. The mitochondrial carnitine
palmitoyltransferase system. From concept to molecular analysis. European 
Journal o f Biochemistry. 244: 1-14.
24. Ravussin, E., and S. R. Smith. 2002. Increased fat intake, impaired fat oxidation, and
failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and 
type 2 diabetes mellitus. Annals O f The New York Academy O f Sciences. 967: 363­
378.
25. Zurlo, F., S. Lillioja, A. Esposito-Del Puente, B. L. Nyomba, I. Raz, M. F. Saad, B.
A. Swinbum, W. C. Knowler, C. Bogardus, and E. Ravussin. 1990. Low ratio of 
fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. 
American Journal o f Physiology. 259: E650-E657.
26. Reddy, J. K., and M. S. Rao. 2006. Lipid metabolism and liver inflammation. II. Fatty
liver disease and fatty acid oxidation. American Journal o f Physiology- 
Gastrointestinal and Liver Physiology. 290: G852-G858.
27. Madsen, L., A. C. Rustan, H. Vaagenes, K. Berge, E. Dyroy, and R. K. Berge. 1999.
Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal 
fatty acid oxidation in relation to substrate preference. Lipids. 34: 951-963.
28. Esser, V., C. Britton, B. C. Weis, D. W. Foster, and J. D. McGarry. 1993. Cloning,
sequencing, and expression of a cDNA encoding rat liver carnitine 
palmitoyltransferase I. Direct evidence that a single polypeptide is involved in 
inhibitor interaction and catalytic function. Journal o f Biological Chemistry. 268: 
5817-5822.
50
29. Price, N. T., F. R. van der Leij, V. N. Jackson, C. G. Corstorphine, R. Thomson, A.
Sorensen, and V. A. Zammit. 2002. A novel brain-expressed protein related to 
carnitine palmitoyltransferase I. Genomics. 80:433-442.
30. Yamazaki, N., Y. Shinohara, A. Shima, and H. Terada. 1995. High expression of a
novel carnitine palmitoyltransferase I like protein in rat brown adipose tissue and 
heart: isolation and characterization of its cDNA clone. FEBS Letters. 363: 41-45.
31. McGarry, J. D. 2001. Travels with carnitine palmitoyltransferase I: from liver to germ
cell with stops in between. Biochemical Society Transactions. 29: 241-245.
32. Swanson, S. T., D. W. Foster, J. D. McGarry, and N. F. Brown. 1998. Roles of the bl­
and C-terminal domains of carnitine palmitoyltransferase I isoforms in malonyl- 
CoA sensitivity of the enzymes: insights from expression of chimaeric proteins 
and mutation of conserved histidine residues. Biochemical Journal. 335: 513-519.
33. Akkaoui, M., I. Cohen, C. Esnous, V. Lenoir, M. Soumac, J. Girard, and C. Prip-
Buus. 2009. Modulation of the hepatic malonyl-CoA-camitine 
palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation 
of de novo fatty acids. Biochemical Journal. 420: 429-438.
34. Saunders, C. L., B. D. Chiodini, P. Sham, C. M. Lewis, V. Abkevich, A. A.
Adeyemo, M. de Andrade, R. Arya, G. S. Berenson, J. Blangero, M. Boehnke, I.
B. Borecki, Y. C. Chagnon, W. Chen, A. G. Comuzzie, H.-W. Deng, R. Duggirala, 
M. F. Feitosa, P. Froguel, R. L. Hanson, J. Hebebrand, P. Huezo-Dias, A. H. 
Kissebah, W. Li, A. Luke, L. J. Martin, M. Nash, M. Ohman, L. J. Palmer, L. 
Peltonen, M. Perola, R. A. Price, S. Redline, S. R. Srinivasan, M. P. Stem, S.
Stone, H. Stringham, S. Turner, C. Wijmenga, and D. A. Collier. 2007. Meta­
analysis of genome-wide linkage studies in BMI and obesity. Obesity. 15: 2263­
2275.
35. Rajakumar, C., M. R. Ban, H. Cao, T. K. Young, P. Bjerregaard, and R. A. Hegele.
2009. Carnitine palmitoyltransferase LA polymorphism P479L is common in 
Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. Journal 
o f Lipid Research. 50: 1223-1228.
36. Lohman, T. G., and A. F. Roche. 1988. Anthropometric Standardization Reference
Manual. (Martorell, R., ed.). Human Kinetics Books, Champaign IL.
37. O’Brien, D. M., A. R. Kristal, M. A. Jeannet, M. J. Wilkinson, A. Bersamin, and B.
Luick. 2009. Red blood cell deltal5N: a novel biomarker of dietary 
eicosapentaenoic acid and docosahexaenoic acid intake. American Journal o f 
Clinical Nutrition. 89: 913-919.
51
38. The International HapMap Consortium. 2003. The International HapMap Project.
Nature. 426: 789-796.
39. Carlson, C. S., M. A. Eberle, M. J. Rieder, Q. Yi, L. Kruglyak, and D. A. Nickerson.
2004. Selecting a maximally informative set of single-nucleotide polymorphisms 
for association analyses using linkage disequilibrium. American Journal o f Human 
Genetics. 74: 106-120.
40. Howie, B. N., C. S. Carlson, M. J. Rieder, and D. A. Nickerson. 2006. Efficient
selection of tagging single-nucleotide polymorphisms in multiple populations. 
Human Genetics. 120: 58-68.
41. Tang, K., D.-J. Fu, D. Julien, A. Braun, C. R. Cantor, and H. KOster. 1999. Chip-
based genotyping by mass spectrometry. Proceedings o f the National Academy o f 
Sciences o f the United States o f America. 96: 10016-10020.
42. Horvath, S., X. Xu, S. L. Lake, E. K. Silverman, S. T. Weiss, and N. M. Laird. 2004.
Family-based tests for associating haplotypes with general phenotype data: 
application to asthma genetics. Genetic Epidemiology. 26: 61-69.
43. Box, G. E. P., and D. R. Cox. 1964. An Analysis of Transformations. Journal o f the
Royal Statistical Society. Series B (Methodological). 26: 211-252.
44. Plaetke, R., and F. Balbi. 2010. PedMerge: merging pedigrees to facilitate family-
based genetic statistical analyses. Bioinformatics. 26: 2790-2791.
45. O’Connell, J. R., and D. E. Weeks. 1998. PedCheck: a program for identification of
genotype incompatibilities in linkage analysis. American Journal o f Human 
Genetics. 63:259-266.
46. Price, A. L., N. J. Patterson, R. M. Plenge, M. E. Weinblatt, N. A. Shadick, and D.
Reich. 2006. Principal components analysis corrects for stratification in genome- 
wide association studies. Nature Genetics. 38: 904-909.
47. Purcell, S., B. M. Neale, K. Todd-Brown, L. Thomas, M. A. R. Ferreira, D. Bender, J.
B. Mailer, P. Sklar, P. I. W. de Bakker, M. J. Daly, and P. C. Sham. 2007. PLINK: 
a tool set for whole-genome association and population-based linkage analyses. 
American Journal o f Human Genetics. 81: 559-575.
48. George, V. T., and R. C. Elston. 1987. Testing the association between polymorphic
markers and quantitative traits in pedigrees. Genetic Epidemiology. 4: 193-201.
52
49. Grove, W. M., and N. C. Andreasen. 1982. Simultaneous tests of many hypotheses in
exploratory research. Journal o f Nervous and Mental Disease. 170: 3-8.
50. Li, J., and L. Ji. 2005. Adjusting multiple testing in multilocus analyses using the
eigenvalues of a correlation matrix. Heredity. 95: 221-227.
51. Nyholt, D. R. 2004. A simple correction for multiple testing for single-nucleotide
polymorphisms in linkage disequilibrium with each other. American Journal o f 
Human Genetics. 74: 765-769.
52. Kraft, R. A., A. H. Jahren, and C. D. Saudek. 2008. Clinical-scale investigation of
stable isotopes in human blood: deltal3C and deltal5N from 406 patients at the 
Johns Hopkins Medical Institutions. Rapid Communications in Mass Spectrometry. 
22: 3683-3692.
53. Hirota, Y., T. Ohara, M. Zenibayashi, S. Kuno, K. Fukuyama, T. Teranishi, K.
Kouyama, K. Miyake, E. Maeda, and M. Kasuga. 2007. Lack of association of 
CPU A polymorphisms or haplotypes on hepatic lipid content or insulin resistance 
in Japanese individuals with type 2 diabetes mellitus. Metabolism. 56: 656-661.
54. Robitaille, J., A. Houde, S. Lemieux, L. Pdrusse, D. Gaudet, and M.-C. Vohl. 2006.
Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase 
I (CPT1) gene interact with fat intake to modulate indices of obesity in French- 
Canadians. Journal o f Molecular Medicine. 85: 129-137.
55. Redden, D. T., and D. B. Allison. 2003. Nonreplication in genetic association studies
of obesity and diabetes research. Journal o f Nutrition. 133: 3323-3326.
56. Buckley, J. D., and P. R. C. Howe. 2009. Anti-obesity effects of long-chain omega-3
polyunsaturated fatty acids. Obesity Reviews. 10: 648-659.
57. Ide, T., H. Kobayashi, L. Ashakumary, I. A. Rouyer, Y. Takahashi, T. Aoyama, T.
Hashimoto, and M. Mizugaki. 2000. Comparative effects of perilla and fish oils on 
the activity and gene expression of fatty acid oxidation enzymes in rat liver. 
Biochimica Et Biophysica Acta- Molecular and Cell Biology o f Lipids. 1485: 23­
35.
58. Ide, T., M. Murata, and M. Sugano. 1996. Stimulation of the activities of hepatic fatty
acid oxidation enzymes by dietary fat rich in alpha-linolenic acid in rats. Journal 
o f Lipid Research. 37: 448-463.
59. Brown, N. F., R. S. Mullur, I. Subramanian, V. Esser, M. J. Bennett, J.-M.
Saudubray, A. S. Feigenbaum, J. A. Kobari, P. M. Macleod, J. D. McGarry, and J.
53
C. Cohen. 2001. Molecular characterization of L-CPTI deficiency in six patients: 
insights into function of the native enzyme. Journal o f Lipid Research. 42: 1134 — 
1142.
60. Greenberg, C. R., L. A. Dilling, G. R. Thompson, L. E. Seargeant, J. C. Haworth, S.
Phillips, A. Chan, H. D. Vallance, P. J. Waters, G. Sinclair, Y. Lillquist, R. J. A. 
Wanders, and S. E. Olpin. 2009. The paradox of the carnitine palmitoyltransferase 
type la P479L variant in Canadian Aboriginal populations. Molecular Genetics 
and Metabolism. 96: 201-207.
61. Bennett, M. J., S. B. Narayan, and A. B. Santani. 2005. In GeneReviews (Pagon, R.,
Bird, T., Dolan, C., and Stephens, K., eds.)., University of Washington, Seattle.
62. Bougn&res, P. F., J. M. Saudubray, C. Marsac, O. Bernard, M. Odi&vre, and J. Girard.
1981. Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase 
deficiency. Journal o f Pediatrics. 98: 742-746.
63. Brivet, M., A. Boutron, A. Slama, C. Costa, L. Thuillier, F. Demaugre, D. Rabier, J.
M. Saudubray, and J.-P. Bonnefont. 1999. Defects in activation and transport of 
fatty acids. Journal o f Inherited Metabolic Disease. 22:428-441.
64. Prasad, C., J. P. Johnson, J.-P. Bonnefont, L. A. Dilling, A. M. Innes, J. C. Haworth,
L. Beischel, L. Thuillier, C. Prip-Buus, R. Singal, J. R. Thompson, A. N. Prasad, 
N. Buist, and C. R. Greenberg. 2001. Hepatic carnitine palmitoyl transferase 1 
(CPT1 A) deficiency in North American Hutterites (Canadian and American): 
evidence for a founder effect and results of a pilot study on a DNA-based newborn 
screening program. Molecular Genetics and Metabolism. 73: 55-63.
65. Collins, S. A., G. Sinclair, S. McIntosh, F. Bamforth, R. Thompson, I. Sobol, G.
Osborne, A. Corriveau, M. Santos, B. Hanley, C. R. Greenberg, H. Vallance, and 
L. Arbour. 2010. Carnitine palmitoyltransferase 1A (CPTIA) P479L prevalence in 
live newborns in Yukon, Northwest Territories, and Nunavut. Molecular Genetics 
and Metabolism. 101: 200-204.
66. Gessner, B. D., M. B. Gillingham, M. A. Johnson, C. S. Richards, W. E. Lambert, D.
Sesser, L. C. Rien, C. A. Hermerath, M. R. Skeels, S. Birch, C. O. Harding, T. 
Wood, and D. M. Koeller. 2011. Prevalence and distribution of the C.1436C—>T 
sequence variant of carnitine palmitoyltransferase 1A among Alaska Native 
infants. Journal o f Pediatrics. 158: 124-129.
2.9 APPENDIX
Supplementary Table 2.9.1: Pairwise linkage disequilibrium (r2) 
between CPT1A polymorphisms with MAF >0.05
SNP N
1
N
£
£
1
t
1 l
e
? !
g
8N
e
P
8
*4
e
I
1
rs2278908 0.67 0.90 0.09 0.02 0.25 0.00 0.00 0.08 0.12 0.14 0.03
rs2278907 0.67 0.63 0.09 0.02 0.29 0.00 0.00 0.08 0.14 0.14 0.04
1*3019598 0.90 0.63 0.08 0.02 0.27 0.00 0.00 0.09 0.13 0.13 0.06
P479L 0.09 0.09 0.08 0.00 0.25 0.07 0.00 0.44 0.58 0.61 0.09
rs2305S08 0.02 0.02 0.02 0.00 0.08 0.75 0.00 0.00 0.00 0.00 0.01
rs4930248 0.25 0.29 0.27 0.25 0.08 0.01 0.00 0.25 0.29 0.28 0.01
n3794020 0.00 0.00 0.00 0.07 0.75 0.01 0.00 0.02 0.04 0.04 0.01
rt2924697 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01
rsll228372 0.08 0.08 0.09 0.44 0.00 0.25 0.02 0.01 0.74 0.74 0.00
rsll228373 0.12 0.14 0.13 0.58 0.00 0.29 0.04 0.01 0.74 0.95 0.16
rs3019594 0.14 0.14 0.13 0.61 0.00 0.28 0.04 0.01 0.74 0.95 0.16
rs597316 0.03 0.04 0.06 0.09 0.01 0.01 0.01 0.01 0.00 0.16 0.16
Pairwise linkage disequilibrium (r3) was calculated using the hapfieq command in FBAT (42).
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Supplementary Table 2.9.2: CPTIA polymorphisms
associated with obesity-related traits with correction for 
BMI112.
SNP Choi HDL ApoAl
rs2278908 0.0738 0.0007 0.04843
(0=-l.O, SE=0.5) (0=-2.1, SE=0.6) (0=-1.5, SE=0.6)
rs2278907 0.1294 0.0542 0.4939
(0=-O.6, SE=0.4) (0=-l.O, SE=1.0) (0=0.4, SE=0.6)
rs3019598 0.125 0.0009 0.1886
(P=-0.9, SE=0.6) (0=-2.1, SE=0.6) (0=-l.O, SE=0.8)
P479L 0.0489 0.0023 0.0526
(0=-O.4, SE=0.2) (P=-0.7, SE=0.2) (0=-O.6, SE=0.3)
rs2305508 0.0247 0.628 0.0453
(0=-O.4, SE=0.2) (P=0.1, SE=0.2) (0=0.5, SE=0.2)
rs4930248 0.0743 0.4877 0.5947
(0=-O.6, SE=0.3) (P=-0.3, SE=0.4) (0=03, SE=0.5)
rs3794020 0.5055 0.2888 0.0182
(P=-0.1,SE=0.2) (0=0.2, SE=0.2) (0=0.6, SE=0.3)
rsl 1228372 0.0089 0.0097 0.0544
(P=-0.8, SE=0.3) (0=-O.9, SE=0.3) (0=-O.8, SE=0.4)
rsl1228373 0.0045 <0.0001 0.0025
(P=-0.7, SE=0.2) (P=-l.l, SE=0.3) (0=-l.O,SE=O.3)
rs3019594 0.0018 <0.0001 0.0036
(0=-O.8, SE=0.2) (0=-l.l, SE=0.3) (0=-l.O, SE=0.4)
rs597316 0.2417 0.0023 0.049
n  j :........ (P=-0.7, SE=0.6) (0=-1.9, SE=0.6) (0=-1.5, SE=0.8)'Association of CPTIA SNPs in a linear regression model adjusted for age, sex, 
community membership, n-3 PUFA intake, and BMI. Estimates of effect size (0) are 
reported using transformed phenotypes.
2Resuhs are significant at p< 0.0063 and highlighted in bold. Multiple test correction 
for 8 tests for a phenotype was estimated using the spectral decomposition of LD 
matrix (51). Total cholesterol (Choi), high-density lipoprotein (HDL), and 
apolipoprotein Al (ApoAl).
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Supplementary Table 2.93: Association of P479L with HDL- 
Cholesterol with correction for PBF and WC
SNP PBF1 WC2
P479L 0.0032 0.0051
___• .• ..
(P=-0.7, SE=0.2) (P=-0.6, SE=0.2)
Association of P479L in a linear regression model adjusted for age, sex, 
community membership, n-3 PUFA intake, and PBF. Estimates of effect size (0) 
are reported using transformed phenotypes.
2Association of P479L in a linear regression model adjusted for age, sex, 
community membership, n-3 PUFA intake, and WC. Estimates of effect size (p) 
are reported using transformed phenotypes.
3Results are significant at p< 0.0063 and highlighted in bold. Multiple test 
correction for 8 tests was estimated using the spectral decomposition of LD matrix 
(51). High-density lipoprotein (HDL) cholesterol, percent body fat (PBF) and 
waist circumference (WC).
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Supplementary Table 2.9.4: Interaction of CPT1A polymorphisms and n-3
Obesity Measures Lipid Measures
SNP BMI PBF HC ThC WC Choi HDL ApoAl LDL VLDL TG
rs22789M 0.6997 0.5860 0.5768 0.3308 0.7987 0.4877 0.5265 0.7858 0.7161 0.3411 0.8915
1x2278907 0.9279 0.8310 0.5648 0.5485 0.7775 0.1824 0.8763 0.1738 0.3854 0.2560 0.5888
1x381959* 0.6398 0.5636 0.6959 0.4958 0.7318 0.5335 0.4480 0.9069 0.7364 0.1764 0.6600
P479L 0.1717 0.1691 0.4205 0.0149 0.2248 0.6630 0.9256 0.4393 0.6964 0.2751 0.2157
1x230550* 0.8947 0.8565 0.5823 0.8936 0.8734 0.4015 0.0154 0.0062 0.5506 0.3590 0.3774
1x493024* 0.1699 0.4673 0.0818 0.0330 0.1034 0.8452 0.9753 0.8425 0.7743 0.7788 0.9990
rs37»4020 0.6887 0.6889 0.7234 0.4303 0.4022 0.3630 8.0032 0.0023 0.2954 0.2715 0.2295
rsll228372 0.4352 0.5819 0.5190 0.1252 0.8422 0.6257 0.7445 0.3664 0.3263 0.9185 0.9420
IXU228373 0.4592 0.6869 0.3925 0.2150 0.8676 0.5157 0.9752 0.6635 0.3784 0.9065 0.8485
1x3019594 0.2141 0.4457 0.2387 0.0885 0.5671 0.5007 0.7437 0.2070 0.3959 0.9058 0.9589
1X597316 0.7939 0.9907 0.5994 0.7873 0.9745 0.3530 0.2152 0.2169 0.6192 0.1509 0.3037
decomposition of LD matrix (51). Body mass index (BMI), percent body fat (PBF), hip circumference (HC), thigh circumference (ThC), waist 
circumference (WC), total cholesterol (Choi), high-density lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density lipoprotein (LDL), very- 
low density lipoprotein (VLDL), triglycerides (TG).
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GENETIC POLYMORPHISMS IN SLC2A4 and SCD ARE ASSOCIATED WITH 
VARIATION OBESITY-RELATED PHENOTYPES IN YUP’IK PEOPLE2
3.1 ABSTRACT
OBJECTIVE: Regular consumption of n-3 polyunsaturated fatty acids (n-3 PUFAs) has 
been associated with protection from obesity-related diseases, in part, by altering the 
activity of genes involved with lipid and glucose metabolism. Stearoyl CoA desaturase 
(SCD), insulin sensitive glucose transporter (<SLC2A4), and steroyl regulatory element 
binding protein (SREBF1) are obesity candidate genes that are transcriptionally regulated 
by n-3 PUFA intake. Although polymorphisms in SCD, SLC2A4, and SREBF1 have been 
associated with obesity-related phenotypes, the extent to which these genetic associations 
are modified by interactions with n-3 PUFA intake remains unknown. DESIGN: Obesity 
and lipid-related phenotypes were measured in a cross-sectional sample of Yup’ik 
individuals (n=1080) enrolled in the Center of Alaska Native Health Research (CANHR) 
study. A comprehensive list of thirty-three single nucleotide polymorphisms within or 
near SCD, SLC2A4, and SREBF1 were tested for association with outcomes of interest in 
linear models accounting for familial correlations. Dietary intake of n-3 PUFAs was 
estimated using nitrogen stable isotope ratios (51SN) of red blood cells (RBC). 
RESULTS: SCD (rsl 1190480 and rs2167444) polymorphisms were positively associated 
with ApoAl levels (p=0.006 and p=0.004, respectively). SLC2A4 polymorphisms (rs5415 
and rs5435) were associated lower fasting HDL-cholesterol (p=0.001 and p=0.003, 
respectively) as well as increased hip circumference (p=0.005 and p=0.027, respectively). 
CONCLUSION: Our results indicate that polymorphisms in SCD and SLC2A4 are 
associated with obesity-related phenotypes in Yup’ik people; however we did not detect
2 Lemas, DJ, Klimentidis YC, Wiener HW, O’Brien DM, Hopkins S, Stanhope KL, 
Havel PJ, Allison DB, Fernandez, JR, Tiwari HK, Boyer BB. 2012. Genetic 
Polymorphisms in SLC2A4 and SCD are Associated with Variation Obesity-Related 
Phenotypes in Yup’ik People. Prepared for submission to The International Journal o f 
Obesity.
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significant n-3 PUFA interactions between SNPs in SCD, SLC2A4, and SREBF1 that 
modified genetic associations with obesity phenotypes.
3.2 INTRODUCTION
In the United States, nearly 70% of adults are overweight and more than half of 
these individuals are obese \  Accumulation of excess body fat increases the risk of 
developing obesity-related diseases that include type 2 diabetes (T2D), cardiovascular 
disease and cancer 2. Moderate weight loss (10% of body weight), as a treatment for 
obesity, has been shown to attenuate the risk of developing obesity-related diseases 3, 
however weight loss is difficult to maintain 4. Given the increasing public health burden 
attributed to obesity and the difficulty achieving and maintaining weight loss 5~7, it is 
important to define genetic and environmental factors that influence the development of 
obesity and lipid-related phenotypes.
Regular consumption of n-3 polyunsaturated fatty acids (n-3 PUFAs) may 
reduce adiposity in humans 8, in part, by regulating the activity of three genes: stearoyl 
CoA desaturase (SCD) 9, insulin sensitive glucose transporter (SLC2A4) 10, and steroyl 
regulatory element binding protein (SREBF1) n . SCD is the rate-controlling enzyme 
catalyzing the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty 
acid substrates I2. SLC2A4 codes for a specialized insulin- stimulated glucose transporter 
that regulates glucose uptake in skeletal muscle, heart, and adipose tissue 13. SREBF1 
encodes a transcription factor that plays a critical role in energy homeostasis by 
promoting glycolysis, lipogenesis, and adipogenesis 14. Although whole-genome linkage 
studies have implicated SCD, SLC2A4, and SREBF1 as obesity candidate genes 15~17, the 
extent to which n-3 PUFA intake modifies the association between polymorphisms in 
SCD, SLC2A4, and SREBF1 and obesity-related phenotypes is unknown.
Given the widely varying intake of n-3 PUFA in this study population of Yup’ik 
people (30-fold range), the proposed health benefit of eating a diet rich in n-3 PUFAs, 
and the availability of a precise biomarker for n-3 PUFA intake (815N; 18); we tested 
polymorphisms in obesity candidate genes regulated by n-3 PUFA for association with
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obesity-related phenotypes in Yup’ik people and investigated the extent to which these 
associations were modified by n-3 PUFA. Specifically, the candidate genes (SCO, 
SLC2A4, and SREBF1) examined in this study were identified in whole-genome linkage 
analysis 16,17,19-23 and tested in Yup’ik participants from the Center for Alaska Native 
Health Research (CANHR) study.
3.3 METHODS
3.3.1 PARTICIPANTS AND METHODS
The CANHR study investigates genetic, behavioral, and dietary risk and 
protective factors underlying obesity and their relationship to diabetes and cardiovascular 
disease among Yup’ik people 24. A community-based participatory research framework 
guides all CANHR investigations, such that participant ascertainment is open to all 
members of the community meeting a specified age minimum. Recruitment of Yup’ik 
participants was initiated in 2003 and continues in 11 Southwest Alaska communities. 
All residents 14 years of age and older are invited to participate and the resulting 
distribution of age in our study sample reflects the age distribution among eligible 
participants according to 2000 U.S. census data. Participants signed informed-consent 
documents before entering the study using protocols that were approved by the 
University of Alaska Institutional Review Board, the National and Alaska Area Indian 
Health Service Institutional Review Boards, and the Yukon-Kuskokwim Health 
Corporation Human Studies Committee. The analyses in this report were performed on 
1080 non-pregnant Yup’ik participants with ages that ranged between 14 and 94 years at 
the time of enrollment.
3.3.2 ANTHROPOMETERIC AND BIOCHEMICAL MEASUREMENT
Trained staff obtained anthropometric measurements using protocols from the 
NHANES III Anthropometric Procedures Manual as previously described . These 
measurements included height, weight and 4 circumferences (waist, hip, triceps, and 
thigh). Percent body fat (PBF) was measured by electrical bioimpedance using a Tanita
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TBF-300A body fat analyzer (Tanita Corp, Arlington Heights, IL, U.S.A.). Blood
samples were collected from participants after an overnight fast, and lipoprotein measures
including total cholesterol, HDL- cholesterol, LDL-cholesterol, VLDL cholesterol,
apolipoprotein A l, and plasma triglycerides levels were assayed as previously described 
26
3.3.3 BIOMARKER FOR MARINE n-3 PUFA INTAKE
n-3 PUFA intake was assessed in Yup'ik individuals using the nitrogen stable 
isotope ratio of red blood cells (RBC) as previously described 18. RBC aliquots were 
autoclaved for 20 minutes at 121°C to destroy blood-borne pathogens, and samples were 
weighed into 3.5 x 3.75 mm tin capsules and freeze dried to a final mass of 0.2 - 0.4 mg. 
Samples were analyzed at the Alaska Stable Isotope Facility by continuous-flow isotope 
ratio mass spectrometry, using a Costech ECS4010 Elemental Analyzer (Costech 
Analytical Technologies, Valencia, CA, USA) interfaced to a Finnigan Delta Plus XP 
isotope ratio mass spectrometer via the Conflo III interface (Thermo-Finnigan Inc., 
Breman, Germany). Isotope ratios are analyzed relative to IAEA-certified reference 
materials calibrated to atmospheric nitrogen, for which 15N/14N = 0.0036765. By 
convention and for ease of interpretation, isotope ratios are presented as delta values in 
“permil” relative to atmospheric nitrogen: 81SN = [(15N/,4Nsample -  15N/14Nstandard)/( 
15N/,4Nstandard)] • 1000%o. We concurrently prepared and ran multiple laboratory 
standards (peptone, 515N = 7.00) to assess analytical accuracy and precision; these were 
analyzed after every eighth sample and gave values of 815N = 7.01 ± 0.24%o (mean ± 
SD). The range of isotopic variation in our dataset (9%o) was very large relative to 
analytical precision (0.2%o). We modeled the effects of n-3 PUFA intake as a categorical 
variable, which is hereafter referred to as 8,5N.
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3.3.4 SNP SELECTION AND GENOTYPING
A comprehensive list of DNA variants were selected for genotyping within and 
near (5 kb upstream and 5 kb downstream) the SCD, SLC2A4 and SREBF1 genes 
collected from HapMap data, release #3, National Center for Biotechnology Information 
(NCBI) B36, dbSNP 126 21. Given that no publically available genotypic information 
exists on Yup’ik people, we referenced the Caucasian (CEU) and Han Chinese (CHB) 
populations in HapMap using the SeattleSNPs database (http://pga.mbt.washington.edu/) 
to identify potential genetic variants that may be common in our study population. A set 
of 27 maximally informative tagging SNPs (tSNPs) within or near SCD, SLC2A4 and 
SREBFlv/ere identified to represent common linkage disequilibrium clusters with the 
LDselect algorithm as implemented in the MultiPop-TagSelect program using thresholds 
of ^ =0.90 and minor allele frequency >1% 28,29. We chose to relax our MAF criteria to 
include SNPs with MAF >0.01 in order to genotype tagging SNPs in the SCD, SLC2A4 
and SREBF1 genes which may be common (MAF>0.05) in Yup’ik people despite being 
rare (MAF<0.05) in CEU and CHB populations. Additional SNPs in SCD (rs41290540 
and rs2167444) were selected based on previous SNP associations with obesity and lipid- 
related phenotypes 30,31. Additional SNPs in SLC2A4 (rs2654185, SNP 12 and SNP 13) 
were selected based on previous associations with HbAlc 32 and resequencing candidate 
genes in participants enrolled in the CANHR study. Specifically, 30 unrelated Yup’ik 
participants enrolled in the CANHR study were selected based on extreme BMI measures 
(15 participants with lowest BMI and 15 participants with highest BMI) and SLC2A4 
resequencing was limited to all protein coding regions, intron-exon boundaries, and 1,000 
bp of 5' and 300 bp of 3' flanking DNA (Agencourt; Beverly, MA). Sequence 
information used to generate primers for SNP 12 and SNP 13 in SLC2A4 is presented in 
Supplementary Table 3.9.1. Our final genotyping list included a total of 34 SNPs in 
SCD (13 SNPs), SLC2A4 (13 SNPs), and SREBF1 (8 SNPs) that were genotyped using 
allele-specific primer extension of multiplex amplified products and detection using 
matrix-assisted laser desorption ionization time-of-flight spectrometry on a Sequenom 
iPLEX platform at the Broad Institute 33. Linkage disequilibrium (LD) among SNPs in
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each gene was based on pairwise haplotype frequencies calculated using the hapfreq 
command in the FBAT program34.
3.3.5 QUALITY CONTROL OF PHENOTYPIC AND GENOTYPIC DATA
Simple linear models were fit to each of the outcome variables using all of the 
covariates (age, sex, community membership) included in the association models, and the 
distributions of the residuals were examined for normality with the R statistical 
programming language (v2.10.1, R Development Core, 2009). We considered a series of 
transformations (square root, log, inverse) to improve normality and the Box-Cox 
transformation35 was identified as the best procedure for phenotypes whose residuals did 
not follow a normal distribution. Family data was extracted from the Progeny database 
(Progeny Software LLC, South Bend, IN, U.S.A.) and merged into a single extended 
pedigree using PedMerge 36. Genotypic data were tested for Mendelian inconsistencies 
using PEDCHECK 37. In this sample, Illumina IV linkage panel (Illumina, Inc., San 
Diego, CA, USA) genotypes were available from ongoing linkage study and were used to 
calculate ancestry using principal components analysis (PCA) program in the 
EIGENSTRAT analysis package 38. The second PC discriminated the individuals in the 
study into two groups that correspond to the proximity of the community to the coast. 
Based on this observation, we defined a dichotomous community group variable. We 
assessed Hardy-Weinberg equilibrium (HWE) for each SNP using an algorithm that 
accounts for relationships among individuals 39. Allele frequencies for each SNP were 
computed using the FREQ module in the program Statistical Analysis for Genetic 
Epidemiology (S.A.G.E., 2009) in the entire dataset. The present study restricted genetic 
analysis to SNPs in SCD, SLC2A4, and SREBF1 that had a MAF > 5% and did not 
deviate from HWE. HWE multiple test correction to control the familywise error rate 
was determined for each gene using spectral decomposition of linkage disequilibrium 
(LD) matrices generated for each pair of genotyped markers 40,41. Given these criteria, 
the HWE multiple test correction was estimated to be 12 tests for SCD (a<0.004), 6 tests 
for SLC2A4 (a<0.008), and 6 tests for SREBF1 (<x<0.008).
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3.3.6 ASSOCIATION ANALYSIS
Each SNP was tested for association with obesity and lipid-related phenotypes 
using the program ASSOC 42 in the S.A.G.E software package which can incorporate 
complex pedigree data, covariates and interactions into association analysis. We 
included both demographic (age, community, and sex) and environmental variables 
(8,5N) in the ASSOC analysis. Likelihood ratio statistics were calculated to compare 3 
nested models and test the null hypothesis of no association between SNPs and obesity 
and lipid-related phenotypes after including demographic and environmental covariates. 
Effect sizes (P) were extracted from linear models adjusted for demographic and 
environmental covariates to illustrate the change in transformed phenotypes according to 
each copy of the minor allele tested.
Model 1 included baseline covariates (age, sex, community membership, and 815N 
quartiles); Model 2 included baseline covariates and SNP to test for an additive genetic 
effect of SNP (defined as the number of minor alleles); Model 3 included baseline 
covariates, the additive genetic effect of SNP, 815N quartiles, and interactions between 
the additive genetic effect and 815N quartiles. Note that the model 3 is the only model to 
test directly gene-diet interaction under the null hypothesis. We have treated each 
phenotype being tested as representing a separate family of null hypotheses and correct 
for the number of tests within each family 43. P-values were compared to the 
conventional significance threshold (p<0.05), as well as significance thresholds adjusted 
for multiple test correction. Multiple test correction for genetic analysis was used to 
control the familywise error rate that was calculated according to the number of non- 
redundant SNPs with MAF >0.05. Given the correlation among neighboring genetic 
markers, the effective numbers of non-redundant SNPs for SCD (12 tests; a<0.004), 
SLC2A4 (6 tests; a<0.008), and SREBF1 (6 tests; a<0.008) were estimated using spectral 
decomposition of LD matrices40,41.
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3.4 RESULTS
3.4.1 CHARACTERISTICS OF YUP’IK PARTICIPANTS
Descriptive statistics on Yup'ik women and men enrolled in the CANHR study 
are presented in Table 3.7.1. In general, Yup’ik women had significantly greater levels 
of adiposity (BMI, PBF, and HC) and higher fasting HDL-cholesterol and ApoAl levels 
relative to Yup’ik men (p<0.0001).
3.4.2 DISTRIBUTION OF 815N IN STUDY POPULATION
We assessed n-3 PUFA intake in 1080 Yup’ik participants using RBC 8I5N as a 
biomarker of EPA and DHA intake. Summary statistics are grouped by gender and 815N 
quartiles and reported in Table 3.7.2. The mean 815N value in this study was 8.9%o, and 
ranged from 6.2%o to 15.2%o. According to the linear relationship between RBC 815N  
and RBC EPA described elsewhere for this study population 18, the corresponding mean 
EPA (%RBC fatty acids) was 2.6%. Measurement of 815N by gender yielded means of 
9.1%o for females and 8.8%o for males. The mean RBC 815N values by quartile were: 
7.3%o, 8.2%o, 9.1%o, 11.0%o in groups 1-4, respectively. These values correspond to EPA 
(% RBC fatty acids) group means of: 0.9%, 1.9%, 2.8%, and 4.7% 18. The standard 
deviation of 815N in this sample did not differ according to gender (1.5%o for both 
females and males).
3.4.3 GENETIC VARIATION IN SCD, SLC2A4, AND SREBF1
A comprehensive list of thirty-three SNPs in SCD, SLC2A4 and SREBF1 were 
genotyped in 1080 Yup’ik participants that had a mean success rate of 94.7% (range 
70.6-94.6%). Genotyping in this study revealed that 6 SNPs were monomorphic 
(SLC2A4: SNP12, SNP13, rs222842 and rs3744404; SREBF1: rsl 1653007 and 
rsl 108511), 5 SNPs had MAF <0.05 and >0.01 (SCD: rsl0883463; SLC2A4: rs2073476, 
rs5412, and rs222847; SREBF1: rs4925118), and 23 SNPs had MAF > 0.05. The 
rs41290540 SNP in SCD (MAF=0.12) was the only polymorphism with MAF >0.05 that 
deviated significantly from HWE proportions (p=0.0002) and was excluded from the
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analysis. The genetic analyses in this study included the 11 SNPs in SCD, 6 SNPs in 
SLC2A4, and 6 SNPs in SREBF1 with MAF > 0.05 that did not deviate from HWE 
proportions (Table 3.7 J ) . Multiple test correction 40,41 was determined for each gene and 
estimated that 7 of the 11 markers in SCD (per-test a level was <0.007), all 6 markers in 
SCL2A4 (per-test a  level was <0.008), and 4 of the 6 markers in SREBFl (per-test a level 
was <0.013) were non-redundant genetic markers.
3.4.4 SNP ASSOCIATIONS WITH LIPID PHENOTYPES
Figure 3.6.1 and Table 3.6.4 presents SNPs in SCD, SLC2A4, and SREBFl with 
MAF >0.05 that were associated with lipid phenotypes. Notably, rsl 1190480 and 
rs2167444 in SCD were in strong LD (^=0.95, Supplementary Table 3.9.2) and 
positively associated with ApoAl levels (p=0.006 and p=0.004, respectively). Additional 
SCD SNPs (rsl 1557927 p=0.008 and rs7849 p=0.008) were very close to passing 
multiple test correction and several SCD SNPs (rsl 1190480, rsl 15579277, and rs7849) 
were nominally associated increased HDL-cholesterol (p=0.029, p=0.045, and p=0.048, 
respectively). The rs5415 and rs5435 polymorphisms in SLC2A4 were in moderately 
strong LD (r2=0.74, Supplementary Table 3.9.3) and negatively associated with fasting 
ApoAl levels (p=0.005 and p=0.003, respectively) and HDL-cholesterol (p=0.001 and 
p=0.003, respectively). Additional SLC2A4 SNPs (rs5417 p=0.009 and rs3744405 
p=0.009) were very close to passing multiple test correction and an SCD SNP 
(rs2654185) was nominally associated (p=0.016) with increased ApoAl levels. We 
found SREBFl SNPs (rs2297508, rs2282180, and rs8066560) in strong LD (^=0.93-1.0); 
Supplementary Table 3.9.4) that were nominally associated with fasting measures of 
LDL-cholesterol (p=0.029, p=0.023, and p=0.014, respectively) and a SREBFl SNP 
(rs8066560) associated with total cholesterol (p=0.014). Finally, we detected significant 
interactions between SCD SNPs (rs2167444, p=0.0068 and rsl 1190480, p=0.0047) and 
n-3 PUFA intake (Supplementary Table 3.9.5); however after correction for HDL- 
cholesterol these results were only nominally significant (rs2167444, p=0.0494 and 
rsl 1190480, p=0.0113) (Supplementary Table 3.9.6),
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3.4.5 SNP ASSOCIATIONS WITH OBESITY PHENOTYPES
Figure 3.7.2 and Table 3.8.5 presents SNPs in SCD, SLC2A4, and SREBF1 with 
MAF >0.05 that were associated with obesity phenotypes. Notably, rs5415 in SLC2A4 
was positively associated with hip circumference (p=0.005) and nominally associated 
with increased thigh circumference (p=0.034). Additional SLC2A4 SNPs (rs2654185, 
rs5417, and rs5435) were nominally associated with increased hip circumference 
(p=0.011, p=0.016, and p=0.027, respectively) and increased thigh circumference 
(p=0.012, p=0.020, and p=0.040, respectively). Furthermore, SNPs (rsl502593 and 
rs3071) in SCD were nominally associated with reduced BMI (p=0.035 and p=0.043, 
respectively) and WC (p=0.028 and p=0.028, respectively) in our study. We did not 
observe SNPs in SREBF1 that were associated with obesity phenotypes. Furthermore, we 
did not detect significant n-3 PUFA interactions between SNPs in SCD, SLC2A4, and 
SREBF1 that modified genetic associations with obesity phenotypes. All interactions 
results for obesity phenotypes are presented in Supplementary Table 3.9.7.
3.5 DISCUSSION
Regular consumption of n-3 polyunsaturated fatty acids (n-3 PUFAs) has been 
associated with protection from obesity 8, in part, by altering the expression of genes 
implicated in obesity pathophysiology. In this study we comprehensively evaluated 
SNPs within or near SCD, SLC2A4, and SREBFl for association with obesity and lipid- 
related phenotypes and explored whether these genetic associations were modified by 
interactions with n-3 PUFA intake in a study population with up to a 30-fold variation in 
consumption of n-3 PUFAs ,8. Our results demonstrate that two SCD polymorphisms 
(rsl 190480 and rs2167444) were associated with elevated fasting ApoAl levels. 
Additionally, SLC2A4 polymorphisms (rs2654185, rs5415, rs5417 and rs5435) were 
associated lower fasting HDL-cholesterol and increased hip circumference and thigh 
circumference. Taken together, our results indicate that polymorphisms in SCD and 
SLC2A4 are associated with variation in obesity and lipid-related phenotypes in Yup’ik
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people; however we did not detect significant n-3 PUFA interactions between SNPs in 
SCD, SLC2A4, and SREBFl that modified genetic associations with obesity phenotypes.
Previous studies that have examined SCD polymorphisms associated with 
obesity-related phenotypes have produced mixed results 30,31,44. Liew et al. failed to 
detect SCD polymorphisms associated with type 2 diabetes (T2D) traits, BMI, or waist- 
hip-ratio in a large European case-control study30. Gong et al. reported that SCD genetic 
variation was associations with metabolic syndrome (MetS) in a Costa Rican cohort 44 
and Warensjd et al. reported SCD polymorphisms were associated with insulin
^ I
sensitivity, reduced BMI and smaller waist circumference in Swedish men .
We did not evaluate the contribution of SCD polymorphisms to T2D and MetS 
given the historically low prevalence of T2D (<3% in Yup’ik people) 24 and MetS (8.6 % 
in men and 19.8% in women) 26 observed among Yup’ik people. Nevertheless, we 
investigated the association between SCD polymorphisms and three of the five traits 
associated with MetS (HDL-cholesterol, triglycerides and WC) and we did not observe 
any significant associations. Furthermore, the SCD polymorphism (rsl502593) 
associated with MetS in Costa Rican adults 44 was nominally associated with reduced 
BMI (p=0.035) and WC (p=0.028) in our Yup’ik study population. The SCD 
polymorphism (rs2167444) associated with improved insulin sensitivity and reduced 
adiposity in Swedish m en31, was positively associated with fasting ApoAl levels, but not 
HDL-cholesterol, in our Yup’ik study population. Taken together, our SCD genetic 
association results are generally consistent with the findings of Warensjd et al. and 
demonstrate that SCD polymorphisms are associated with elevated fasting ApoAl levels 
and reduced obesity Yup’ik people.
In mice, SCD1 (mouse SCD homolog) deficiency is associated with increased 
energy expenditure 4S, reduced adiposity 46, increased insulin sensitivity 4?, protection 
against hypertriglyceridemia 48, and elevated HDL levels 48. Consumption of 
polyunsaturated fatty acids transcriptionally regulates SCD 49 by repressing SCD mRNA 
levels in the liver 9 and adipocytes 50. Our results demonstrate that SCD polymorphisms 
were associated with reduced BMI, smaller hip circumference and elevated fasting
69
ApoAl levels, the major apolipoprotein found in HDL-cholesterol, in a population with 
widely varying n-3 PUFA intake. Although functional evidence suggests consumption of 
n-3 PUFA transcriptionally regulates SCD activity, our analyses did not find that n-3 
PUFA intake modified genetic associations between SCD polymorphisms and obesity 
phenotypes in this Yup’ik study population.
Interrogation of SLC2A4 genetic variation has largely focused on identifying 
polymorphisms associated with T2D status 5,-61. Early studies using restriction fragment 
length polymorphism analyses did not detect SLC2A4 (also known as GLUT4 [Glucose 
transporter type 4] gene) associations with T2D in European whites 51,60*61, African 
Americans 57,61, Chinese 61, Japanese 61 and Asian Indians 61. Similarly, analysis of 
single-strand conformation polymorphism analysis in Welsh 60, British 52 and Italian 53 
cohorts failed to detect SLC2A4 polymorphisms associated with T2D. Finally, linkage 
analysis in a French cohort55 and direct sequence analysis in a mixed US sample 54 did 
not reveal significant SLC2A4 variations associated with T2D status.
Candidate gene studies that have examined SLC2A4 polymorphisms for 
association with obesity-related phenotypes have produced mixed results 56,58,59’61’62. BMI 
was not associated with SLC2A4 polymorphisms in a cohort of German children 62 or 
case-control studies for T2D 5,’56'58>61. in contrast, SLC2A4 polymorphisms were 
associated with fasting insulin levels in a South Indian cohort63 and fasting HbAlc levels 
in a cohort of Japanese men 32. Taken together, these studies suggest that genetic 
variation in SLC2A4 may contribute to changes in T2D-related traits.
Our results demonstrate that SLC2A4 polymorphisms (rs5435 and rs2654185) 
previously associated with T2D-related traits32’63, are associated with lower fasting HDL- 
cholesterol (p=0.003 and p=0.016, respectively) in Yup’ik people. Additionally, the 
SLC2A4 polymorphism (rs5435) reported by Bodhini et al. to be positively associated 
with fasting insulin levels, was in strong LD (^=0.74) with a SLC2A4 polymorphism 
(rs5415) associated with reduced fasting HDL-cholesterol (p=0.001) and ApoAl levels 
(p-0.005) as well as increased hip circumference (p=0.005) in our study population.
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Taken together, our results extend the findings of Bodhini et a l and Xi et a l by showing 
that SLC2A4 genetic variation is associated with T2D and obesity-related traits.
SREBFl polymorphisms have been associated with atherogenic lipid profiles 64, 
plasma adiponectin levels 65, HIV-related hyperlipoproteinaemia 66, odds of developing 
T2D 67~69, extreme obesity 67, as well as variation in total cholesterol 68,70,71 and LDL 
cholesterol 68,69,72. The non-synonymous G952G (rs2297508) variant in SREBFl has 
been associated with T2D 65,67’69,73*74, obesity 61, and cholesterol metabolism 66,70,71,73. 
Interestingly, two previous studies have failed to observe significant associations between 
G952G (rs2297508) and total and LDL-cholesterol 67,73. Our analysis did not evaluate 
SREBFl polymorphisms for association with T2D-related traits; however we did detect 
nominally significant associations with fasting lipid phenotypes. We observed SREBFl 
SNPs (rs8066560 and rs2282180) including the G952G (rs2297508) variant nominally 
(p<0.05) associated with elevated fasting LDL-cholesterol levels in our study population. 
Interestingly, the rs8066560 polymorphism was nominally associated with elevated 
fasting total cholesterol levels (p=0.025) and in strong LD with G952G (rs2297508) 
(^=0.93). Our results provide preliminary evidence of association between the non- 
synonymous G952G (rs2297508) variant in SREBFl and fasting LDL-cholesterol levels 
in Yup’ik people.
Our gene-by-diet analysis revealed n-3 PUFA intake modified the association 
between SCD polymorphisms (rsl 190480 and rs2167444) and fasting total cholesterol 
levels in Yup’ik people. Relative to individuals homozygous for the major allele, our 
analysis indicated that participants carrying the minor allele for either SNP (rsl 190480 
and rs2167444) had higher fasting cholesterol levels for any level of n-3 PUFA intake 
with the exception of n-3 PUFA intake at quartile 3. Although statistically significant, it 
is unclear why individuals homozygous for the SCD minor alleles would be expected to 
have lower fasting cholesterol levels at moderately high levels of n-3 PUFA intake 
(quartile 3). Given these SCD (rsl 190480 and rs2167444) polymorphisms were 
associated with HDL-cholesterol levels, we adjusted these analyses for HDL-cholesterol 
and found that total cholesterol levels were no longer significantly modified by
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interactions with SCD polymorphisms and n-3 PUFA intake (Supplementary Table 
3.9.6). Taken together, these results suggest the interaction of SCD polymorphisms and 
n-3 PUFA intake on total cholesterol levels may, in part, be mediated by changes in 
fasting HDL-cholesterol levels.
Our Yup‘ik study population was ideally suited to investigate the impact of n-3 
PUFA 75,76 and genetic factors 77 on obesity and lipid-related phenotypes given the 30­
fold range of n-3 PUFA consumption in this population 78, the traditional beliefs and 
scientific evidence that subsistence foods rich in n-3 PUFAs are healthy, and the 815N 
variable which can precisely estimate n-3 PUFA intake in large epidemiologic samples 
using nitrogen stable isotope ratios from red blood cell 18. The strengths of this study 
include a sample size large enough to detect significant SNP associations and a statistical 
approach that accounts for relationships among participants while also allowing for 
covariates 42. Factors that may account for the differences in results reported by the 
present study and the other investigations may include, but are not limited to, small 
sample size, population stratification and differences in statistical analysis 79,8°.
In summary, we have shown that polymorphisms within or near SCD, SLC2A4, 
SREBF1 are associated with obesity and lipid-related phenotypes in a study population 
with widely varying n-3 PUFA intake, however we did not detect significant n-3 PUFA 
interactions between SNPs in SCD, SLC2A4, and SREBF1 that modified genetic 
associations with obesity phenotypes. Additional genomic studies will be required in 
larger cohorts with variable intake of n-3 PUFAs in order to determine the validity and 
public health implications of our findings.
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Figure 3.6.3: SCD, SLC2A4 and SREBF1 polymorphisms with MAF > 5% that are associated with 
Upid phenotypes.
Association of SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 
PUFA intake. The red line represents multiple test correction adjusted for each gene that was estimated 
using the spectral decomposition of LD matrix (50). Total cholesterol (Choi), high-density lipoprotein 
(HDL), apolipoprotein Al (ApoAl), low-density lipoprotein (LDL), very-low density lipoprotein (VLDL) 
and triglycerides (TG).
73
r > o.oooi
SCD SLC2A4
Polymorphism* with MAF 2 5X
J u l a i i k L
SREBFl
Figure 3.6.4: SCD, SLC2A4 and SREBFl polymorphisms with MAF > 5% that are associated with 
obesity phenotypes.
Association of SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 
PUFA intake. The red line represents multiple test correction adjusted for each gene that was estimated 
using the spectral decomposition of LD matrix (50). Body mass index (BMI), percent body fat (PBF), hip 
circumference (HC), thigh circumference (ThC) and waist circumference (WC).
3.7 TABLES
Table 3.7.1: Description of Yup'ik people according to 
gender1,2.______________________________________
Variables Women Men p-values
No. of participants 566 517
Age (yrs) 40.2 ±3.6 38.6 ±2.6 0.1286
Obesity Measures
BMI (kg/m2) 28.7 ±5.6 26.3 ± 5.6 < 0.0001
Percentage Body Fat (%) 42.6 ±1.4 27.6 ± 1.1 < 0.0001
Waist Circumference (cm) 87.9 ±21.6 87.5 ±21.5 0.6646
Hip Circumference (cm) 105.4 ±43.0 98.7 ±43.0 < 0.0001
Thigh Circumference (cm) 51.0±21.4 50.3 ±21.3 0.0239
Lipid Measures
Cholesterol (mg/dL) 198.5 ± 67.8 191.3 ±67.0 0.0122
HDL (mg/dL) 66.4 ±20.0 57.0 ±19.8 <0.0001
Apolipoprotein At (mg/dL) 175.7 ±60.4 163.1 ± 59.9 < 0.0001
LDL (mg/dL) 128.9 ±1.1 129.4 ± 1.0 0.8213
VLDL (mg/dL) 15.0 ± 1.0 15.1 ±1.0 0.8424
Triglyceride (mg/dL) 74.6 ±23.5 73.8 ±23.1 0.6319
1 Values are reported as mean (± S.E.) predicted from linear model accounting 
for familial correlations.
2 P-values for differences by gender are derived using student t-test.
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Table 3.7.2: Distribution of the RBC nitrogen stable isotope ratio (51SN) in 
Yup'ik people1,2________________________________________  ______
Sex Quartile! of 815N"
Total Women Men Qt Q2 Q3 Q4
No. of participant! 1080 564 515 259 262 273 285
Mean ± SD (*.) 8.9 ±1.5 9.1 ±1.5 8.8 ±1.5 7.3 ±0.3 8.2 ±0.2 9.1 ±0.3 11.0 ±1.0
Maximum 15.2 15.2 13.5 7.8 8.6 9.8 15.2
Minimum 6.2 6.4 6.2 6.2 7.8 8.6 9.8
Ranee (X*) 9 8.8 7.3 1.6 0.8 1.2 5.4
’isotope ratios are presented as delta values in “permil” relative to atmospheric nitrogen: 8I5N = 
[(,5N/l4NM, le-  15N/,4N8tt*i«d)/( 15N/14N8UmdlKi)] • 1000%o.
2The relationship between 8,5N and EPA follows the linear model: EPA (%RBC fatty acid) =1.04 
81SN -  6.7%o, as previously described for this population18.
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Table 3.7.3: SCD, SLC2A4, and SREBFl polymorphisms with MAF >0.05
Gene1 Chr2 SNP3 Allele4 MAF5 Genotype*
Individual
s7
Genotyped
HWE
p-value*
SCD 10 rsl 502593 G>A 0.21 747 266 26 1039 0.361
SCD 10 rs522951 C>G 0.34 482 470 113 1065 0.600
SCD 10 rsl 1190480 A>G 0.12 871 241 16 1128 0.689
SCD 10 rs3071 A>C 0.19 764 271 17 1052 1.000
SCD 10 rs3829160 G>A 0.34 487 473 110 1070 0.727
SCD 10 rs2234970 A>C 0.34 487 461 111 1059 0.375
SCD 10 rs599961 T>G 0.32 394 512 166 1072 1.000
SCD 10 rs41290540 A>C 0.12 820 255 1 1076 0.372
SCD 10 rs3978768 A>G 0.33 496 433 113 1042 0.073
SCD 10 rsl 1557927 T>G 0.09 769 146 7 922 0.195
SCD 10 rs7849 T>C 0.44 279 557 238 1074 0.741
SCD 10 rs2167444 T>A 0.13 799 232 17 1048 0.390
SLC2A4 17 rs2654185 A>C 0.31 615 386 71 1072 0.707
SLC2A4 17 rs5415 T>C 0.5 309 479 215 1003 0.613
SLC2A4 17 rs5417 O A 0.31 616 382 69 1067 0.702
SLC2A4 17 rsl6956647 OT 0.15 702 326 44 1072 0.252
SLC2A4 17 rs5435 T>C 0.48 310 555 209 1074 0.873
SLC2A4 17 rs3744405 G>A 0.3 621 389 72 1082 0.460
SREBFl 17 rs2297508 G>C 0.46 294 498 212 1004 0.098
SREBFl 17 rs2282180 G>A 0.05 963 107 2 1072 1.000
SREBFl 17 rs9899634 T>A 0.49 266 554 245 1065 0.200
SREBFl 17 rs8066560 T>A 0.44 320 554 197 1071 0.333
SREBFl 17 rs9902941 OT 0.49 265 561 246 1072 0.340
Candidate gene; Chromosome; Seattle SNPs Genome Variation Server on March 
2008 (dbSNP build 126) Version 5.01;4 Major/ Minor allele;5 MAF computed using 
FREQ in S.A.G.E.;6 AA=Homozygous Recessive, AB= Heterozygous, BB=Homozygous 
Dominant; 7 Number of individuals genotyped for each SNP;8 HWE p-values computed 
using PLINK.
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Table 3.7.4: SCD, SLC2A4, and SREBF1 polymorphisms associated with fasting 
lipid phenotypes1,2____________________________________________________
Gcae/
SNP Choi HDL ApoAl LDL VLDL TG
SCD 0.928 0.168 0.774 0.569 0.424 0.227
n 1302593 (0* 0.2 i  S.E.- 0.2) (0--O.4iS.fi.-0.3) (0--0.1 iS.E.*0.3) (8= 0.2 i  S.E.- 0.3) (8- 0.3 i  S.E.- 0.3) (8-0.4 i  S .E -0.3)
SCD 0.535 0.544 0.023 0.571 0.480 0.546
1*522951 (0* -0.1 i  S .E- 0.2) (8--0 .liS .fi.-0 .2) (8- -0.6 i  S.E.- 0.2) (8- -0.1 i  S.E.- 0.2) (8- 0.2 i  S.E.* 0.2) (8-0.1 i S . E - 0.2)
SCD 0.417 0.029 0.006 0.860 0.106 0.113
ra il190480 (8- 0.2 i  S.E.-0.2) (0- 0.7 i  S.E.HJ.3) (8- 1.0iS.E.HL4) (8 -0 .1 i S.E.-0.3) (8- -0.6 i  S.E.H).4) (8- -0.5 i  S.E.-0.3)
SCD 0.669 0.385 0.867 0.317 0.549 0.374
r*3071 (8*0.1 ± S.E-0.2) (8- -0.2 i  S.E.- 0.3) (8“ -0.1iS.E.*0.3) (8= 0.3 i  S.E.- 0.3) (8* 0.2 i  S.E.- 0.3) (8- 0.3 i  S.E.- 0.3)
SCD 0.484 0.531 0.021 0.510 0.589 0.659
ra3829160 (8- -0.1 iS.E.-0.2) (8* -0.1 ±S.E.“  0.2) (8- -0.6 i  S.E.- 0.3) (8“ -0.1 iS .E -0 .2 ) (B- 0.1 iS.E.-0.3) (8- 0.1 iS .E -0 .2 )
SCD 0.556 0.492 0.022 0.554 0.376 0.444
ra2234970 (8«-0.1iS.E.-0.2) (8- -0.1 iS.E.-0.2) (8- -0.6 i  S.E.- 0.3) (8= -0 .1 iSX -0.2) (8- 0.2 i  S.E.- 0.2) (8- 0.2 i  S.E.- 0.3)
SCD 0.938 0.540 0.433 0.774 0.648 0.522
rs59996! (8- 0.0iS.E.« 0.2) (8-0.1 iS .E .-0.2) (8- 0.2 i  S.E.- 0.2) (8- -0 .liS .E -0 .2 ) (8= -0.1 iS .E .- 0.2) (8- -0.1iS.E.- 0.2)
SCD 0.864 0.762 0.052 0.882 0.464 0.531
r*3978768 (8* 0.0 ± S.E- 0.2) (8- 0.0 i  S.E.* 0.2) (8* -0.5 i  S.E.- 0.3) (8- 0.0 i  S.E- 0.2) (8- 0.2 i  S.E.- 0.2) (8-0.1 iS .E -0 .2 )
SCD 0.515 0.045 0.008 0.965 0.103 0.096
n l  1557927 (8* 0.2 i  S.E.- 0.3) (1H 0.7 i  S.E- 0.4) (0» 1.2iS.E.-0.4) (8- -0 .1 iSX -0 .4 ) (8* -0.7 i  S.E.- 0.5) (8- -0.7 i  S.E.- 0.4)
SCD 0.648 0.048 0.008 0.934 0.170 0.092
r*7849 (8- 0.0 ± S .E- 0.2) (8- -0.4 i  S.E.- 0.2) (8- -0.6 i  S.E.- 0.2) (0- 0.1 i  S.E.- 0.2) (8- 0.3 iS .fi.- 0.2) (p -0 .4 iS .E - 0.2}_
SCD 0.441 0.059 0.004 0.768 0.168 0.130
(V2167444 (8-0.2 ± S.EHJ.2) (8«0.6iS.EH>.3) (8-1.0 i  S.E.HL4) (8-0.1 iS.E.H>.3) (8- -0.5 ± S.E.H).4) (8--0.5±S.E.H>.3)
SLC2A4 0.531 0.016 0.166 0.731 0.177 0.148
ra2654185 (0--0.1 iS .E -0 .2 ) (0- -0.5 i  SJE.-0.2) (P--0.4iS.E«0.3) (8-0.1 iS.E.-0.2) (0- 0.4 i  S.E.- 0.3) (8- 0.4 i  S.E.- 0.3)
SLC2A4 0.064 0.001 0.005 0.337 0.054 0.074
7*5415 (8- -0.3 ± S.E.-0.2) (0--O .7iS.EHU ) (8--®.7±SX«4J) (8* -0.2 i  S.E.H).2) (8- 0.5 i  S.E.-0.2) (8- 0,4 i  S.E.H).2)
SLC2A4 0.336 0.009 0.138 0.917 0.211 0.205
ra5417 (8* -0.2 i  SJL- 0.2) (0- -0.6 i  S.E.- 0.2) (0- -0.4 i  S.E- 0.3) (8- 0.0 iS .fi.- 02) (8- 0.3 i  S.E.- 0.3) (8- 0.3 i  S.E- 0.3)
SLC2A4 0.117 0.134 0.060 0.110 0.177 0.308
1*16956647 (8- -0.4iS.fi.-0.2) (8- -0.4 i  SJ2.- 0.3) (8--0.6iS .E .* 0.3) (0- -0.4 i  S.E.* 0.3) (8- 0.4 i  S.E.* 0.3) (0- 0.3 i  S.E.- 0.3)
SLC2A4 0.127 0.003 0.003 0.703 0.124 0.228
r*5435 (8- -0.3 ± S.E.-0.2) (0--0.6iSX .H U ) (0- -0.7 ± S.B.-OJ) (8- -0.1 ±S.E.-0.2) (6- 0.4 i  S.E.HJ.2) (8- 0.3 i  S.E.H>.2)
SLC2A4 0.226 0.009 0.076 0.933 0.344 0.435
r«3744405 (8* -0.2 ± SJE.- 0.2) (8- -0.6 ± S.E.- 0.2) (8=-0.5iS.E.-0.3) (0- 0.0 i  S.E.- 0.2) (8- 0.2 i  S.E.- 0.3) (8-0.2iS.E.-0.3)
SREBF1 0.506 0.824 0.613 0.346 0.894 0.339
n49251t4 (0 --0 .liS .E -0 .2 ) (0- 0.1 i  S.E.- 02) (8-0.1 ±S.fi.- 0.2) (8—0.2iS.E.-0.2) (8-0.0iS .E .-0.2) (8-0.2 iS .E -0 .2 )
SREBF1 0.063 0.554 0.569 0.029 0.490 0.995
1*2297508 (8- 0.3 i  S.E.- 0.2) (8- 0.2 i  S.E.- 0.2) (8= 0.2 i  S.E- 0.2) (8 -0 .5 iS .E -0 J) (8- -0.2 i  SJB.- 0.2) (8-0.0 i  S.E. -  0.2)
SREBF1 0.117 0.272 0.841 0.023 0.979 0.972
7*2282180 (8*-0.5±S.E.-0.4) (8*0.5iS.E.-0.5) (8-0.1 i  S .E -0.5) (8- !.0iS.E.«0.5) (0- 0.0 i  S.E.- 0.5) (8-0.0 i  S .E- 0.5)
SREBF1 0.210 0.285 0.546 0.236 0.586 0.937
7*989963 (8- -0.2 i  S.E.* 0.2) (8*-0.2iS.E.«0.2) (8- -0.2 i  S.E.- 0.2) (8- -0.3iS.E.» 0.2) (8-0.1 iS.E,-0.2) (8- 0.0 i  S.E- 0.2)
SREBF1 0.025 0.546 0.853 0.014 0.910 0.659
1*8066560 (8* 0.4 i  S.E.- 0.2) (0- 0.2 iS .fi.- 0.2) (8*0.1 iS .R -0 .2) (8- 0.5 i  S.E.- 0.2) (8- 0.0 i  S.E.- 0.2) (8-0.1 iS .E -0 .2 )
SREBF1 0.220 0.250 0.647 0.237 0.545 0.945
r*9902941 (0- -0.3 i  S.E.- 0.2) (8- -0.3 i  S.E.- 0.2) (8- -0.1 i  SJE.- 0.2) (8- -0.3 i  S.E.- 0 J ) (8-0.1 iS .E .- 0.2) (8-0.1 iS .E -0 .2 )
1 Association of SNPs in a linear regression model adjusted for age, sex, community membership,
lipid medication and n-3 PUFA intake. Multiple test correction for SCD (7 tests), SLC2A4 (6 test), 
and SREBF1 (4) were estimated using the spectral decomposition of LD matrix . Results in bold are 
significant for SCD at p< 0.007, significant for SCL2A4 at p<0.008 and significant for SREBF1 at 
p<0.013. Estimates of effect size (P) are reported using transformed phenotypes.
2Total cholesterol (Choi), high-density lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density 
lipoprotein (LDL), very-low density lipoprotein (VLDL) and triglycerides (TG).
Table 3.7.5: SCD, SLC2A4, and SREBFl polymorphisms associated with
Gom/SNF BMI PBF HC ThC WC
SCD 0.035 0.098 0.028 0,096 0.142
tv1502593 (0- -0.5±S.E.-0.2) (0= -0.4 * S .E- 0.2) (8- -0.5 * SE.= 0.2) (0- -0.5 * S.E.- 0.3) (0- -0.5 * S.E * 0.3)
SCD 0.242 0.786 0.367 0.482 0.397
re522951 (0- 0.2 * S.E- 0.2) (0-O.O±S.E.- 0.2) (0- 0.2* S.E.- 0 J ) (0- 0.2 * S.E.- 0.2) (0- 0.2 * S.E.- 0.2)
SCD 0.143 0.102 0.101 0.378 0.092
til  1190480 (0--O.4*S.E.K>.3) (0- -0.4 * S.E.-0.2) (0* -0.4 * S.E.-0.3) (0- -0.3 ± S.E.-0.3) (0- -0.6 * S.E.-0.3)
SCD 0.043 0.150 0.028 0.062 0.182
rs3071 (0--O.5±S.E.-O.3) (0= -0.3 * S.E.* 0.2) (0--0.6 * S.E.- 0.3) (0- -0.6 * S.E.- 0.3) (0— -0.4±S.E.- 0.3)
SCD 0,306 0.894 0,450 0.627 0.525
ra3829160 (0- 0.2 * S.E.- 0.2) (0- 0.0 * S.E.- 0.2) (0-0.1 ± S .E -0.2) (0-0.1 ±S.E.= 0.2) (0- 0.2 * S.E.- 0.2)
SCD 0.271 0.848 0.509 0.641 0.444
n2234970 ( ^  0.2 * S.E.* 0.2> (0- 0.0 * S.E.- 0.2) (0-0.1 ±S.E.-0.2) (0-0.1 ±S.E.- 0.2) (0- 0.2 * S.E.- 0.2)
SCD 0.523 0.235 0.347 0.608 0.469
rv599961 (0-0.1 ± S .E -0.2) (0- 0.2 ± S.E.- 0.2) (0- 0.2 * S.E.- 0.2) (0- 0.1 * S.E.- 0.2) (0- 0.2 * S.E.- 0.2)
SCD 0.265 0.735 0.474 0.516 0.458
n3978768 (|H 0.2 ± S.E- 0.2) (0- 0.1 * S.E.- 02) (0-0.1 ±SJJ.- 0.2) (0- 0.1±S.E.= 0.2) (0- 0.2 * S.E -  0.2)
SCD 0.801 0.494 0.613 0.775 0.612
til 1557927 (0- 0.0 * S.E- 0.3) (0- -0.2 * S.E.- 0.3) (0= -0.2 * S.E.- 0.3) (0- 0.1 *S.E.- 0.4) (0- -0.2 * S.E.- 0 J )
SCD 0.786 0.492 0.543 0.631 0.866
tv7849 (0- 0.0 * S.E.- 0.2) (0- -0.1 * S.E.- 0.2) (0- ±SE.-) (0--O.l*S.E.= 0.2) (0- 0.0 * S.E -  0.2)
SCD 0.652 0.615 0.760 0.910 0.499
rv2167444 (0- -0.1 ± SE-0.3) (0--O.US.E.-O.2) (0= -0.1±SE.-0.3) (0= 0.0 * S.E-0.3) (0--O.2±S.E.m.3)
SLC2A4 0.251 0.117 0.011 0.012 0.456
r*2654185 (0- 0.2 * S.E.- 0.2) (0= 0.3 *  S.E- 0.2) (0- 0.5 * S.E.- 0.2) (0- 0.6* S.E-0.2) (0- 0.2 * S.E.- 0.3)
SLC2A4 0.273 0.093 0.005 0.037 0.235
ra5415 (0- 0.2±S.E.-0.2) (0- 0.3 * S.E-0.2) (0- * S .E ^ J ) (0- 0.5 * S.E.-0.2) (0- 0.3 * S.E.-0.2)
SLC2A4 0.322 0.156 0.016 0.020 0.566
n5417 (0- 0.2 * S.E.- 0.2) (0- 0.2* S .E -0.2) (0- 0.5 * S.E.- 0.2) (0-0.4* S.E- 0.4) (0- 0.1* S.E- 0.3)
SLC2A4 0.736 0.832 0.725 0.703 0.781
n!6956647 (0- -0.1 ±S.E.-0.2) (0- 0.0 * S.E- 0.2) (0- 0.1 ±S.E.= 0.2) (0- -0.1 ±S.E.- 0.3) (0= 0.1 ± S .E - 0.3)
SLC2A4 0.365 0.099 0.027 0.040 0.097
n5435 (0- 0.2 * S.E.HJ.2) (0- 0.3 * S.E-O.2) (0- 0.4 * S.E.-0.2) (0- 0.5 * S.E.-0.2) (0- 0.4 * S.E.-0.2)
SLC2A4 0.491 0.267 0.055 0.069 0.846
H3744405 (0-0.1 ±S .E .-0.2) (0- 0.2 ± S.E- 0.2) (0- 0.4 * S.E.- 02) (0-0.4* S .E -0.2) (0- 0.0 * S.E- 0.3)
SREBFl 0.568 0.489 0.677 0.901 0.729
ra492SU4 (0- -0.1 ±S.E.- 0.2) (8--0.I ±S.E.-0.2) (0- -0.1*S.E.-0.2) (0-0.0* S .E -0.2) (0- 0.1 *S.E.-0.2)
SREBFl 0.384 0.374 0.658 0.692 0.677
n2297508 (0- -0.2 * S.E.- 0.2) (0»-O.l±S.E.*O.2) (0= -0.1 ± S .E - 0.2) (0- -0.1 ±S.E.- 0.2) (0--0.1±S.E.-O.2)
SREBFl 0.558 0.772 0.848 0.500 0.421
112282180 (0- 0.2 ± S .E -0.4) (0- * S.E.-) (0- 0.1 ± S .E - 0.4) (0- 0.3 * S.E.- 0.5) (0-0.4* S .E -0.5)
SREBFl 0.503 0.489 0.643 0.837 0.959
r«989963 (0- 0.1 * S.E.* 0.2) (0*0.1 ± S .E - 0.2) (0- 0.1±S.E.-0.2) (0- 0.0 * S.E.- 0.2) (0-0.0* S.E- 0.2)
SREBFl 0.366 0.464 0.703 0.577 0.769
rv8066S60 (0- -0.2 ± S.E.- 0.2) (0--O.1 *S.E.-0.2) (0- -0.1* S.E.— 0.2) (0- -0.1 * S.E-0,2) (0- -0.1 * S.E.-0.2)
SREBFl 0.480 0.444 0.686 0.892 0.953
ii9902941 (0- 0.1 * S.E.- 0.2) (0-0.1 ±S.E-0.2) (B-0.1 ± S .E - 0.2) (0- 0.0 * S.E.- 0.2) (0- 0.0* S .E -0.2)
1 Association of SNPs in a linear regression model adjusted for age, sex, community 
membership and n-3 PUFA intake. Multiple test correction for SCD (7 tests), SLC2A4 (6 
test), and SREBFl (4) were estimated using the spectral decomposition of LD matrix 41. 
Results in bold are significant for SCD at p< 0.007, significant for SCL2A4 at p<0.008 and 
significant for SREBFl at p<0.013. Estimates of effect size (J3) are reported using transformed 
phenotypes.
2Body mass index (BMI), percent body fat (PBF), hip circumference (HC), thigh 
circumference (ThC) and waist circumference (WC).
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3.9 APPENDIX
Supplementary Table 3.9.1: Sequence information used to design primers for 
SLC2A4 SNPs identified through resequencing1.
SNP FASTA Sequence
TGGAGGGCAGGGGTGGGGGAAACAGGAAGGGAGCCACTGCTGGGTGCCCTCACCCTCACAG 
CCTCACTCTGTCTGCCTGCCAGGAAAAGGGCCATGCTGGTCAACAATGTCCTGGCGGTGCTGG 
GGGGCAGCCTCATGGGCCTGGCCAATGCTGCTGCCTCCTATGAAATGCTCATCCTTGGACGAT 
TCCTCATTGGCGCCTACTCAGGTACTCACGGGCACCACAGCCCTGCCTAGCGCCCTGTTCTCT 
TTCACCATGCCTGGGCTTTCAGATGGGAATGGACACCTGCCCTCAGCCCTCTCTTCTTCCCTCG 
CCCAGGGCTGACATCAGGGCTGGTGCCCATGTACGTGGGGGAGATTGCTCCCACTCACCTGC 
GGGGCGCCCTGGGGACGCTCAACCAACTGGCCATTGTTATCGGCATTCTGATCGCCCAGGTG 
SNP 12 ACC [A/G]
GAGCAAGCCTCATGGGTGCCTGGGCAGTGGTTAGAGTGGGGCTCTGGAGAATATGGTGGGCT
TCCAAGGTAAGGCAGAAGGGCTGAGTGACCTGCCTTCTTTCCCAACCTTCTCCCACAGGTGCT
GGGCTTGGAGTCCCTCCTGGGCACTGCCAGCCTGTGGCCACTGCTCCTGGGCCTCACAGTGCT
ACCTGCCCTCCTGCAGCTGGTCCTGCTGCCCTTCTGTCCCGAGAGCCCCCGCTACCTCTACATC
ATCCAGAATCTCGAGGGGCCTGCCAGAAAGAGTAAGCTCTCCCGCTGCAGCCTGGCCCAGGC
CCATGCCTCCGCCTCATCTTGCTAGCACCTGGCTTCCTCTCAGGTCCCCTCAGGCCTGACCTTC
_________ CCTTCTCCAGGTCTGAAGCG_____________________ _^______________________________
TCCCCGGGGCAAGTACACCTGGCCCGTCCTCTCCTCTCAGACCCCACTGTCCAGACCCGCAGA 
GTTTAAGATGCTTCTGCAGCCCGGGATCCTAGCTGGTGGGCGGAGTCCTAACACGTGGGTGG 
GCGGGGCCTTTTGTTCCAGGGACTCTTTTCTCAAAACTTCCCAGTCGGAGGCTGGCGGGAACC 
CGAGAGGCGTGTCTCGCCAGCCACGCGGAGGGGCGTGGCCTC [A/G]
TTGGCCCGCCCCACCAACTCCAGCCAAACTCTAAACCCCAGGCGGAGGGGGCGTGGCCTTCT 
GGGGTGTGCGGGCTCCTGGCCAATGGGTGCTGTGAAGGGCGTGGCCCGCGGGGGCAGGAGC 
SNP 13 GAGGTGGCGGGGGCTTCTCGCGTCTTTTCCCCCAGCCCCGCTCCACAAGATCCGCGGGAGCCC 
CACTGCTCTCCGGGTCCTTGGCTTGTGGCTGTGGGTCCCATCGGGCCCGCCCTCGCACGTCAC 
TCCGGGACCCCCGCGGCCTCCGCAGGTTCTGCGCTCCAGGCCGGAGTCAGAGACTCCAGGAT 
CGGTTCTTTCATCTTCGCCGCCCCTGCGCGTCCAGCTCTTCTAAGACGAGATGCCGTCGGGCT 
TCCAACAGATAGGCTCCGAAGTAGGATTCATCATGAGGGGGCGGGGCGGGGGGGCACGGGT 
CCCGCTTTTCTTGGGCTGGGGTCGCGGTTGGGGTCAGCTGGGGGTGGTTCCTGCGCAGGCGCA 
_________ GGGGGTG AAGGT AGGGGGCTGGCTATTTAT AC ____  _____ ________
1 FASTA sequence for SNP 12 and SNP 13 upstream/ downstream primers extracted from Homo sapiens 
build 37.3 genome database, accession number: NT010718.16.
Supplementary Table 3.9.2: Pairwise linkage disequilibrium (r2) 
between SCD polymorphisms with MAF > 0.05.______________
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pm
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i
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pp
nl502593 1.00 0.99 0.90 1.00 1.00 1.00 1.00 0.98 0.57 0.98
n5229Sl 1.00 0.99 1.00 0.98 0.97 0.31 0.96 1.00 0.53 0.99
n i l 190480 0.99 0.99 0.99 1.00 1.00 0.99 0.99 0.82 0.64 0.95
r*3071 0.90 1.00 0.99 1.00 1.00 1.00 0.99 0.98 0.60 1.00
n3829160 1.00 0.98 1.00 1.00 0.99 0.31 0.97 1.00 0.53 0.99
n2234970 1.00 0.97 1.00 1.00 0.99 0.31 0.97 1.00 0.53 1.00
rs599961 1.00 0.31 0.99 1.00 0.31 0.31 0.31 1.00 0.60 1.00
n3978768 1.00 0.96 0.99 0.99 0.97 0.97 0.31 1.00 0.52 1.00
n i l 557927 0.98 1.00 0.82 0.98 1.00 1.00 1.00 1.00 0.74 0.85
n7849 0.57 0.53 0.64 0.60 0.53 0.53 0.60 0.52 0.74 0.64
n2167444 0.98 0.99 0.95 1.00 0.99 1.00 1.00 1.00 0.85 0.64
Pairwise linkage disequilibrium (r2) was calculated using the hapfreq command in FBAT
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Supplementary Table 3.9.3: Pairwise linkage disequilibrium (r2) between 
SLC2A4 polymorphisms with MAF > 0.05.__________________________
m00WN
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?
rs2654185 0.38 0.99 1.00 0.38 0.93
rs5415 0.38 0.37 0.46 0.74 0.33
rs5417 0.99 0.37 1.00 0.37 0.93
rsl6956647 1.00 0.46 1.00 0.43 0.99
rs5435 0.38 0.74 0.37 0.43 0.37
rs3744405 0.93 0.33 0.93 0.99 0.37
Pairwise linkage disequilibrium (r2) was calculated using the hapfreq command in
FBAT M.
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Supplementary Table 3.9.4: Pairwise linkage disequilibrium (r2) between 
SREBF1 polymorphisms with MAF > 0.05.
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rs4925114 0.55 0.83 0.54 0.55 0.55
rs2297508 0.55 1.00 0.82 0.93 0.83
rs2282180 0.83 1.00 0.85 0.99 0.85
rs9899634 0.54 0.82 0.85 0.78 1.00
rs8066560 0.55 0.93 0.99 0.78 0.78
rs9902941 0.55 0.83 0.85 1.00 0.78
Pairwise linkage disequilibrium (r2) was calculated using the hapfreq command in
FBAT34.
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Supplementary Table 3.9.5: Interaction of n-3 PUFAs with SNPs associated 
with fasting lipid phenotypes
Gene SNP Choi HDL ApoAl LDL VLDL TG
SCD rsl 502593 0.8662 0.3811 0.8268 0.5660 0.2541 0.4402
SCD rs522951 0.2281 0.8279 0.7315 0.0829 0.4033 0.9184
SCD rsl 1190480 0.0047 0.9044 0.7741 0.0114 0.2841 0.2141
SCD rs3071 0.9051 0.6751 0.8079 0.7486 0.2077 0.4208
SCD rs3829160 0.1895 0.7512 0.6030 0.0435 0.5592 0.9704
SCD rs2234970 0.1831 0.8314 0.6240 0.0403 0.5529 0.9297
SCD rs599961 0.2418 0.4961 0.2955 0.4177 0.4964 0.5826
SCD rs3978768 0.4872 0.5900 0.2671 0.1544 0.5402 0.9584
SCD rsl 1557927 0.0367 0.4547 0.2774 0.1164 0.8575 0.8680
SCD rs7849 0.2757 0.9062 0.9227 0.1966 0.2482 0.7979
SCD rs2167444 0.0068 0.3715 0.2477 0.0420 0.5656 0.4656
SLC2A4 rs2654185 0.2275 0.7318 0.8961 0.2581 0.2134 0.4742
SLC2A4 rs5415 0.4927 0.3046 0.8049 0.1734 0.2367 0.3403
SLC2A4 rs5417 0.2320 0.7664 0.8896 0.2443 0.2279 0.4614
SLC2A4 rsl 6956647 0.4212 0.4561 0.5396 0.6295 0.3108 0.2143
SLC2A4 rs5435 0.1049 0.9924 0.4728 0.0289 0.9975 0.9698
SLC2A4 rs3744405 0.1786 0.5428 0.4536 0.1921 0.4040 0.6017
SREBF1 rs4925114 0.6395 0.7611 0.6492 0.3862 0.7563 0.6924
SREBF1 rs2297508 0.4669 0.3693 0.5635 0.8818 0.5992 0.3834
SREBF1 rs2282180 0.3959 0.6507 0.9422 0.2718 0.2324 0.2260
SREBF1 rs9899634 0.3962 0.4781 0.8808 0.6098 0.9859 0.9324
SREBF1 rs8066560 0.7545 0.3883 0.8447 0.9583 0.7097 0.7330
SREBF1
It____
rs9902941 0.3351 0.4362 0.8801 0.5589 0.9669 0.9511
community membership and lipid medication. Multiple test correction for SCD (7 tests), SLC2A4 (6 
test), and SREBF1 (4) were estimated using the spectral decomposition of LD matrix41. Results in 
bold are significant for SCD at p< 0.007, significant for SCL2A4 at p<0.008 and significant for 
SREBF1 atp<0.013.
2Total cholesterol (Choi), high-density lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density 
lipoprotein (LDL), very-low density lipoprotein (VLDL) and triglycerides (TG).
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Supplementary Table 3.9.6: Interaction of n-3 PUFAs with SCD SNPs associated 
with cholesterol after correction for HDL-Cholesterol
Gene SNP HDL
SCD rsl 1190480 0.0113
SCD 
1, .
rs2167444 0.0494
community membership, lipid medication and HDL-cholesterol. Multiple test correction for SCD (7 
tests) was estimated using die spectral decomposition of LD matrix 41. Results in bold are significant 
for SCD at p< 0.007.
2Total cholesterol (Choi), high-density lipoprotein (HDL), apolipoprotein Al (ApoAl), low-density 
lipoprotein (LDL), very-low density lipoprotein (VLDL) and triglycerides (TG).
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Supplementary Table 3.9.7: Interaction of n-3 PUFAs with SNPs associated 
with obesity phenotypes
Gene Chr SNP BMI PBF HC ThC WC
SCD 10 rsl 502593 0.1497 0.1159 0.2032 0.4985 0.0906
SCD 10 rs522951 0.5770 0.4491 0.4985 0.2010 0.5257
SCD 10 rsl 1190480 0.3189 0.4121 0.6211 0.6051 0.1512
SCD 10 rs3071 0.1953 0.1911 0.3325 0.2852 0.0769
SCD 10 rs3829160 0.6801 0.4347 0.5418 0.2593 0.5929
SCD 10 rs2234970 0.6465 0.5018 0.5480 0.2448 0.6016
SCD 10 rs599961 0.3996 0.7416 0.7654 0.5990 0.1629
SCD 10 rs3978768 0.6603 0.4614 0.5171 0.2304 0.5954
SCD 10 rsl 1557927 0.0208 0.0745 0.0907 0.1139 0.0406
SCD 10 rs7849 0.9300 0.8702 0.9177 0.7431 0.3354
SCD 10 rs2167444 0.2666 0.4612 0.5347 0.5101 0.1921
SLC2A4 17 rs2654185 0.4226 0.7133 0.8995 0.3010 0.9028
SLC2A4 17 rs5415 0.3955 0.4168 0.6639 0.5996 0.3415
SLC2A4 17 rs5417 0.7591 0.6869 0.8890 0.2810 0.8792
SLC2A4 17 rsl 6956647 0.2915 0.2121 0.5556 0.1387 0.5453
SLC2A4 17 rs5435 0.8464 0.6722 0.7169 0.9704 0.8436
SLC2A4 17 rs3744405 0.2330 0.4205 0.2421 0.1065 0.3141
SREBFl 17 rs4925114 0.9581 0.6534 0.8754 0.3503 0.8454
SREBFl 17 rs2297508 0.4590 0.3597 0.4123 0.5249 0.4195
SREBFl 17 rs2282180 0.7614 0.1722 0.8973 0.5014 0.6044
SREBFl 17 rs9899634 0.4897 0.3004 0.5648 0.2227 0.3570
SREBFl 17 rs8066560 0.7541 0.4570 0.6558 0.7643 0.6912
SREBFl 17 rs9902941 0.3957 0.2636 0.4799 0.1768 0.3059
Interaction of SNPs and n-3 PUFA intake in a linear regression model adjusted for age, sex, 
community membership and lipid medication. Multiple test correction for SCD (7 tests), SLC2A4 (6 
test), and SREBFl (4) were estimated using the spectral decomposition of LD matrix 41. Results in 
bold are significant for SCD at p< 0.007, significant for SCL2A4 at p<0.008 and significant for 
SREBFl at p<0.013.
2Body mass index (BMI), percent body fat (PBF), hip circumference (HC), thigh circumference 
(ThC) and waist circumference (WC).
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OBESITY POLYMORPHISMS IDENTIFIED IN GENOME-WIDE 
ASSOCIATION STUDIES INTERACT WITH n-3 POLYUNSATURATED 
FATTY ACID INTAKE AND MODIFY GENETIC ASSOCIATIONS WITH 
ADIPOSITY PHENOTYPES IN YUP’IK PEOPLE3
4.1 ABSTRACT
BACKGROUND: n-3 polyunsaturated fatty acids (n-3 PUFAs) have anti-obesity effects 
that may modulate risk of obesity, in part, through interactions with genetic factors. 
Genome-wide association studies (GWAS) have identified genetic variants associated 
with BMI; however the extent to which these variants influence adiposity through 
interactions with n-3 PUFAs remains unknown. DESIGN: We evaluated 10 obesity 
GWAS SNPs for individual and cumulative associations with adiposity phenotypes in a 
cross-sectional sample of Yup’ik people (n=1073) and evaluated whether genetic 
associations with obesity were modulated by n-3 PUFA intake. A genetic risk score 
(GRS) was calculated by adding the BMI-increasing alleles across all 10 SNPs. Dietary 
intake of n-3 PUFAs was estimated using nitrogen stable isotope ratios (815N) of red 
blood cells (RBC) and genotype-phenotype analyses were tested in linear models 
accounting for familial correlations. RESULTS: FTO was positively associated with 
percent body fat (PBF, p=0.0039) and ETV5 was negatively associated with hip and thigh 
circumference (HC, p=0.002 and ThC, p=0.003, respectively). GRS was positively 
associated with adiposity phenotypes including: BMI (p=0.012), PBF (p=0.022), ThC 
(p=0.025) and waist circumference (WC, p=0.038). The variance in adiposity 
phenotypes explained by the GRS included: BMI (0.7%), PBF (0.3%), ThC (0.7%) and 
WC (0.5%). GRS interactions with n-3 PUFAs modified the association with adiposity
3 Lemas, DJ, Klimentidis YC, Wiener HW, O’Brien DM, Hopkins S, Allison DB, 
Fernandez, JR, Tiwari HK, Boyer BB. 2012. Obesity Polymorphisms Identified in 
Genome-Wide Association Studies Interact with n-3 Polyunsaturated Fatty Acid Intake 
and Modify Genetic Associations with Adiposity Phenotypes in Yup’ik People. Prepared 
for submission to The International Journal o f Obesity.
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and accounted for more than twice the phenotypic variation (-1-2%), relative to GRS 
associations alone. CONCLUSION: Obesity GWAS SNPs contribute to adiposity in this 
study population and interactions with n-3 PUFA intake potentiated the risk of fat 
accumulation among individuals with high obesity GRS. These data suggest the anti­
obesity effects of n-3 PUFAs among Yup’ik people, in part, may be dependent upon an 
individual’s genetic predisposition to obesity.
4.2 INTRODUCTION
Obesity contributes to a series of metabolic abnormalities including elevated 
triglycerides and inflammatory cytokines, and insulin resistance which ultimately 
increases the risk of developing type 2 diabetes (T2D) and other diseases.1 Given the 
increasing public health burden associated with obesity and the difficulty achieving and 
maintaining weight loss,2-4 it is important to define mechanisms that influence body 
weight.
The heritability of obesity has been estimated to between 40-70%.5,6 A recent 
meta-analysis of obesity genome-wide association studies (GWAS) conducted primarily 
in European samples has identified single nucleotide polymorphisms (SNPs) associated 
with variation in BMI.7 The extent to which these loci are associated with adiposity 
phenotypes in other ethnic groups is unclear.8,9 Furthermore, although considerable 
progress has been made in elucidating SNPs associated with excess body weight, the 
heritability of obesity explained by these loci remains low (<2%).7 Increasingly, gene- 
by-environment interactions have been suggested to account for the “missing heritability” 
in complex traits.10 Experimental evidence demonstrating that interactions between 
genetic variants and environmental factors partially account for the heritability of obesity 
may help elucidate important mechanisms that can modulate the risk of obesity related 
co-morbidities through lifestyle interventions.
Total dietary fat has been implicated in the development of obesity,11 however a 
growing body of evidence indicates that not all dietary fatty acids are equally
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obesigenic.12 Regular consumption of n-3 polyunsaturated fatty acids (n-3 PUFAs) may 
reduce adiposity in humans,13 in part, by inhibiting adipogenesis14 and stimulating fat 
oxidation.15 Animal models have shown significant reductions in fat mass when dietary 
n-3 PUFAs, namely eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), are 
substituted for saturated fats,16 monosaturated fats,17 and n-6 polyunsaturated fats,18 after 
controlling for caloric intake. These findings have largely been confirmed by human 
studies,19 however information regarding whether the anti-obesity effects attributed to n-3 
PUFA is dependent upon a specific genotype remains limited. Knowledge about the 
interplay between genetic factors and consumption of n-3 PUFA may facilitate the choice 
of more effective and specific measures of obesity prevention based upon individualized 
genetic make-up.
Given the anti-obesigenic effects of n-3 PUFAs, the widely varying intake of n-3 
PUFA in this study population of Yup’ik people (nearly 30-fold range), and the 
availability of a precise biomarker for n-3 PUFA intake (815N ;21); we evaluated whether 
n-3 PUFA intake modifies the association between GWAS SNPs and adiposity 
phenotypes. The individual and cumulative effects of 10 SNPs reproducibly associated 
with BMI22-26 were tested in a sample of Yup’ik people from the Center for Alaska 
Native Health Research (CANHR) study. We evaluated the cumulative effects of these 
SNPs using a genetic risk score (GRS) that estimates an individual’s genetic 
predisposition to obesity by adding the BMI-increasing alleles across all 10 SNPs.
4.3 METHODS
4.3.1 PARTICIPANTS AND STUDY DESIGN
The CANHR studies genetic, behavioral, and dietary risk factors underlying 
obesity and their relationship to diabetes and cardiovascular disease among Yup’ik 
people.27 Recruitment of Yup’ik participants was initiated in 2003 and continues in 11 
Southwest Alaskan communities. All residents >14 years old were invited to participate 
and the resulting distribution of age in our study sample reflects the age distribution
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among eligible participants according to 2000 U.S. census data. Participants signed 
informed-consent documents before entering the study using protocols that were 
approved by the University of Alaska Institutional Review Board, the National and 
Alaska Area Indian Health Service Institutional Review Boards, and the Yukon 
Kuskokwim Human Studies Committee. Summary statistics regarding family data were 
calculated using PEDINFO in the Statistical Analysis for Genetic Epidemiology 
(S.A.G.E., 2009) software. The analyses in this report included 1073 non-pregnant 
Yup’ik participants (41 founders, 920 non-founders, and 112 singletons) with ages 
ranging between 14 and 94 years at enrollment. There were 195 pedigrees in this data set 
with a mean size 5.52 individuals (range, 1-849) and 696 sibships with a mean size of 
1.32 (range, 1-9).
4.3.2 ANTHROPOMETERIC AND BIOCHEMICAL MEASUREMENT
Trained staff obtained anthropometric measurements using protocols from the 
NHANES III Anthropometric Procedures Manual 28 as previously described.29 These 
measurements included height, weight and 4 circumferences (waist, hip, triceps, and 
thigh). Percent body fat (PBF) was measured by electrical bioimpedance using a Tanita 
TBF-300A bioimpedance analyzer (Tanita Corp, Arlington Heights, IL, U.S.A.).
4.3.3 BIOMARKER OF n-3 PUFA INTAKE
n-3 PUFA intake was assessed using the nitrogen stable isotope ratio (815N) of red 
blood cells (RBC), which has been validated as a biomarker for EPA and DHA intake as 
previously described.21 The time to 50% turnover of RBC is approximately 45 days 30, 
therefore, the mean RBC 8I5N values reflect a mean n-3 PUFA intake over 1.5 months.
1.8 pi aliquots of RBC were pipetted into 3.5 x 3.75 mm tin capsules, autoclaved for 20 
minutes at 121°C to destroy blood-bome pathogens, and dried to a constant mass of 0.2 -
0.4 mg. Capsules were crushed into a ball for loading into an autosampler. Samples were 
analyzed at the Alaska Stable Isotope Facility by continuous-flow isotope ratio mass
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spectrometry, using a Costech ECS4010 Elemental Analyzer (Costech Analytical 
Technologies, Valencia, CA, USA) interfaced to a Finnigan Delta Plus XP isotope ratio 
mass spectrometer via the Conflo III interface (Thermo-Finnigan Inc., Breman, 
Germany). Isotope ratios are analyzed relative to IAEA-certified reference materials 
calibrated to atmospheric nitrogen, for which 15N/14N = 0.0036765. By convention and 
for ease of interpretation, isotope ratios are presented as delta values in “permil” relative 
to atmospheric nitrogen: 815N = [(,5N/14Nsampie -  15N/14NstaiKiardy(15N/14Nslandard)] • 1000%o. 
We concurrently prepared and ran multiple laboratory standards (peptone, 51SN = 7.00) to 
assess analytical accuracy and precision; these were analyzed after every eighth sample 
and gave values of 81SN = 7.01 ± 0.24%o (mean ± SD). The range of isotopic variation in 
our dataset (9%o) was very large relative to analytical precision (0.2%o). We modeled the 
effects of n-3 PUFA intake as a categorical variable with four groups by quartile, which 
is hereafter referred to as 815N.
4.3.4 SNP SELECTION AND GENOTYPING
SNP genotyping for the present study was completed in 2009 and include 10 
obesity loci that have recently been implicated in an obesity GWAS meta-analysis.7 In 
situations where more than a single SNP has been identified for a given gene, we 
genotyped the SNP most frequently reported in these studies. Genotyping was carried 
out at the Broad Institute (Cambridge, MA) by allele-specific primer extension of 
multiplex amplified products and detection using matrix-assisted laser desorption 
ionization time-of-flight spectrometry on a Sequenom iPLEX platform.31 We compared 
the frequency of the GWAS BMI-increasing ‘risk alleles’ in Yup’ik people to five 
HapMap populations.32
4.3.5 QUALITY CONTROL OF PHENOTYPIC AND GENOTYPIC DATA
Simple linear models were fit to each phenotype using all covariates (age, sex, 
community group) included in the association models, and the distributions of the
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residuals for each phenotype were examined for normality with the R statistical 
programming language (v2.10.1, R Development Core, 2009). We considered a series of 
transformations (square root, log, inverse) to improve normality and the Box-Cox 
transformation33 was identified as the best procedure for phenotypes whose residuals did 
not follow a normal distribution. Information regarding the power transformation for 
each adiposity phenotypes is presented in Supplementary Table 4.9.1, Family data 
were stored in the Progeny database (Progeny Software LLC, South Bend, IN, U.S.A.) 
and merged into a single extended pedigree comprised of multiple independent families 
using PedMerge.34 Genotypic data were tested for Mendelian inconsistencies using 
PEDCHECK.35 In this sample, Illumina IV linkage panel (Illumina, Inc., San Diego, CA, 
USA) genotypes were available from an ongoing linkage study and were used to 
construct principal components using the EIGENSTRAT analysis package. The first 
PC did not have an obvious interpretation to the data however the second PC 
discriminated individuals into two groups that corresponded to either coastal or inland 
communities. Based on this, we defined a dichotomous community group variable that 
indicates either coastal or inland. We assessed Hardy-Weinberg equilibrium (HWE) in 
the founders using PLINK (vl.07)37 and determined minor allele frequency (MAF) for 
each SNP using the FREQ module in the Statistical Analysis for Genetic Epidemiology 
(S.A.G.E 2009) program. The present study restricted association and interaction analysis 
to SNPs with MAF > 5% that did not deviate from HWE (p<0.005). HWE multiple test 
correction was determined using a Bonferroni correction for 10 tests (a<0.005).
4.3.6 ASSOCIATION ANALYSIS
Each SNP was tested using as additive model for association with obesity-related 
phenotypes using the ASSOC module in the S.A.G.E. software package.38 We included 
both demographic (age, community group, and sex) and environmental covariates (815N) 
in the association analysis and calculated likelihood ratio statistics to compare 4 nested 
models. Model 1 included demographic covariates (age, sex and community group);
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Model 2 included baseline covariates and SNP to test for an additive genetic effect of 
SNP (defined as the number of minor alleles); Model 3 included demographic covariates, 
the additive genetic effect of SNP, and 815N (defined by quartiles of 8,5N) as an estimate 
of n-3 PUFA intake; Model 4 included all covariates from Model 3 and an interactions 
between the additive genetic effect and 8I5N categories. Note that the model 4 is the only 
model to test gene-diet interactions. Correction for multiple testing in genetic analyses 
(models 1-4) for SNPs with MAF >0.05 employed a Bonferroni correction for 10 tests 
(a<0.005). Effect sizes (p) were presented for association analyses as the change in 
transformed phenotypes according to BMI-increasing “risk allele” adjusted for 
demographic and environmental covariates.
4.3.7 GENETIC RISK SCORE ANALYSIS
The obesity genetic risk score (GRS) was calculated by summing the number of 
risk alleles that each individual possessed. The obesity risk alleles were defined as those 
that were associated with higher BMI (defined as BMI > 25 kg/m2) in previous GWAS 
studies.7,25’26 To account for missing genotypes, we divided the sum of risk alleles by the 
number of loci included in the score. The GRS was split into three groups by tertiles 39 
and a categorical variable was created to allow for non-linear effects without being 
unduly influenced by extreme values. We tested the GRS for association with obesity 
traits using two models (model 5 and 6) run with the ASSOC module in S.A.G.E. Model 
5 included the GRS as a main effect and controlled for demographic (sex, age, and 
community group) covariates. Model 6 tested the GRS for interaction with 8,5N and 
controlled for demographic covariates and 81SN. Model 7 tested for interactions 
(815N*GRS) in a model that included demographic covariates and interactions between 
the GRS and quartiles of 81SN. Note that model 7 is the only model to test gene-diet 
interaction. In a subset of participants (n=488), we evaluated 24 Hour Recalls (24HR) to 
estimate total energy (kcal) and total fat intake (% calories) as potential confounding 
dietary variables in the 815N*GRS interaction model (model 7). The variance explained
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by the fixed effects in the GRS association models were calculated as the difference 
between the total variance of the trait and the sum of the random effects in the model (i.e. 
the residual variance and the family effect). The proportion of variance explained by 
random effects was calculated whereby the ratio of the difference noted above was 
included in the numerator and the total variance of the trait was included in the 
denominator. We defined the proportion of the variance explained by each term in the 
GRS association model as the difference in proportion of variance explained by models 
with and without the terms of interest. Results were considered significant in the GRS 
analyses (models 5-7) if the p-value was < 0.05 (2-tailed).
4.4 RESULTS
4.4.1 DESCRIPTIVE STATISTICS
Descriptive statistics on Yup'ik men (n=510) and women (n=563) enrolled in this 
study are presented in Table 4.7.1. Yup'ik women in this study had a mean age of 38.5 
(±1.6) years and had more adiposity than men that reported a mean age of 36.6 (±0.6) 
years. Specifically, women had more adiposity that included greater BMI (p<0.0001), 
percentage body fat (p<0.0001) and hip circumference (p<0.0001) compared to men. 
Interestingly, we did not detect significant differences between women and men with 
respect to waist circumference.
4.4.2 DISTRIBUTION OF 815N IN THE STUDY POPULATION
We assessed n-3 PUFA intake in 1073 Yup’ik participants using RBC 515N as a 
biomarker of EPA and DHA intake. Summary statistics are grouped by gender and 815N 
quartiles and reported in Table 4.7.2. The mean 815N value in this study was 9.0%o, and 
ranged from 6.4%o tol5.2%o. According to the linear relationship between RBC 815N and 
RBC EPA described elsewhere for this study population,21 the corresponding mean EPA 
(%RBC fatty acids) was 2.66%. Measurement of 815N by gender yielded means of 9. l%o 
for females and 8.7%o for males. The mean RBC 815N values according to the four
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groups by quartile were: 7.3%o, 8.2%o, 9.1%o, 11.0%o in groups 1-4, respectively. These 
values correspond to EPA (% RBC fatty acids) group means of: 0.9%, 1.8%, 2.8%, and 
4.7% 21. The standard deviation of 815N in this sample did not differ according to gender 
(1.5%o for both females and males).
4.4.2 GENETIC VARIATION AMONG OBESITY SNPS
Allele frequencies for 10 SNPs that showed significant association with obesity 
and/or BMI in large-scale GWAS are presented in Table 4.7.3. The frequencies for risk 
alleles observed in this sample of Yup’ik people were comparable to frequencies reported 
in other populations (Table 4.7.3). Notable exceptions include the rs l0838738 (MTCH2) 
and the rs7498665 (SH2B1) risk alleles which are at higher frequencies among this 
sample of Yup’ik people. All genotyped SNPs were consistent with expected HWE 
(p>0.002) and had MAF > 0.05 with the exception of rs6265 (BDNF) which had 
MAF=0.04.
4.4.3 INDIVIDUAL SNPS AND ADIPOSITY PHENOTYPES
Without adjustment for n-3 PUFA intake (515N), no SNPS were significantly 
associated with adiposity phenotypes after Bonferroni multiple test correction 
(Supplementary Table 4.9.2). Although not significant, 8 of the 10 SNPs tested in this 
study had direction-consistent associations trends with BMI that were in agreement with 
reports from GWAS. After adjusting our analyses for n-3 PUFA intake (SlsN), we found 
that rs9939609 (FTO) and rs7647305 (ETV5) risk alleles were associated with adiposity 
phenotypes (Figure 4.6.1 and Table 4.7.4). Specifically, rs9939609 (FTO) was 
positively associated with percent body fat (PBF, p=0.004) and rs7647305 (ETV5) was 
negatively associated with hip and thigh circumference (HC, p=0.002 and ThC, p=0.003, 
respectively). We did not detect significant SNP interactions with n-3 PUFA intake that 
modified any associations with adiposity phenotypes (Supplementary Table 4.9.3).
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4.4.4 GENETIC RISK SCORE AND ADIPOSITY PHENOTYPES
The GRS was positively associated with adiposity as measured by BMI 
(p=0.012), PBF (p=0.022), ThC (p=0.025) and WC (p=0.038) after adjusting for n-3 
PUFA intake (815N) (Table 4.7.5). The GRS interactions with n-3 PUFA intake were 
significant for BMI (p=0.011), PBF (p=0.025), and WC (p=0.018). Figure 4.6.2 and 
Table 4.7.5 show that n-3 PUFA intake significantly modifies the GRS association with 
BMI, such that people with the highest BMI also had high levels n-3 PUFA intake (Q4) 
and a high GRS (T3). In contrast, our results show that people with a low GRS (Tl) and 
high levels of n-3 PUFA intake (Q4) had a lower BMI, relative to individuals with the 
same GRS (Tl) and low n-3 PUFA (QI) intake (Figure 4.6.1). The GRS interaction with 
n-3 PUFA explained approximately twice the phenotypic variation in adiposity 
phenotypes relative to GRS associations with adiposity alone (Table 4.7.6).
4.5 DISCUSSION
In this study, we evaluated 10 SNPs identified in a previous meta-analysis of 
obesity GWAS7 for individual and cumulative associations with adiposity phenotypes in 
a cohort of Yup’ik people and assessed whether exposure to n-3 PUFAs modified these 
associations. After corrections for n-3 PUFA consumption, we found rs9939609 (FTO) 
was positively associated PBF and rs7647305 (ETV5) was negatively associated with 
ThC and HC. Interestingly, controlled feeding studies in rodents have shown that n-3 
PUFAs decrease adiposity by reducing central fat mass;40 however epidemiological 
evidence in humans supporting the anti-obesity effects of n-3 PUFAs remains 
controversial.13 Our analyses indicate that genetic predisposition to obesity, as measured 
by the GRS, was positively associated with adiposity and interactions with n-3 PUFA 
intake modified these associations whereby among individuals with a low GRS, n-3 
PUFA intake did not increase BMI. However, if you have a moderate (2) or high (3) 
GRS, n-3 PUFAs intake is obesigenic. Taken together, these results suggest the anti­
obesity effects of n-3 PUFA in humans may be dependent upon an individual’s genetic
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predisposition to obesity. Consistently, GWAS have identified SNPs associated with BMI 
in European populations that are located within the first intron of FTO.7,22,26 To date, 
most FTO candidate gene studies have been conducted on the rs9939609 SNP mainly 
because this variant has the strongest known association of any SNP with BMI.41 
Subsequent to the discovery of the rs9939609 SNP, European,42 African,43 and Asian44 
study populations have largely confirmed the association of FTO with BMI, although this 
is not without exception.9,45 Our data indicates the rs9939609 (FTO) risk allele was 
positively associated with PBF in Yup’ik people and supports other studies indicating 
that variation in FTO contributes to fat accumulation.46
In contrast to rs9939609 (FTO), candidate gene studies that have replicated the 
rs7647305 (ETV5) association with obesity remain limited.47-49 A prospective sample of 
7,146 European children showed the ETV5 (rs7647305) SNP was associated with 
increased BMI and body weight 47 and a cohort of 18,014 middle-aged Danish adults 
demonstrated the ETV5 (rs7647305) SNP was associated with increased odds of being 
overweight and/or obese.49 Finally a prospective study among 20,428 European adults 
with an average follow-up of 12.9 years demonstrated the ETV5 (rs7647305) SNP was 
associated with protection from developing T2D and this association was stronger after 
correcting for BMI48 Our study was not able to evaluate whether the ETV5 (rs7647305) 
SNP was associated with protection from developing T2D in Yup’ik people due to our 
cross-sectional study design. However, our results do support the ETV5 (rs7647305) 
locus in obesity pathogenesis by showing the ETV5 (rs7647305) C allele was associated 
with reduced HC and ThC and near associations for reduced BMI, PBF, and WC. 
Moreover, despite the fact that overweight and obesity prevalence among Yup’ik people 
resembles the prevalence of overweight and obesity in the general U.S. population, T2D 
prevalence remains low (~3%).27 These results are consistent with the finding of Li et al. 
(2011) in that ETV5 (rs7647305) was associated with protection from T2D 48. 
Interestingly, the ETV5 (rs7647305) associations with adiposity phenotypes in Yup’ik 
people were “opposite” to those reported in subjects of Europeans ancestry47,49
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Although this lack of consistency can be attributed to type I error, theoretical modeling 
has argued that “flip-flop” association can be attributed to population differences that 
occur when the SNP of interest is correlated with the causal variant through linkage 
disequilibrium.50
The GRS, which evaluates the cumulative association of 10 obesity GWAS loci, 
was positively associated with several measures of obesity (BMI, PBF, ThC, WC) in our 
study population. Consistent with previous studies, our analysis demonstrated the GRS 
predicts < 1% of the BMI variation in this sample of Yup’ik people (0.7% for BMI). Li 
et al. included 12 SNPs that explained 0.9% of BMI variation in Europeans,51 Takeuchi 
et al. calculated a GRS with 14 SNPs that explained 0.65% among Japanese,52 and 
Peterson et al. included 56 SNPs explained 0.66% of the variation in BMI among a 
mixed sample of European- and African-Americans.53 We calculated a GRS in this study 
using 5 obesity GWAS SNPs that overlap with Li et al., 51 7 obesity GWAS SNPs that 
overlap with Takeuchi et al.52 and 9 obesity GWAS SNPs that overlap with Peterson et 
al..53 Taken together, these results suggest that while considerable progress has been 
made in gene discovery, obesity SNPs highly replicated in GWAS do not yet predict a 
significant proportion of the heritability attributed to adiposity phenotypes.
Increasingly, experimental designs are considering gene-environment interactions 
to account for the “missing heritability” associated with complex phenotypes like 
obesity.10 Given the established contribution of n-3 PUFAs to changes in adiposity 
phenotypes and the availability of a precise biomarker for n-3 PUFA intake (815N) in 
Yup’ik people,21 we tested whether individual SNPs and the GRS associations with 
adiposity phenotypes were modified by consumption of n-3 PUFA. Our analysis 
demonstrated that elevated n-3 PUFA intake with an increased GRS strengthened the 
association with adiposity phenotypes. Interestingly, the interaction of GRS with n-3 
PUFA intake accounted for approximately twice the phenotypic variation as the genetic 
risk score alone. These results are consistent with gene-by-environment analysis 
conducted by Li et al. that demonstrated physical activity interactions with a GRS,
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calculated from 12 obesity risk alleles, accounted for twice as much phenotypic variation 
in obesity-related traits relative to the genetic risk score alone.51
The strengths of this study include a sample size large enough to detect significant 
SNP associations and a statistical approach that accounts for relationships among 
participants while also allowing for covariates. Our study population of Yup’ik people 
was ideally suited to test the contribution of n-3 PUFA intake 54,55 and genetic factors 56 
to changes in adiposity phenotypes. Given the 30-fold range of n-3 PUFA 
consumption57 in this study population, an additional strength of this study includes a 
biomarker of EPA and DHA intake (8,5N) that can be precisely estimated in large 
epidemiological studies.21 A potential limitation of our study was that n-3 PUFA intake 
may be confounded by total fat and total energy intake due to a traditional diet pattern 
that is high in fat. Given this limitation, it is possible that the 515N*GRS interaction with 
adiposity phenotypes may have been influenced by total fat or total energy intake. We 
evaluated this limitation in a subset of participants (n=488) by including total energy 
(kcal) and total fat intake (% calories), derived from 24 Hour Recalls (24HR), as an 
additional covariate in the 815N*GRS interaction model (model 7). Our follow-up 
analysis did not find that including total energy and total fat or intake in the 815N*GRS 
interaction model significantly changed the results (Supplementary Table 4.9.4). These 
data indicate the GRS’"n-3 PUFA interactions were not appreciably confounded by total 
fat and total energy intake and suggest that n-3 PUFA intake may modulate the risk 
associated with obesity susceptibility genes.
In conclusion, cross-sectional studies of this nature have potential to elucidate 
novel gene-diet interactions that may ultimately help account for some of the “missing 
heritability” associated with obesity.58 To the extent that genetic predisposition to 
obesity is estimated by 10 SNPs reproducibly identified through GWAS, our results 
suggest that including n-3 PUFA interactions increased the ability to detect the 
contribution of these SNPs to changes in BMI. In contrast, individuals with no genetic 
predisposition to obesity, as measured by GRS, had less adiposity in the presence of high
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n-3 PUFA intake. Although animal and human studies have reported that consumption of 
n-3 PUFAs may reduce adiposity,13 our results indicate the anti-obesity effects of n-3 
PUFAs may, in part, be dependent upon an individual’s genetic predisposition to obesity. 
Characterizing gene-diet interactions in with high intakes of n-3 PUFAs may help 
identify individuals that are likely to benefit from specific dietary interventions. 
Interestingly, these analyses do suggest anti-obesity effects of n-3 PUFA intake are 
dependent upon an individual’s genotype and may play an essential role in determining 
the risk associated with obesity susceptibility genes among Yup’ik people. Additional 
genomic studies will be required to replicate these results in large circumpolar 
populations with widely varying intake of n-3 PUFA in order to determine the validity 
and public health implication.
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Figure 4.6.5: Obesity GWAS polymorphisms associated with adiposity phenotypes.
Association of SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 
PUFA intake. The red line represents multiple test correction that was estimated using the Bonferroni 
correction. Body mass index (BMI), percent body fat (PBF), hip circumference (HC), thigh circumference 
(ThC) and waist circumference (WC).
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Figure 4.6.6: n-3 PUFA intake modifies the genetic risk score (GRS) association with BMI.
n-3 PUFA intake (815N) is represented as a categorical variable with four groups by quartile (Q1-Q4) 
where Q1 is lowest level of n-3 PUFA intake and Q4 is the highest level of n-3 PUFA intake (p=0.011). 
The GRS is represented as a categorical variable with three groups by tertiles (T1-T3) where T1 is lowest 
obesity GRS and T3 is highest obesity GRS.
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4.7 TABLES
Table 4.7.1: Descriptive statistics of adiposity phenotypes 1,2
Variables Women Men P-vaiues
No. of participants 563 510
Age (yrs) 38.5 ± 1.6 36.6 ±0.6 0.0740
BMI (kg/m2) 28.7 ±5.6 26.3 ± 5.6 <0.0001
Percentage Body Fat (%) 42.8 ±1.4 27.8 ± 1.1 <0.0001
Waist Circumference (cm) 88.1 ±21.6 87.5 ±21.5 0.5039
Hip Circumference (cm) 105.4 ±43.0 98.7 ±43.0 <0.0001
Thigh Circumference (cm)
i ... _ _ _
51.1 ±21.4 50.3 ±21.3 0.0110
1 Values are reported as mean (± S.E.) predicted from linear model accounting for familial 
correlations.
2 P-values for differences by gender are derived using student t-test.
I l l
Table 4.7.2: Distribution of the RBC nitrogen stable isotope ratio (815N)1,2
Sex Q uartiles of
Total W omen M en Ql Q2 Q3 Q4
No. of participants 1073 565 510 262 261 269 281
M ean ± SD (V ) 9.0 ±1.5 9.1 ±1.5 8.7 ±1.5 7.3 ±0.3 8.2 ±0.2 9.1 ±0.3 11.0 ±1.1
M aximum 15.2 15.2 13.5 7.8 8.6 9.8 15.2
M inim um 6.4 6.4 6.4 6.4 7.8 8.6 9.8
Range (X#)
I t ___ _________________________  _____
8.8 8.8 7.1 1.4 0.8 1.2 5.4
'Isotope ratios are presented as delta values in “permil” relative to atmospheric nitrogen: 8 I5N = [(15N/1',NMmpie -  
“N/'X-artW ,SN/14N«»d«d)] • 1000%o.
2The relationship between 6 15N and EPA follows the linear model: EPA (%RBC fatty acid) =1.04 • 8,5N -  6.1%,, as
previously described for this population.21
Table 4.7.3: Obesity GWAS SNP polymorphisms1’2’3’4
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Gene SNP1 Chr
RUk
Allele
Frequency
Frequency of Riik Allele la HAPMAP 
population*
HWE
(p-v*lnc)
Reference
YRI CEU HCB JPT MEX
NEGRI r*2815752 1 A 0.81 0.53 0.64 0.88 0.92 0.73 0.2007 751
TUEMIS ts7561317 2 G 0.85 0.79 0.85 0.91 0.88 0.88 0.1768
ETV5 1*7647305 3 C 0.94 0.61 0.79 0.94 0.94 0.81 0.478 23
GNPDA2 r*10938397 4 G 0.15 0.21 0.45 0.25 0.37 NA 0.2097 /;»
BDNF [*6265 11 G 0.96 0.99 0.81 0.38 0.63 0.79 1 7.26
MTCH2 ral0838738 11 G 0.66 0.04 0.36 0.35 0.35 0.4 0.0037 20
SH2BI r*7498665 16 G 0.66 0.21 0.38 0.15 0.13 0.38 0.462
FTO 1*9939609 16 A 0.19 0.51 0.46 0.12 0.19 NA 0.3223
MC4R r*17782313 18 C 0.08 0.31 0.27 0.14 0.24 0.14 1
KCTDI5 1*29941 19 C 0.31 0.86 0.68 0.22 0.26 0.65 0.4179 v s
Seattle SNPs Genome Variation Server on March 2008 (dbSNP build 126) Version 5.01.
2 Frequency of risk allele computed using FREQ module in S.A.G.E.
3 Frequency of risk allele among five HapMap populations: Yoruba in Ibadan, Nigeria (YRI), Utah 
residents with ancestry from northern and western Europe (CEU), Han Chinese in Beijing, China 
(CHB), Japanese in Tokyo, Japan (JPT), Mexican ancestry in Los Angeles, California.
4HWE p-value computed using founders in PLINK.
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Table 4.7.4: Obesity polymorphisms associated with adiposity after 51SN 
adjustment1’2
Gene SNP BMI PBF HC ThC WC
NEGRI ra2815752 0.222 0.056 0.109 0.055 0.081
(P= -0.3, SB- 0.2) (p= -0.4, SE= 0.2) 0 =  -0.4, SB- 0.2) (p= -0.6, SE-0.3) (P=-0.5, SE-0.3)
TMEM1S 1*7561317 0.048 0.073 0.103 0.202 0.034
(P= 0.5, SE= 0.2) 0 =  0.4, SE= 0.2) 0 =  0.4, SE-0.2) (P= 0.4, SE-0.3) (P= 0.6, SE-0.3)
ETV5 1*7647305 0.006 0.006 0.002 0.003 0.009
(P= -1.5, SE= 0.6) (p=-1.4, SE-0.5) 0 =  -1.8, SE= 0.6) (P= -2.0, SE= 0.7) (P= -1.9, SE= 0.7)
GNPDA2 1*10938397 0.821 0.761 0.315 0.267 0.867
(P= 0.1, SE= 0.2) 0= 0 .1 , SE= 0.2) (P-0.2, SE-0.2) (P-0.3, SE-0.3) (p-0.1, SE-0.3)
BDNF 1*6265 0.531 0.646 0.943 0.859 0.396
(P= 0.4, SE= 0.6) 0 =  0.2, SE- 0.5) (P= 0.0, SE= 0.6) (P-0.1, S B -0.7) (P - 0.6, S B -0.7)
MTCH2 1*10838738 0.682 0.550 0.556 0.440 0.797
(P»0.1 SE= 0.2) (P= 0.1, SE= 0.2) (P-0.1, SE-0.2) (P-0.2, SE-0.2) (p-0 .1 , S B -0.2)
SH2B1 1*7498665 0.111 0.136 0.239 0.092 0.179
0 =  0.3, SE= 0.2) 0= 0 .2 , SE-0.2) (P-0.2, SE-0.2) (P= 0.4, S B -0.2) (P-0.3, SE-0.2)
n o 1*9939609 0.010 0.904 0.008 0.010 0.020
(p- 0.6, SE= 0.2) 0= 0.6, SE-0.2) (P= 0.6, SE-0.2) (p= 0.7, S B -0.3) (P= 0.7, SE-0.3)
MC4R 1*17782313 0.377 0.726 0.243 0.094 0.328
(P= 0.3, SE- 0.3) (p-0.1, SE-0.3) (P= 0.4, SE-0.3) (P= 0.6, SE-0.4) (p= 0.4, SE-0.4)
KCTDI5 1*29941 0.301 0.192 0.319 0.177 0.405
(P-0.2, SE-0.2) (p-0.2, SE-0.2) (P-0.2, SE-0.2) (P -0 .3 , S B -0.2) (P-0.2, S B -0.3)
P-values for association of obesity SNPs adjusted for age, sex, community group, and n-3 PUFA 
intake. Estimates of effect size (P) are reported for additive model and BMI-increasing alleles using 
transformed phenotypes.
2Results significant at p< 0.005 are highlighted in bold. Body mass index (BMI), percent body fat 
(PBF), hip circumference (HC), thigh circumference (ThC) and waist circumference (WC).
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Table 4.7.5: Interaction with n-3 PUFA intake modifies the Genetic Risk 
Score association with adiposity phenotypes1’2’
Outcome Main Effect1 Interaction2
BMI (kg/m2) 0.012 0.011
Percentage Body Fat (%) 0.022 0.025
Hip Circumference (cm) 0.080 0.068
Thigh Circumference (cm) 0.025 0.084
Waist Circumference (cm) 0.038 0.018
1 P-values for GRS analysis adjusted for sex, age, community group, and n-3 PUFA intake.
2 P-values for interaction analysis (GRS*n-3 PUFA) adjusted for sex, age, community group 
and n-3 PUFA intake.
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Table 4.7.6: Variation (%) in adiposity phenotypes explained by GRS 
association and GRS interactions with n-3 PUFA intake1,2,3
Variable BMI PBF HC ThC WC
GRS 0.7 0.3 0.5 0.7 0.5
GRS*S13N 1.7 0.8 1.4 1.5 1.4
Variation attributed to GRS after adjustment for age, sex, community group, and n-3 PUFA 
intake.
Variation attributed to GRS*n-3 PUFA interaction after adjustment for age, sex, community 
group and n-3 PUFA intake.
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Supplementary Table 4.9.1: Skewness, kurtosis, and transformation information 
for adiposity phenotypes
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4.9 APPENDIX
U ntransform ed T ransform ed
V ariables K urtosis Skewness K urtosis Skewness
Power
T ransform ation
BM I (kg/m2) 5.08 1.16 2.69 0.13 -0.7
Percentage Body F at (% ) 2.12 0.17 2.13 0.00 0.75
W aist C ircum ference (cm) 3.80 0.82 2.66 0.04 -0.84
H ip C ircum ference (cm) 6.58 1.26 2.95 0.14 -2.19
Thigh Circum ference (cm)
l c .  - - “ - j . • *
6.31 0.22 3.55 0.07 -0.3
1 Skewness and kurtosis for obesity phenotypes were computed using R.
2 Power transformation were computed using R.
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Supplementary Table 4.9.2: Association of obesity SNPs with obesity phenotypes 
without 8ISN adjustment1,2
Gene SNP BMI PBF HC ThC WC
NEGRI rs2815752 0.6607 
(P=0.3, SE=0.2)
0.2671 
(0=0.4, SE= 0.2)
0.4394 
(0=0.4, SE= 0.2)
0.2953 
(0=0.6, SE= 0.3)
0.3526 
(0=0.6, SE= 0.3)
TMEM18 1*7561317 0.3414 
(0=0.4, SE-0.2)
0.4273 
(0=0.3, SE= 0.2)
0.5323 
(0=0.4, SB= 0.2)
0.6557 
(0=0.4, SE= 0.3)
0.2390 
(0=0.6, SE= 0.3)
ETV5 1*7647305 0.0684 
(p=1.5, SE= 0.6)
0.0884 
(0=1.3, SE= 0.5)
0.0219 
(0=1.8, SE= 0.6)
0.0163 
(0=2.2, SE= 0.7)
0.0794 
(0=1.9, SE= 0.8)
GNPDA2 1*10938397 0.9880 
(0=0.1, SE-0.2)
0.9820 
(0=0.1 ,SE= 0.2)
0.6998 
(0=0.3, SE= 0.2)
0.6224 
(0=0.4, SE= 0.3)
0.9866 
(0=0.1 ,SE= 0.3)
BDNF rs6265 0.9641 
(0=0.3 , SE= 0.6)
0.9880 
(0=0.2, SE= 0.5)
1.0000 
(0=0.03, SE= 0.6)
0.9999 
(0=0.0, SE= 0.7)
0.9204 
(0=0.6, SE= 0.7)
MTCH2 1*10838738 0.9891 
(0=0.1 ,SE= 0.2)
0.9649 
(0=0.1, SE=0.2)
0.9231 
(0=0.1, SE=0.2)
0.8434 
(0=0.2, SE= 0.2)
0.9998 
(0=0.0, SE= 0.2)
SH2B1 1*7498665 0.4243 
(P=-0.3 ,SE= 0.2)
0.5391 
(0=0.2, SE= 0.2)
0.6617 
(0=0.2, SE= 02.)
0.4145
(0=0.4 , SE= 0.2)
0.6373 
(0=0.3, SE= 0.2)
FTO 1*9939609 0.0704 
(0=0.6, SE= 0.2)
0.0499 
(0=0.6, SE= 0.2)
0.0558 
(0=0.6, SE= 0.2)
0.0399 
(0=0.8, SE= 0.3)
0.1322 
(0=0.7, SE= 0.3)
MC4R 1*17782313 0.8323 
(0=0.3, SE= 0.3)
0.9883 
(0=0.1, SE=0.3)
0.6604 
(0=0.4, SE= 0.3)
0.3373 
(0=0.7, SE= 0.4)
0.7588 
(0=0.4, SE-0.3)
KCTD1S 1*29941 0.8091 
(0=0.2, SE= 0.2)
0.6474 
(0=0.2, SE= 0.2)
0.8082 
(0=0.2, SE= 0.2)
0.5921 
(0=0.1 ,SE= 0.3)
0.8604 
(0=0.3, SE=0.2)
'P-values for association of obesity SNPs adjusted for age, sex, community group. Estimates of effect 
size (p) are reported using transformed phenotypes.
2Results significant at p< 0.005 are highlighted in bold. Body mass index (BMI), percent body fat 
(PBF), hip circumference (HC), thigh circumference (ThC) and waist circumference (WC).
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Supplementary Table 4.9.3: Interaction between n-3 PUFA 
intake and obesity SNPs modifies association with obesity 
traits1*2
Gene SNP BMI PBF HC ThC WC
NEGRI re2815752 0.4367 0.3861 0.0544 0.1084 0.1944
TMEM18 rs7561317 0.0249 0.1545 0.1961 0.2057 0.0389
ETV5 rs7647305 0.0243 0.0243 0.0092 0.0127 0.0283
GNPDA2 rsl0938397 0.4953 0.2321 0.2648 0.5940 0.2610
BDNF rs6265 0.7193 0.9837 0.8573 0.7912 0.6430
MTCH2 rsl0838738 0.6633 0.6681 0.2420 0.3675 0.2571
SH2B1 rs7498665 0.3626 0.4967 0.6919 0.5326 0.3517
FTO rs9939609 0.0516 0.0080 0.0140 0.0293 0.0238
MC4R rsl7782313 0.3179 0.6694 0.3265 0.2669 0.3837
KCTD15
.;■
rs29941 0.6724 0.1702 0.5267 0.5932 0.8650
community group, and n-3 PUFA intake.
2Results significant at p£ 0.005 are highlighted in bold. Body mass index 
(BMI), percent body fat (PBF), hip circumference (HC), thigh circumference 
(ThC) and waist circumference (WC).
Supplementary Table 4.9.4: Interaction with n-3 PUFA intake 
modifies the genetic risk score (GRS) association with obesity 
phenotypes after correction for intake of total fat and total 
energy (n=492)
Outcome Total Fat (%)' Total Energy (kcal)2
BMI (kg/m") 0.034 0.033
Percentage Body Fat (%) 0.228 0.180
Hip Circumference (cm) 0.347 0.340
Thigh Circumference (cm) 0.134 0.079
Waist Circumference (cm) 0.056 0.038
’P-values for GRS*n-3 PUFA analysis adjusted for sex, age, community group 
and total fat intake (%).
2P-values for GRS*n-3 PUFA analysis adjusted for sex, age, community group 
and total energy intake (kcal).
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SUMMARY AND FUTURE DIRECTIONS
5.1 DISSERTATION OBJECTIVES
Obesity is a highly heritable trait that ultimately increases the risk of developing 
T2D, CVD, and other diseases (1). Although molecular approaches have expedited the 
discovery of human obesity genes, the heritable component of obesity explained by these 
genes remains low (<2%) (2). In parallel to these observations, accumulating evidence 
show n-3 PUFA intake has anti-obesity effects (3), yet the extent to which n-3 PUFA 
intake modulates the genetic risk of obesity is unknown.
Increasingly, isolated populations have been shown to facilitate the discovery of 
genetic and environmental factors underlying variation in complex phenotypes (4). 
Isolated populations are homogeneous sub-groups of individuals that are often 
characterized by a shared environment and geographic isolation over long periods of time 
(5). Candidate gene studies have benefited from sampling genetically isolated 
populations, in part, because large families that share a uniform environment are expected 
to increase the power of detecting genetic factors associated with complex phenotypes 
such as obesity (6). The dissertation analyzed data from the CANHR study (7), a 
geographically isolated cohort of Yup’ik participants that belong to large extended 
families, engage in traditional subsistence activities and have widely varying 
consumption of n-3 PUFAs (8). Prevalence of T2D is currently low in this population 
however the prevalence of T2D among Yup’ik people is reported to be rising rapidly (9), 
and a better understanding of obesity and its determinants will help in developing 
interventions effective for this population.
The CANHR study is ideally suited to investigate the contribution of n-3 PUFA 
intake and genetic factors to variation in obesity phenotypes due to the 30-fold range of 
n-3 PUFA consumption (10) that can be precisely estimated in large samples using a 
validated biomarker (11). Moreover, our studies provide an opportunity to directly 
investigate the health benefits of a subsistence diet that is rich in PUFAs and has great
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cultural importance to Yup’ik people. Specifically, we assessed the differences in n-3 
PUFA intake among CANHR study participants using nitrogen stable isotope ratios 8,5N 
as an objectively measured biomarker of n-3 PUFA intake (11). Estimating n-3 PUFA 
intake using 815N should provide us with an integrated signal of n-3 PUFA intake that 
could modulate candidate gene expression over a 3-4 month period (range of RBC 
lifetime is approximately 120 days). Finally, this dissertation benefited from a large 
cohort of Yup’ik participants and statistical methodologies that account for large- 
extended families (6).
Thus, the overall objective of this work was to examine gene-diet interactions in a 
study population with widely varying n-3 PUFA intake: to evaluate the extent to which 
genetic polymorphisms are associated with obesity-related phenotypes in Yup’ik people, 
and assess how these associations may be modified by n-3 PUFA intake. The selected 
candidate genes presented in this dissertation included: (1) candidate genes with a strong 
physiological role in obesity pathophysiology; (2) candidate genes identified in obesity 
whole-genome linkage studies that are also regulated by n-3 PUFAs; and (3) candidate 
genes reproducibly implicated in obesity genome-wide association studies. In the 
following sections, I outline the objectives of each study and summarize our major 
findings.
5.2 DISSERTATION SUMMARY
5.2.1 PHYSIOLOGY
We selected carnitine palmitoyltransferase 1A {CPTIA) as a strong physiologocal 
candidate gene that is implicated in obesity pathophysiology. CPTIA controls fatty acid 
oxidation in liver tissue (12) and facilitates the transfer of long-chain fatty acids (LCFA) 
across the mitochondrial membrane for ^-oxidation (13). A meta-analysis of whole- 
genome linkage studies has implicated CPTIA as an obesity candidate gene (14) and the 
P479L variant of CPTIA polymorphism has been associated with elevated fasting HDL- 
cholesterol and ApoAl levels in Greenland Eskimos (15). Given that consumption of n-3
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PUFA increases the activity of CPT1A (16) and functional evidence demonstrates L479 
allele of P479L both reduces CPT1A activity (-80%) and abolishes CPT1A inhibition by 
Malonyl CoA (17); this study examined 28 tagging CPT1A SNPs, including the P479L 
polymorphism, for association with obesity-related phenotypes in Yup’ik people and 
explored whether these associations were modified by n-3 PUFA intake.
Our results demonstrate the P479L (rs80356779) polymorphism in CPT1A is 
negatively associated with all obesity phenotypes in Yup’ik people and we also replicated 
the positive association of P479L with fasting HDL-cholesterol. Specifically, we found 
that individuals homozygous for the L479 allele have a lower percentage body fat, 
smaller BMI, and reduced thigh, hip, and waist circumferences compared to P479 
homozygotes. Furthermore, our analyses indicate the P479L association with fasting 
HDL-cholesterol was still significant after correcting for BMI, percent body fat (PBF), or 
waist circumference (WC). Taken together, our results suggest that there will be net 
increase in the basal activity of CPT1A among individuals carrying the L479 allele and 
the P479L variant in Eskimo/Inuit populations with elevated consumption of n-3 PUFAs, 
and this may be cardio-protective (through increased HDL-cholesterol) and reduced 
adiposity.
5.2.3 WHOLE-GENOME LINKAGE STUDIES
We selected SCD, SLC2A4, and SREBF1 as candidate genes for this study based 
on evidence from obesity whole-genome linkage analyses (18-20) and functional studies 
indicating that SCD gene expression (21), SLC2A4-mediated glucose transport (22), and 
SREBF1 gene transcription (23) are regulated by n-3 PUFA intake. Previous candidate 
gene studies have demonstrated that SCD, SLC2A4, and SREBF1 polymorphisms are 
associated with obesity-related traits (24-28), however the extent to which n-3 PUFA 
intake modifies these genetic associations remains unknown. Our results demonstrate 
that in Yup’ik people, SCD polymorphisms (rsl 190480 and rs2167444) are associated 
with reduced BMI, smaller hip circumference and elevated fasting ApoAl levels, the
128
major apolipoprotein found in HDL-cholesterol. Furthermore, SLC2A4 polymorphisms 
are associated with increased adiposity and lower fasting HDL-cholesterol levels. In 
light of functional evidence that demonstrates n-3 PUFA intake transcriptionally 
regulates SCD (21) and SLC2A4 (22), we did not find that consumption of n-3 PUFA 
intake modified SCD and SLC2A4 polymorphisms associated with obesity phenotypes in 
this Yup’ik study population. We did observe SCD polymorphisms (rsl 190480 and 
rs2167444) associated with fasting total cholesterol levels that were modified by n-3 
PUFA intake; however these gene-diet interactions were only nominally significant after 
adjusting for HDL-cholesterol. Taken together, these results suggest the interaction of 
SCD polymorphisms and n-3 PUFA intake on total cholesterol levels may, in part, be 
mediated by changes in fasting HDL-cholesterol levels.
5.2.4 GENOME-WIDE ASSOCIATION STUDIES
We selected NEGRI, TMEM18, ETV5, GNPDA2, BDNF, MTCH2, SH2B1, 
FTO, MC4R and KCD15 as obesity candidate genes based on evidence that these genes 
were reproducibly implicated in obesity GWAS. Previous candidate genes studies have 
largely replicated the association of obesity GWAS polymorphisms in diverse 
populations (29); however, the extent to which obesity GWAS polymorphisms are 
associated with obesity phenotypes in Yup’ik people and how these polymorphisms 
interact with modifiable environmental factors such as n-3 PUFA intake was lacking. 
Our results demonstrate that the rs9939609 SNP in the FTO gene was positively 
associated with percent body fat and supports other studies indicating that variation in 
FTO contributes to fat accumulation (30). Interestingly, we found that the rs7647305 
SNP in the ETV5 gene was associated with adiposity phenotypes in our study; however, 
the direction of the association was the reverse of that reported in participants of 
Europeans ancestry (31, 32). Although our results in this Yup’ik study population are 
“opposite” to those observed in Europeans, theoretical modeling has argued that “flip- 
flop” associations can be attributed to population specific differences in linkage
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disequilibrium patterns among SNPS in a particular genomic region (33).
We estimated the cumulative effects of obesity GWAS polymorphisms to changes 
in adiposity phenotypes in Yup’ik people using a genetic risk score (GRS) for obesity. 
An obesity GRS is designed to estimate an individual’s genetic predisposition to obesity 
by adding the BMI-increasing alleles across all the obesity SNPs of interest. We found 
the GRS was positively associated with adiposity phenotypes, and this association was 
modified by n-3 PUFA intake. Specifically, genetic predisposition to obesity, as 
measured by the GRS, was positively associated with adiposity and n-3 PUFA intake 
modified these associations whereby among individuals with a low GRS, n-3 PUFA 
intake did not increase BMI. However, in individuals with a moderate (2) or high (3) 
GRS, n-3 PUFAs intake is obesigenic. Taken together, these results suggest the anti­
obesity effects of n-3 PUFA in humans may be dependent upon an individual’s genetic 
predisposition to obesity.
Our analysis that examined the extent to which gene-by-diet interactions 
explained the heritable component of obesity revealed the interactions of GRS and n-3 
PUFA intake on adiposity accounted for more than twice the phenotypic variation (~2% 
variation explained), relative to GRS associations alone (~1% variation explained). 
Although modest, our results support the findings of Li et al. (34) that demonstrated 
physical activity interactions with a GRS, calculated from 12 obesity risk alleles, 
accounted for twice as much phenotypic variation in obesity-related traits relative to the 
genetic risk score alone (34). Taken together, this study provides evidence that 
interactions between n-3 PUFA intake and obesity GWAS polymorphisms may account 
for a small portion of the “missing heritability” attributed to obesity. Furthermore, the 
results of this study extends what is known about n-3 PUFAs by demonstrating the anti­
obesity effects of n-3 PUFA intake may be dependent upon an individual’s genetic 
predisposition to obesity.
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5.3 CONCLUSIONS
Advanced molecular approaches such as high-throughput genotyping and whole- 
genome sequencing have expedited the discovery of human obesity genes, however the 
heritable component of obesity explained by the aggregate of these loci remains low 
(<2%) (2). Evidence that obesity occurs in response to interactions between genetic and 
environmental factors may help account for the “missing heritability” attributed to 
obesity and inform personalized interventions. In this dissertation, we examined (1) 
candidate genes with a strong physiological role in obesity pathophysiology; (2) 
candidate genes identified in obesity whole-genome linkage studies that were regulated 
by n-3 PUFAs; and (3) candidate genes reproducibly implicated in obesity GWAS. Our 
investigation of candidate genes based on physiology demonstrates the non-synonymous 
polymorphisms called P479L in CPTIA was associated with elevated fasting HDL- 
cholesterol and all obesity phenotypes. Our investigation of candidate genes that are 
regulated by n-3 PUFAs and implicated in obesity whole-genome linkage studies 
demonstrate that polymorphisms in SCD and SLC2A4 were associated with obesity- 
related phenotypes and n-3 PUFA intake modified the SCD polymorphisms associated 
with fasting cholesterol levels. Finally, our investigation of candidate genes reproducibly 
implicated in obesity GWAS demonstrated that genetic predisposition to obesity, 
estimated using a GRS, is associated with adiposity and that interactions with n-3 PUFA 
intake accounted for more than twice the phenotypic variation in adiposity. Taken 
together, this dissertation suggests that selecting candidate genes based on large-scale 
genomic dataset, such as linkage analyses and GWAS, has the potential to identify gene- 
by-environment interactions that partially account for the “missing heritability” attributed 
to obesity.
5.5 FUTURE DIRECTIONS
Existing epidemiological approaches have elucidated genetic and environmental 
risk factors that increase the risk of developing obesity; however mechanistic information
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that accounts for these observations is limited. Epigenetics describes the phenomena 
where inherited alterations in gene function occur independently of changes in the 
nucleotide sequence (35). In the case of obesity, epigenetic modifications (DNA 
methylation and histone modification) are associated with changes in body weight among 
genetically identical mice (36). Interestingly, diet and physical activity have been shown 
to impact epigenetic modification (37) and this observation generates an intriguing 
hypothesis that epigenetic processes are actively influenced by lifestyle (38). Taken 
together, future directions should consider epigenetic modification as a putative 
mechanism explaining how specific environmental exposures can impact obesity 
independent of genetic variation (39).
132
1. Ogden, C. L., S. Z. Yanovski, M. D. Carroll, and K. M. Flegal. 2007. The
Epidemiology of Obesity. Gastroenterology. 132: 2087-2102.
2. Speliotes, E. K., C. J. Wilier, S. I. Bemdt, K. L. Monda, G. Thorleifsson, A. U.
Jackson, H. L. Allen, C. M. Lindgren, J. Luan, R. Magi, J. C. Randall, S. 
Vedantam, T. W. Winkler, L. Qi, T. Workalemahu, I. M. Heid, V. Steinthorsdottir, 
H. M. Stringham, M. N. Weedon, E. Wheeler, A. R. Wood, T. Ferreira, R. J. 
Weyant, A. V. Segrfc, K. Estrada, L. Liang, J. Nemesh, J.-H. Park, S. Gustafsson,
T. O. Kilpelainen, J. Yang, N. Bouatia-Naji, T. Esko, M. F. Feitosa, Z. Kutalik, M. 
Mangino, S. Raychaudhuri, A. Scherag, A. V. Smith, R. Welch, J. H. Zhao, K. K. 
Aben, D. M. Absher, N. Amin, A. L. Dixon, E. Fisher, N. L. Glazer, M. E. 
Goddard, N. L. Heard-Costa, V. Hoesel, et al. 2010. Association analyses of 
249,796 individuals reveal 18 new loci associated with body mass index. Nature 
Genetics. 42: 937-948.
3. Buckley, J. D., and P. R. C. Howe. 2009. Anti-obesity effects of long-chain omega-3
polyunsaturated fatty acids. Obesity Reviews. 10: 648-659.
4. Kristiansson, K., J. Naukkarinen, and L. Peltonen. 2008. Isolated populations and
complex disease gene identification. Genome Biology. 9: 109.
5. Heutink, P., and B. A. Oostra. 2002. Gene finding in genetically isolated populations.
Human Molecular Genetics. 11: 2507-2515.
6. Bourgain, C., and E. Genin. 2005. Complex trait mapping in isolated populations: Are
specific statistical methods required? European Journal o f Human Genetics. 13: 
698-706.
7. Mohatt, G. V., R. Plaetke, J. Klejka, B. Luick, C. Lardon, A. Bersamin, S. Hopkins, M.
Dondanville, J. Herron, and B. B. Boyer. 2007. The Center for Alaska Native 
Health Research Study: a community-based participatory research study of obesity 
and chronic disease-related protective and risk factors. International Journal o f 
Circumpolar Health. 66: 8-18.
8. Boyer, B. B., G. V. Mohatt, C. Lardon, R. Plaetke, B. R. Luick, S. H. Hutchison, G. A.
De Mayolo, E. Ruppert, and A. Bersamin. 2005. Building a community-based 
participatory research center to investigate obesity and diabetes in Alaska Natives. 
International Journal o f Circumpolar Health. 64: 281-290.
5.6 REFERENCES
133
9. Narayanan, M. L., C. D. Schraer, L. R. Bulkow, K. R. Koller, E. Asay, A. M. Mayer,
and T. W. Raymer. 2010. Diabetes prevalence, incidence, complications and 
mortality among Alaska Native people 1985-2006. International Journal o f 
Circumpolar Health. 69:236-52.
10. Bersamin, A., B. R. Luick, I. B. King, J. S. Stem, and S. Zidenberg-Cherr. 2008.
Westernizing diets influence fat intake, red blood cell fatty acid composition, and 
health in remote Alaskan Native communities in the center for Alaska Native 
health study. Journal o f the American Dietetic Association. 108: 266-273.
11. O’Brien, D. M., A. R. Kristal, M. A. Jeannet, M. J. Wilkinson, A. Bersamin, and B.
Luick. 2009. Red blood cell deltal5N: a novel biomarker of dietary 
eicosapentaenoic acid and docosahexaenoic acid intake. American Journal o f 
Clinical Nutrition. 89: 913-919.
12. McGarry, J. D., and N. F. Brown. 1997. The mitochondrial carnitine
palmitoyltransferase system. From concept to molecular analysis. European 
Journal o f Biochemistry. 244: 1-14.
13. McGarry, J. D. 2001. Travels with carnitine palmitoyltransferase I: from liver to germ
cell with stops in between. Biochemical Society Transactions. 29: 241-245.
14. Saunders, C. L., B. D. Chiodini, P. Sham, C. M. Lewis, V. Abkevich, A. A.
Adeyemo, M. de Andrade, R. Arya, G. S. Berenson, J. Blangero, M. Boehnke, I.
B. Borecki, Y. C. Chagnon, W. Chen, A. G. Comuzzie, H.-W. Deng, R. Duggirala, 
M. F. Feitosa, P. Froguel, R. L. Hanson, J. Hebebrand, P. Huezo-Dias, A. H. 
Kissebah, W. Li, A. Luke, L. J. Martin, M. Nash, M. Ohman, L. J. Palmer, L. 
Peltonen, M. Perola, R. A. Price, S. Redline, S. R. Srinivasan, M. P. Stem, S.
Stone, H. Stringham, S. Turner, C. Wijmenga, and D. A. Collier. 2007. Meta­
analysis of genome-wide linkage studies in BMI and obesity. Obesity. 15: 2263­
2275.
15. Rajakumar, C., M. R. Ban, H. Cao, T. K. Young, P. Bjerregaard, and R. A. Hegele.
2009. Carnitine palmitoyltransferase LA polymorphism P479L is common in 
Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. Journal 
o f Lipid Research. 50: 1223-1228.
16. Madsen, L., A. C. Rustan, H. Vaagenes, K. Berge, E. Dyroy, and R. K. Berge. 1999.
Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal 
fatty acid oxidation in relation to substrate preference. Lipids. 34: 951-963.
134
17. Brown, N. F., R. S. Mullur, I. Subramanian, V. Esser, M. J. Bennett, J.-M.
Saudubray, A. S. Feigenbaum, J. A. Kobari, P. M. Macleod, J. D. McGarry, and J.
C. Cohen. 2001. Molecular characterization of L-CPTI deficiency in six patients: 
insights into function of the native enzyme. Journal o f Lipid Research. 42: 1134 — 
1142.
18. Bell, C. G., M. Benzinou, A. Siddiq, C. Lecoeur, C. Dina, A. Lemainque, K. Clement,
A. Basdevant, B. Guy-Grand, C. A. Mein, D. Meyre, and P. Froguel. 2004. 
Genome-wide linkage analysis for severe obesity in french Caucasians finds 
significant susceptibility locus on chromosome 19q. Diabetes. 53: 1857-1865.
19. Dong, C., S. Wang, W.-D. Li, D. Li, H. Zhao, and R. A. Price. 2003. Interacting
genetic loci on chromosomes 20 and 10 influence extreme human obesity. 
American Journal o f Human Genetics. 72: 115-24.
20. Hager, J., C. Dina, S. Francke, S. Dubois, M. Houari, V. Vatin, E. Vaillant, N.
Lorentz, A. Basdevant, K. Clement, B. Guy-Grand, and P. Froguel. 1998. A 
genome-wide scan for human obesity genes reveals a major susceptibility locus on 
chromosome 10. Nature Genetics. 20: 304-8.
21. Ntambi, J. M. 1992. Dietary regulation of stearoyl-CoA desaturase 1 gene expression
in mouse liver. Journal o f Biological Chemistry. 267: 10925-30.
22. Manco, M., M. Calvani, and G. Mingrone. 2004. Effects of dietary fatty acids on
insulin sensitivity and secretion. Diabetes, Obesity & Metabolism. 6: 402-413.
23. Jump, D. B. 2002. Dietary polyunsaturated fatty acids and regulation of gene
transcription. Current Opinion in Lipidology. 13: 155-64.
24. Bodhini, D., V. Radha, S. Ghosh, P. P. Majumder, M. R. S. Rao, and V. Mohan.
2011. GLUT4 gene polymorphisms and their association with type 2 diabetes in 
south Indians. Diabetes Technology & Therapeutics. 13: 913-20.
25. Eberl6, D., K. Clement, D. Meyre, M. Sahbatou, M. Vaxillaire, A. Le Gall, P. Ferr6,
A. Basdevant, P. Froguel, and F. Foufelle. 2004. SREBF-1 gene polymorphisms 
are associated with obesity and type 2 diabetes in French obese and diabetic 
cohorts. Diabetes. 53: 2153-2157.
26. Gong, J., H. Campos, S. McGarvey, Z. Wu, R. Goldberg, and A. Baylin. 2011.
Genetic Variation in Stearoyl-CoA Desaturase 1 Is Associated with Metabolic 
Syndrome Prevalence in Costa Rican Adults. Journal o f Nutrition. 141: 2211­
2218.
135
27. Warensjd, E., E. Ingelsson, P. Lundmark, L. Lannfelt, A.-C. SyvSnen, B. Vessby, and
U. Risdrus. 2007. Polymorphisms in the SCD1 gene: associations with body fat 
distribution and insulin sensitivity. Obesity. 15: 1732-40.
28. Xi, C., K. Miyaki, S. Ikeda, Y. Song, T. Sinbo, and M. Muramatsu. 2012. Association
of GLUT4 gene variants with HbAlc level in Japanese men. Endocrine Journal.
29. Loos, R. J. F. 2009. Recent progress in the genetics of common obesity. British
Journal o f Clinical Pharmacology. 68: 811-829.
30. Moore, S. C., M. J. Gunter, C. R. Daniel, K. S. Reddy, P. S. George, S. Yurgalevitch,
N. Devasenapathy, L. Ramakrishnan, N. Chatteijee, S. J. Chanock, S. L Bemdt, A. 
Mathew, D. Prabhakaran, and R. Sinha. 2011. Common Genetic Variants and 
Central Adiposity Among Asian-Indians. Obesity.
31. Elks, C. E., R. J. F. Loos, S. J. Sharp, C. Langenberg, S. M. Ring, N. J. Timpson, A.
R. Ness, G. Davey Smith, D. B. Dunger, N. J. Wareham, and K. K. Ong. 2010. 
Genetic Markers of Adult Obesity Risk Are Associated with Greater Early Infancy 
Weight Gain and Growth. PLoS Medicine. 7: 8.
32. Sandholt, C. H., M. A. Vestmar, D. S. Bille, A. Borglykke, K. Almind, L. Hansen, A.
Sandbaek, T. Lauritzen, D. Witte, T. Jorgensen, O. Pedersen, and T. Hansen. 2011. 
Studies of metabolic phenotypic correlates of 15 obesity associated gene variants. 
PloSONE. 6:e23531.
33. Lin, P.-I., J. M. Vance, M. A. Pericak-Vance, and E. R. Martin. 2007. No gene is an
island: the flip-flop phenomenon. American Journal o f Human Genetics. 80: 531— 
8.
34. Li, S., J. H. Zhao, J. Luan, U. Ekelund, R. N. Luben, K.-T. Khaw, N. J. Wareham,
and R. J. F. Loos. 2010. Physical activity attenuates the genetic predisposition to 
obesity in 20,000 men and women from EPIC-Norfolk prospective population 
study. PLoS Medicine. 7: 9.
35. Jaenisch, R., and A. Bird. 2003. Epigenetic regulation of gene expression: how the
genome integrates intrinsic and environmental signals. Nature Genetics. 33 Suppl: 
245-54.
36. Koza, R. A., L. Nikonova, J. Hogan, J.-S. Rim, T. Mendoza, C. Faulk, J. Skaf, and L.
P. Kozak. 2006. Changes in gene expression foreshadow diet-induced obesity in 
genetically identical mice. PLoS Genetics. 2: e81.
136
37. Ling, C., and L. Groop. 2009. Epigenetics: a molecular link between environmental
factors and type 2 diabetes. Diabetes. 58: 2718-25.
38. Mariman, E. C. M. 2008. Epigenetic manifestations in diet-related disorders. Journal
ofNutrigenetics andNutrigenomics. 1: 232-239.
39. Franks, P. W., and C. Ling. 2010. Epigenetics and obesity: the devil is in the details.
BMC Medicine. 8: 88.
APPENDIX
Appendix 6.1 Alaska Area Institutional Review Board
M  *4
4315 Diplomacy Drive 
Anchorage, Alaska 99508 
(907)563-2662 October 28.2003
OeraW Mohatt, PHD. .•  - t i  a— *«-«» - | \ I. .||j| aaa---------- s_vwWT ipr mmnh rmw nwn nNWut
Institute of Arctic Biotoby 
University of A W a Fafcbanks 
311 Irving 1, Box 757000 
Fallbacks, Alaska 90778-7000
OearOr. Mohatt
The responses to our comments oo your last submission far propoaal 0S-P-1I “A Study of Obesity and 
D tib U t among Yup*Ht m m "  .woro ooniirtwTHl ithmubta mth thft ftjcmino djrtfiotiofn.
•  You aro required to axpicMy state that whan pattic$anti turn Itiyaars of age tie  parent* 
oonsont that teas leashed ter lhalrptdolpetton la no longer veld. Anarytaofprevlouaiyabtalnad 
data may occur, but no further information im y bo ootiadodftom thooo p m tn i urtiooo MMdub 
adult om ant it oMrinmi,
• Your moot rocont ratponaa did not (notate any finnllofl of the ipNbm n bmUn9 protocol. Wo 
require that you agree to abide by 8 *  currently approved Alaska Arsa/COC aarum bank.
You art again commended for your prompt and Oierough attention to our previous comments. It the 
above conditions are met, the prefect la approved tar one year. You are required to AM  tie  education 
requirement by having a l personnel InvoMed In a aubetanUva way In the research protect complete t »  
wrabaka training at aaaia.miainl.adutearso If sou haws not done so. the Instniclons ate attached.
Anv ffuniitftD ii <y wiMtihi |n r rvM raiarv or ih ifcaob for maatino araaantation muU bo auhmlNad flo Drn iV T  * f  MBt9etNM>»Mrs9 tiM  p s w i w w i w v i  aw  enM PsasM ^aa ssm  *  i  rw w sn  n p  i n w M a n s u n a f  11 n a n  ainv m n M Sfv ea^n e  n #  a^ s *
Rirth Etasl and Dr. Anna Lanier fer raMaw PRIOR TO 8UBMITTAL. Please subwl  ooplae otthafinal 
ppprovs vwnoni io m i irtB Kv your pranooi vvb. rnaaMMaovsaovwifaaaaran vwannnQAMiiB 
Native Tribal Heatti Consortium muet be revteared by Dr. Ruth Etasl. Southoentiat Foundation and Or. 
Ame Lanier, ANTHC. "*«■«■ ^■""*“~ v ~ " ~ ^ * " "»««»«M*«nnffiim ^ A0>tnl|»<3tinthtuini. .
'This IR8 action does not oonstihrte review or oompSanc* with HIPAA requirements. Prior to eooaea 
anc/or use of Oala, you muet raoetve approval trom tie  spproprisia insHtutionsl offcasts releasing this 
Information under the current HIPAA lequtramente.*
You can write to Jennifer at Mtf>»mc.oro at the ANMC address. or cel her at (907) 729-2061 between 
the hours ol 8:00 am and 4:30 pm, Monday through Friday tor any questions you mtghthevs Thar* you
Sincerely,
Terry J. M.Povral
Deputy Chairperson 
Alaska Area IRB
cc: 03-P-15
Appendix 6.2 Indian Health Service Institutional Review Board
DEPARTMENT OP HEALTH It HUMAN SERVICES Public h«.Mi tanfe.
mown rmmmn bntviqi 
RoekvWc MO a o a s
S E P  J 6  2EXB
Gerald V. Mohatt, EdD
Director, Center for Alaska Native Health Research 
Irving I, room 311 
P.O. Box 757000 
Fairbanks, Alaska 99775
RE: Research Protocol’ 9AK03 “A atady of Obesity and Diabetes among Yap’ik Eskimot” 
Dear Mr. Mohatt:
The Indian Health Service (IHS) National Institutional Review Board (IRB) has reviewed your 
protocol entitled. "A stady of Obesity and Diabetes among Yup’ik Eskimos The IRB 
approved your protocol.
The approval ia good for one year, from the date o f thia letter and will require continuation 
approval if  the research project extends beyond September 15,2004. The project is approved to 
proceed with the understanding that it will adhere to the Health Insurance Portability and 
Accountability Act (HIPAA) guidelines, which it currently meets as proposed. Please remember 
that any major changes can not be made to the research protocol without receiving prior approval 
from the National IHS 1RJB.
If you have m y questions about the IRBY decision, please contact me at (301) 443-6528 , or by e* 
mail at Psmith@iKie.ihs.gov. Thank you for submitting this research proposal to die National 
IHS IRB. We appreciate your interest in providing the benefits o f hcahh research to American 
Indian and Alaskan Native individuals and communities.
Phillip Smith, MD, MPH 
Chair, National IHS IRB 
M P A -1493
cc: Dave Barrett, Chair, Alaska IHS IRB
Terry Powell, Co-Chair, Alaska IHS IRB
. . .
Appendix 6.3 Yukon-Kuskokwim Health Corporation Institutional Review Board
A Yu k o n -Ku s k o k w im  H ea lth  C o r p o r a t io n"Fostering Native Self-DeierminaUon in Primary Cart, Prevention and Health Promotion."
March 8,2004
Gerald Mohatt, EdD, 
Irving I. Room 311 
P.O. Box 757000 
Fairbanks, Alaska 99775
Dear Mr. Mohatt.
This letter is confirmation that on October 22,2003, the Yukon Kuskokwim Health 
Corporation’s Executive Board approved the CANHR study propose). For YKHC 
tracking purposes it has been labeled 02.W.WCANHR: A Study of Obesity and 
Diabetes Among Yup’ik Eskimos. Please reference this title and YK1IC number in all 
correspondence regarding this study.
These special stipulations for the CANHR protocol were requested.
1. Change consent check boxes to initial boxes.
2. Add to F in consent form “used in future by YKHC Board approval for genetic 
and medical studies.”
3. For H- change Bethel to YK region
4. The Dietary Intake form has both participant ID, name, and DOB. Do not collect 
name only ID number.
5. Add in consent non-identifier raw data may be used in conjunction with EARTH 
study.
6. Obtain YK Release of Information form if  chart review* are anticipated.
It is expected that annual updates will be submitted in an electronic format until such 
time the study is completed. A copy of fee study update format is being attached to the 
email version of tins confirmation.
This approval is valid for one year and will be updated annually. Notification o f any 
advene events should be reported to my office immediateiy. 'Foiwlal YKHC approval is 
required for any abstracts, papers, or publications arising firom YKHC approved research 
(see profcesSlSelow).................''
- ;i ■; fT-r '  .. ,-v; a t  •• -. . i - l  '• . t  J f ,  V S  ’ ,
YKHC supports the work you are doingiih^ncrtasihg die lfohWi$3$-6Pfe5rt health 
practices for our population through your fesearch? We aniieijiitf thlii your work will
P .O . B ox 5 2 8  —  B e t h e l ,  A l a s k a  9 9 5 5 9 -----9 0 7 - 5 4 3 - 6 0 0 0 ------- I - 8 0 0 - 4 7 S - 3 3 2 1
lead to forma] publications in the future. To assist in time))' approval of ftiture 
manuscripts, please plan on providing YKHC at least a two-month window to review and 
approve any such manuscrij*s. The YKHC Executive Board meets every other month 
and depending on time of submission, approval could take even longer since time must 
be allowed for the YKHC Human Studies Committee to review the manuscript and then 
recommend it to die YKHC Board for approval. For best results we would suggest 
beginning communications with my office as early as possible to help coordinate timing 
of submittal for review so as to assist in a quick approval process. Also keep in mind that 
if  village traditional council approval was required for this study, that annual updates 
should be made to the vi!lage(s). Approval for publications may also need to be obtained 
from such villages.
When Submitting manuscripts for approval, please provide:
1. An electronic c o p y  of the fall manuscript (email to ioe kleika@vkhc.orn)
2. Complete the YKHC manuscript info sheet (attached to email copy o f this letter) 
and submit electronically as well.
3. Provide designated fee to offset costs incurred by YKHC in review process
Once again, YKHC sincerely appreciates your work, enthusiasm, and effort, and looks 
forward to your continued success.
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June 4,2007 
Dr. Bert Boyers
Center for Alaska Native Health Research 
311, Irving I Bldg 
Fairbanks, Alaska 99775
Dear Dr. Boyer
This letter is confirmation that on April 25,2007, die Yukon Kuskokwim 
Health Corporation’s Full Board of Director’s approved die proposal for the 
Genetics of Obesity in Yup'ik Eskimos study. For YKHC bracking 
purposes it has been labeled 07.t2.01 Genetic ef Obesity in Yap’Ik 
Eskimos. Please reference this tide and YKHC number in all 
correspondence regarding this study.
Special stipulations for the 07.02.01 Genetic of Oberfty m Yup’ik Eskimos 
were requested prior to conducting the study.
1) Rephrase statement regarding DNA ownership (review with Aileen 
Havilland and myself).
2) Assure that Release of Information (ROD is obtained from participants 
if medical record review is to be performed.
3) Correct the discrepancy between the protocol and the consent form 
regarding native blood quantum.
4) On the consent form, remove the phrase stating that treatment is 
available at no cost
5) Correct statement that 26cc is less than a tablespoon.
6) Changes needed regarding item E on consent form regarding banking of 
blood specimens (obtain appropriate language from Aileen Havilland 
and myself).
7) To mitigate exercise-testing risk, please add to your protocol a screen 
for resting pulse (needs to be less than 100) and resting blood pressure 
(needs to be less than 160/100) prior to exercise testing.
It is expected that annual updates will be submitted in an electronic format 
until such time the study is completed. A copy of the study update format is 
being attached to the email version of this confirmation.
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This approval is valid for one year and will be updated annually.
Notification of any adverse events should be reported to my office 
immediately. Formal YKHC approval is required for any abstracts, papers, 
or publications arising from YKHC approved research (see process below).
Y KHC supports the work you are doing in increasing the knowledge of best 
health practices for our population through your research. We anticipate that 
your work will lead to formal publications in toe future. To assist in timely 
approval of future manuscripts, please plan on providing Y KHC at least a 
two-month window to review and approve any such manuscripts. The 
YKHC Executive Board meets every other month and depending on time of 
submission, approval could take even longer since time must be allowed for 
the YKHC Human Studies Committee to review the manuscript and then 
recommend it to the YKHC Board for approval. For best results we would 
suggest beginning communications with my office as early as possible to 
help coordinate timing of submittal for review so as to assist in a quick 
approval process. Also keep in mind that if village traditional council 
approval was required for this study, that annual updates should be made to 
the village(s). Approval for publications may also need to be obtained from 
such villages.
When submitting manuscripts for approval, please provide:
1. An electronic copy of the full manuscript (email to 
Joseph kleikafltykhc.org)
2. Complete toe YKHC manuscript info sheet (attached to email copy of 
this letter) and submit electronically as well.
3. Provide designated fee to offset costs incurred by YKHC in review 
process
Once again, YKHC sincerely appreciates your work, enthusiasm, and effort, 
and looks forward to your continued success.
Sincerely,
Joseph Kiqjka, MD 
YKHC Corporate Medical Director 
907-543-6028 or 6027 
fax 907-543-6091 or 6006
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Appendix 6.4 University of Alaska Fairbanks Institutional Review Board
University of Alaska Fairbanks
I fS m u n O N iL S E V IE W B C U R D
Kuia C anton
R a u c h  ComoitM Coontatlor 
Offictof R a u c h  integrity 
Unremty of A lula FBibink*
206 Etetoo Braiding, P.O. Boi 757560 
FU rtw to** 99775-7560
(9071474-7800 
mailt iL to ito n #  lof.adu
April 30, 2003
Subject IRB review of Human Sufyects Application form IRB #03-16
DearDr. Mohatfc
The following Human Subjects Application was reviewed by the University of Alaska Fairbanks 
Institutional Review Board (IRB) at the March 27, 2003, March 28,2003 and April 24.2003 meetings:
IRB Protocol Number: 
Investigator# nstnicton 
Tide of Project/Course:
Date Received:
Date Approved:
Annual Renewed:
#03-14
Gerald Mohatt
Center for Alaska Native Health Research (COBRE Grant 1 P20 
RR16430-01): Obesity, cardiovascular disease, and diobetes among
Y u p 'ik  E skim os
March 17,2003 
April 24, 2003
Due April 2004 (Annual Renewal is required)
Minority Opinions:
None.
Procedural changes or amendments must be reported to the IRB, and no changes may be implemented 
withoutpriorlRB approval.
Kann Davidson
Research Committee Coordinator
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(907) 474*7800
(907) 474-5444 fa* 
fytftxj&uafedu 
wv»v*u«focluM>
Institutional ReMew Board
909 N Koyukuk Dr. Suite 212. P O. Box 757270 Fakbanka Alaska 99775-7270
Decembers, 2006
To: Bert Boyer, PhD 
Principal Investigator
From: Bridget Stockdale, Research Integrity Administrator
Office of Research Integrity
Re: 1RB Protocol Application
The University of Alaska Fairbanks' Institutional Review Board (IRB) tabled the following protocol at their 
November 1,2006 meeting until the requested clarifications/modifications were received. The revised 
protocol and forms received on November 29,2006 were reviewed at the December 6,2006 meeting and die 
board voted to approve them by the following vote: 5 for, 0 against, 0 abstain, and 4 absent Therefore, on 
behalf of die IRB 1 am pleased id issue final approval for this protocol.
Protocol#: 06-72
Tide: Genetics of Obesity in Yup'ik Eskimos
Received: October 5,2006 (orig)
Approved: Decembers, 2006
Any modification or change to this protocol must be approved by the IRB prior to 
implementation. Modification Request Porms are available on the IRB website 
(http://www.uaf.edu/irb/Forms.htm). Please contact the Office of Research Integrity if you have 
any questions regarding IRB policies or procedures.
U N I V E R S I T Y  O F  A L A S K A  F A I R B A N K S
November 29,2006 (rev)
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Fa ir b a n k s  I n s t i t u t i o n a l  R e v i e w  B o a r d
CONTINUING REVIEW REPORT
—wirai,T
Beit Boyer, PhD Phene; 4W-TOJ t-util: bboyer#dMkMdu
' ftwo* or ' ' •' - '
Plti|j«iTKie: Qeneticsof Obesity m Yup'ik Eskimos
Afcfic Biology
Approve! Date: Raview Laval: ■
COMPLETE ALL ITEMS.
1. Pteare check u  appropriate:
Q  Project Completed.
S3 Renew IRB Protocol for another year.
O  Project not funded. Withdrew IRB Protocol.
2. Maximum lumber of people epproved for inclusion in thit study: 1,000
3. Total number of people enrollod in thit protocol to due: 4(3
4. Are new people continuing to be enrolled in thit protocol? SI Yet Q  No
3. is due collection ongoing with currently enrolled individualt? □  Yet E l No
6. Have any unexpected ritkt or problemt been encountered since the hue review? □  Yet {3  No
If yet, detcribe the ritkt or probtenn. (attach additional information ifneceuary)
7. Were any individuals withdrawn from this ttody? E l Yes G  No
If yet, detcribe rentons for withdrawal, (attach additional information, if necessary)
Two participtmt withdrew becauw of pregnancy ead four othen withdrew due to time conetraiots.
I. Have sny grievances/complaints been received since the last review of this study? O  Yes 0  No 
If yet, describe grievance or complaint (attach additional Information, if nccettary)
9. Whal it the ament disposition (meant o f disposal or ttorage location) of collected human biological tpneiment?
AH templet are stored m a locked -IOC freezer in room 230 WRRB (plasma, serum, RBCt) or la e locked 
•tOC ftater in the Freezer Storage Room 244 AHRB. Hah tamplet are Meted in Room 2 Id AHRB or hi Diane O’Brien’s 
leb Room 221.
10. Provide a summary of advtnces in thit field tinct the last review of thit protocol. Provide no mote that five relevant 
chatioas from peer-reviewed literature.
The biggest advances in die field of  obethy generics htve come from Genome Wide Attociallon Studies (GWAS) 
where typically 300,000 • 1,000,000 tingle nucleotide polymorphitmt (SNPt) are genotyped hi 3,000-20,000 
unrelated individuaie. The SNPt ere evenly distributed throughout the genome end when one finds a significm  
association between a SNP end obesity phenotype, it tuggetlt that the gene in which the SNP resides, may influence 
the development of obethy. Several CWAS heve been completed and this presents an opportunity to more closely 
scrutinize the genet of interest, replicnte the associations In other papulation groups, and to investigate gene by 
environment interactions that may modify the association between the SNP and obesity phenotype. We are 
Investigating the asaocuuion o f SNPs in candidate genes for obesity (identified In OWAS and linkage studies), end
also looking at gene by environment interactions. The two main environmental modifiers we are studying are 
physical activity and polyunsaturated fatty acids in the diet. Here are 5 relevant citations: I. Andreascn CH, 
Andersen 0 . Cene-environmant interactions and obesity—ftirther aspects o f genomewide association studies. 
Nutrition. 2009Oct25(10):99*-I003. Epub 1009 Jul 12. Review. PubMed PMID; 195961*6.2. Shuldiner AR. 
Obesity genes and gene-envlronment-behavior interactiont: recommendations for a way forward. Obesity (Silver 
Spring). 200* Dec;)6 Suppl 3:S794I. PubMed PMID: 19037219; PubMed Central PMCID: PMC2703439.3. 
Heard-Costa NL, Zillikens MC, Monda KL, Johansson A. et al. NRXN3 is a novel locus for waist circumference: a 
genome-wide association study from the CHARGE Consortium. PLoS Genet. 2009 Jun;S(6):t 1000539. Epufa 2009 
Jun 26. PubMed PMID; 19557197; PubMed Central PMCID: PMC2695005.4. Undgren CM, Heid IM, Randall JC, 
Lamina C .etal. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fin 
distribution. PLoS Genet. 2009 Jun;5(6):el00050*. Epub 2009 Jua 26 Erratum in: PU S  Genet. 2009 Jul;3<7) doi:
10. l37l/mnotation/b6e*f9f6-2496-4a40-b0e3-eldl390cl92S. PubMed PMID: l9357l61;PubMed Central PMCID: 
PMC269577*. s. Wilier CJ, Spelioies EK, Loos RJ, Li S, et al. Six new loci associated with body mass index 
highlight a neuronal Influence on body weight regulation Nat Genet. 2009 Jan;41(l ):25-34. Epub 2001 Dec 14. 
PubMad PMID: 19079261; PubMed Central PMCID: PMC269S662.
II. Summarize your interim fmdinga, and any amendments or modiftcaikms to the research since tbe last review.
The following modifications have been submitted and approved sine* the last review approved II/I WM:
1. Approved February 25.2009-Addition o f  Salens B ta . Student employee in CANHR EB Core.
2. Submitted September 20,2009 and currently under review- a) To add Marjorie Richards, Research Nurse, and 
Anna Peter-RabofT, Translator to the study protocol; b) To include the measurement o f stable isotope ratios 
(I3C/I2C. 15N/I4N, 35S/34S, IVH, and 1*0/160) in blood samples o f study participants.
3. Submitting modification on December 9,2009 with this review - request to modify consent forms (see attached 
modification request wife consents).
12. What type of fending supports this project?
G  Internal Source:
0  External UAF Proposal or Grant« 7997
O  Unfunded
Agency N!H R0I DK074M2
13. Provide a list o f all penonnel currently working on this protocol:
Name
Email Address
UAF email fax: ffabcD rm nlredfyrfaatlty, sta ff and undents
Scarlett Hookies Mhopkins20ialaska.edu
Jynene Black jablachflalaaka sdu
EluaOrr smontSalaska.sdu
Dominick Lcmaa dlcmaa<%alask*.edu
Maria Bray mdbray@ilaska.edu
Peggy Williams, Field Research Asst. 
Henry Lupie, Field Research Asst. 
Paul Andrew. Field Research Aset
Fancy Lomack, Field Rtuearch Asst. 
Film* Peter. Field Research Asst.
Aana Angarsk, Field Research Asst. 
Katharine Charles, Field Research 
Asst
Marjorie Richards, Research Nurse marichards@alaski.edu
Anna Patar-Raboff, Translator eeetenabofi@elaske.edu
SalensBias skbtas^alaska.edu
Maria Anattario manaslario@Btsska.edu
14. Please check all that are applicable:
13 Written consent forms approved by the UAF IRB are used with this protocol.
Attach a  copy o f the current form(s)
{3 Written parental eo u ea t forms approved by the UAF IRB are used with this protocol 
Attach a  copy o f the current form(s)
13 Written child assent forms approved by the UAF IRB a n  used with this protocol.
Attach a  copy o f the currentformfs)
PRINCIPAL INVESTIGATOR DECLARATION: On behalf o f my co-investigators, associated students, staff and 
mysett, I agree: To perform the research according to UAF policy and the underpinning ethical principles on which It is 
besed; to stricdy adhere to the research protocol at it relates to human subjects, and to ensure thit no changes will be nude In 
the activity without obtaining prior IRB approval (except that a change may be mode to dimimte apparent  immediele 
hazards to the subject); to comply with any contingencies upon which approval may be granted; to promptly notify the Ofike 
of Research Integrity verbally (with written confirmation following) of unanticipated problems involving risk to subjects or 
others sod of any other adverse circumitincei or reactions affecting the subjects that arise from the research. Note: ThetHB 
no longer requires the W 'a signature on Continuing Review Reports provided the farm  is submitted electronically by the PI 
(i t . from  the P i's UAF email account).
